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Foreword 
 
“Infectious disease is one of the few genuine adventures left in the world. The dragons are all 
dead and the lance grows rusty in the chimney corner … About the only sporting proposition 
that remains unimpaired by the relentless domestication of a once free-living human species is 
the war against those ferocious little fellow creatures, which lurk in dark corners and stalk us in 
the bodies of rats, mice and all kinds of domestic animals; which fly and crawl with the insects, 
and waylay us in our food and drink and even in our love.” 
– Hans Zinsser. Rats, Lice and History. (1935) 
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Abstract 
 
Analysis of post-mortem specimens from the 1918 influenza pandemic showed that although 
many people were infected with this virus, of those that died the vast majority had a secondary 
bacterial pneumonia. Such complications are now recognised as a dangerous consequence of 
many inflammatory lung diseases. 
The innate immune rheostat determines the responsiveness of the immune system to 
infection. We aim to map the signalling pathways which influence the rheostat in the lung at 
homeostasis; and how prior infection with Respiratory Syncytial Virus or Influenza virus alters 
this to cause secondary bacterial pneumonia and sepsis. Our central hypothesis is that prior 
inflammation in the lung alters subsequent innate responsiveness by modulating specific 
immune regulatory pathways, and that the extent of this change is dictated by the severity of 
the first inflammatory insult. 
We show that susceptibility to bacterial complication extends far beyond the period of 
acute viral disease in all viral models studied. Concentrating on alveolar macrophage, the front 
line of defence in the lung, we observe that viral infection leads to Toll-like receptor 
desensitisation, an increase in the expression of innate negative regulators, and a dramatic 
change in the microRNA profile of these cells. Similar alterations in the microRNA profile of 
alveolar macrophage were observed following a variety of inflammatory insults, suggesting this 
represents a universal phenomenon. By manipulating these microRNAs it seems possible to 
reset the threshold of activation of alveolar macrophage, suggesting that these small molecules 
may be viable therapeutic targets.  
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Chapter 1: Introduction 
Foreword 
The lung is exposed to a myriad of innocuous antigens on a daily basis and must maintain a state 
of immune ignorance or tolerance to these harmless stimuli to retain pulmonary homeostasis 
and to prevent potentially fatal immunopathology. In the lower airways, resident cell 
populations including alveolar macrophage (AMΦ) contribute to the immune regulatory 
strategies that restrain inflammation. During viral infection, these suppressive signals must be 
overcome to elicit a protective immune response that eliminates the virus. After resolution of 
severe infection, the lung does not return to the original homeostatic state, and an altered state 
characterised by heightened regulation can persist for long periods. This heightened regulation 
in resolution leaves the lung more susceptible to other infectious insults, and in part explains 
the high incidence of secondary bacterial complications following initial viral infections in the 
lung. 
1.0:   Mucosal immunology 
In mammals the mucosal surfaces of the body, including the respiratory tract, form the largest 
surface exposed to pathogens and exogenous antigens in the body. Designed to carry out key 
functions such as gaseous exchange and nutrient absorption, these surfaces also contain the 
largest collection of lymphoid tissue in the body, challenged with protecting from opportunistic 
and invading pathogens, whilst also maintaining a state of immune ignorance or tolerance to 
harmless stimuli, which they are constantly exposed to.  
1.1:  The lung at homeostasis 
With a surface area of 70 m2 the human lungs are an extensive interface with the outside 
world. Approximately 500cm3 of air is taken in with each breath alongside a myriad of antigens 
including pollutants, commensal bacteria, allergens as well as harmful pathogens. To avoid 
detrimental and continuous inflammation directed against harmless antigens; at homeostasis the 
threshold above which a particle is perceived as a threat is set high in the lung compared to 
more sterile tissues. Accordingly the lung exhibits multiple site-specific immune regulatory 
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strategies, imparted by unique resident cellular populations, to restrain inflammation. Lung 
dendritic cells (DCs) are immature and incapable of supporting T-cell maturation without 
multiple inflammatory signal [1], whilst TLR (toll like receptor) expression in mucosal 
epithelium is intracellular or basolateral to prevent exposure to innocuous antigen [2]. Some 
key regulatory strategies are outlined in Figure 1.1 (adapted from [3]). 
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Figure 1.1: Active maintenance of immunological homeostasis within the lower 
airways of the respiratory tract 
 
Type II epithelial cell derived surfactant proteins suppress AMΦ activation through impeding 
recognition of TLR ligands and imparting inhibitory signals through negative immune regulator 
SIRP-α. (A). Epithelial cells further limit AMΦ activation through the release of soluble anti-
inflammatory mediators TGF-β, nitric oxide (NO) and IL-10, and via cell-contact-mediated 
inhibition imparted by negative regulator CD200 and surface glycoprotein MUC1 (B). Plasmacytoid 
and myeloid DCs promote immunological tolerance to antigen through the release of IL-10 and 
induction of regulatory T cells. Activation and maturation of DCs is further suppressed by AMΦ-
derived NO and interstitial macrophage IL-10 (C). Airway epithelial cells also limit DC 
responsiveness through TGFβ, NO and GM-CSF (D). Airway epithelial cells further act to limit the 
development of an adaptive immune response by preferentially promoting monocyte development 
into phagocytic macrophages as opposed to more capable antigen-presenting DCs (E). AMΦ are poor 
APCs that are incapable of eliciting adaptive immunity owing to low co-stimulatory molecule 
expression or elevated expression of CD80 that preferentially binds negative T cell regulator CTLA-
4. AMΦ also directly inhibit T cell responses via the secretion of prostaglandins and TGFβ that 
render T cells inactive. AMΦ also constitutively express PPAR-γ that negatively regulates the 
expression of proinflammatory genes (F). Lung fibroblasts act as a reservoir for triglycerides that 
subsequently protect the lung from oxygen-radical-imposed injury. Fibroblasts further act to 
suppress inflammation through PGE2-mediated inhibition of monocyte TNF and IL-12 production 
and repression of T cell TNF production, activation and proliferation (G). Endothelia express high 
levels of CD200 that imparts an inhibitory signal to immune cells as they egress and migrate into the 
lung (H). Figure taken from Snelgrove, Godlee and Hussell. Trends Immunol. 2011.
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1.2:  AMΦ suppression at homeostasis 
AMΦ are the key sentinels of the airway and at homeostasis actively suppress both adaptive and 
humoral immunity via the production of nitric oxide (NO), prostaglandins, interleukin-4 and -
10(IL-4, IL-10), and transforming growth factor-β (TGF-β) [4-6]. They represent 90 % of all 
leukocytes in the alveolar lumen, and in mice have a low turnover rate of 40 % in 1 year [7]. 
AMΦ have a unique phenotype amongst macrophage expressing high levels of CD11c, which 
can only be induced on bone-marrow adherent cells by culture with surfactant protein D or 
granulocyte-macrophage colony-stimulating factor (GM-CSF), both of which are abundant in 
the airspaces [8]. Additionally they express lower levels of the phagocytotic receptor 
Macrophage 1 antigen (Mac-1, (CD11b)) and MHCII than macrophage from more sterile sites, 
thereby limiting both phagocytosis and antigen presentation  [9, 10]. At homeostasis AMΦ are 
in close proximity and in some cases even adhere to airway epithelial cells, and are subject to 
regulation by epithelium-secreted factors. Surfactant proteins A and D (SP-A and SP-D) which 
are abundant in the epithelial lining fluid and produced in the lower airways by alveolar type II 
cells  [11], reduce the phagocytic activity of alveolar macrophages by binding to a macrophage-
expressed negative regulator, signal inhibitory regulatory protein (SIRP)-α [12] (Figure 1.1). 
This regulatory role in normal conditions is exemplified in SP-D-deficient mice that show 
constitutive alveolar macrophage activation [13]. SP-A binds (via its carbohydrate recognition 
domain) to TLR 4, MD-2 [14], TLR2 [15] and CD14 [16], thereby impeding interaction between 
AMΦ and their respective TLR ligands.  
 
1.2.1: Negative regulators of AMΦ 
Several confirmed and putative negative regulators of AMΦ function are investigated in this 
thesis including CD200R, TREM2 and TAM receptors. 
1.2.1.1: CD200R 
The expression profile of CD200R appears to be conserved between mice, rats and humans and 
is largely confined to myeloid cells (DCs, neutrophils, basophils and mast cells) [17-20] although 
a number of studies describe expression of CD200R on peripheral blood CD4+ T cells and B 
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lymphocytes in mice and humans, and high levels of CD200R mRNA expression in Th2 
polarised T cells [18, 21]. CD200R binds to CD200 which is expressed on thymocytes, B cells, 
activated T cells, neurons, follicular dendritic cells, endothelium, and epithelium and in 
reproductive organs [17, 22-26]. Limited studies exist characterising the downstream signalling 
events following CD200R ligation, however in mast cells phosphorylation of the cytoplasmic 
tail of CD200R is induced upon ligation with CD200. This leads to the recruitment of adaptor 
proteins Dok-1 and Dok-2, which are in turn phosphorylated and associate with RasGAP and 
SH2- containing inositol phosphatase (SHIP), ultimately inhibiting the phosphorylation of 
ERKs, p38 and JNK [19].  The intracellular tail of CD200 is 67 amino acids shorter than that of 
its ligand, and lacks phosphorylation sites, suggesting that the action of CD200 ligation is solely 
delivered through the receptor and is not bi-directional [17, 18].  
 Characterisations of knock out (KO) mice for both CD200 and its receptor have 
highlighted the importance of this interaction in immune regulation. CD200 KO mice develop 
splenomegaly, enlarged lymph nodes, heightened levels of myeloid activation and are at 
increased risk of developing autoimmune conditions such as collagen induced arthritis (CIA) 
[27]. Symptoms of autoimmune diseases develop faster in CD200R KO mice, and lesions contain 
greater macrophage numbers in a heightened activation state [27]. Additional support to the 
concept of CD200 attenuating inflammatory is provided by the recent identification of viral 
homologues of CD200 that transmit an inhibitory signal to macrophage and dendritic cells 
thereby reducing their ability to prime T cells and preventing viral clearance [20, 28-30].  
In the lung CD200R is expressed at high levels on AMΦ, compared to macrophage from 
more sterile sites including those within the lung parenchyma and spleen, suggesting the 
importance of this interaction in maintaining a high threshold of immune activation at mucosal 
sites [31]. Its ligand, CD200 is expressed on the luminal aspect of the lower airway epithelial 
cells in mice. AMΦ from CD200R KO mice produce significantly higher levels of pro-
inflammatory cytokines such as TNF-α in response to IFN-γ than WT controls, and also 
spontaneously activate in the absence of IFN-γ [31]. CD200 KO mice develop excessive 
inflammation following influenza infection, whilst artificially enhancing the CD200-CD200R 
negative signal using CD200 antibody during influenza infection reduces inflammation, and 
disease severity without hindering viral clearance [32]. Interestingly AMΦ present in resolution 
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from severe influenza infection express higher levels of CD200R than those at homeostasis, and 
this heightened regulation in resolution is in part responsible for susceptibility to secondary 
bacterial infections, since CD200R KO mice are protected from bacterial complications [31, 32]. 
1.2.1.2:  TREM2 
TREM2 (Triggering Receptors Expressed on Myeloid Cells), which is found on many myeloid 
cells, including macrophages, microglia, osteoclasts and dendritic cells is structurally similar to 
TREM1 containing three domains: an extracellular V-type immunoglobulin-like domain, a 
transmembrane region containing lysine residues with positive charge and a short cytoplasmic 
tail [33-35]. These related receptors both signal through the adaptor protein DAP12. However 
whilst TREM1 has pro-inflammatory effects, multiple studies suggest that TREM2 dampens 
TLR signalling and has an anti-inflammation role. The ligand for TREM-2 is not yet identified, 
however after stimulation with an agonistic antibody, the transmembrane domain of TREM-2 
phosphorylates the ITAM on DAP12, which recruits the tyrosine kinase SYK and leads to the 
activation of PI3K and MAPK [36]. Other downstream events include ERK phosphorylation 
and Ca2+ mobilisation. Unlike TREM1, TREM2 ligation does not induce the degradation of 
IkB-α or the subsequent nuclear translocation of NF-κB [36]. Initial work suggests that TREM2 
suppresses macrophage TNF-α and IL-6 production and promotes an anti-inflammatory state in 
microglia [35]. Gene silencing of TREM-2 results in increased production of TNF in response to 
the TLR2/6 ligand zymosan and the TLR9 ligand CpG [35].Consistent with this finding, bone 
marrow derived macrophage from TREM2 knockout mice secrete significantly more TNF and 
IL-6 in response to LPS than wild-type controls [37, 38]. Additionally TREM2 signalling 
inhibits cell motility by reducing β2 integrin expression via plexin a1and semaphorin receptors 
[39, 40]. 
1.2.1.3: TAM receptors 
TAM receptors (Tyro3, Axl and MerTK), are tyrosine kinase receptors and are expressed on a 
broad range of myeloid cells including macrophage. TAM receptors recognise apoptotic cells 
indirectly via ligation of GAS6 or Protein S; which are structurally closely related and act as 
bridging molecules between phagocytic cells and externalised phosphatidylserine on apoptotic 
cells [41]. Ligation ultimately leads to efferocytosis of the apoptotic cell, which is invariably an 
Chapter 1: Introduction  26 
 
anti-inflammatory process. TAM receptor signalling contributes to the anti-inflammatory effect 
of effercytosis by initiating a negative feedback loop which dampens TLR signalling. On up-
regulation, TAM receptors physically associate with type 1 interferon receptor (IFNAR) thereby 
interfering with the downstream IFNAR-STAT-1 signal transduction cascade.  This leads to a 
reduction in NF-κB levels and the subsequent broad de-sensitisation of TLRs by induction of 
Suppressor of cytokine signalling 1 and 3 (SOCS1 and 3) [42, 43]. 
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Figure 1.2: Current understanding of TAM, TREM2 and CD200R signalling 
pathways 
 
  
TAM receptors (red and signalling pathway in pink) are tyrosine kinases composed of 2 extracellular 
IgG like domains, a FNIII domain, and intracellular PTK domain, that indirectly bind to apoptotic 
cells via GAS6 or protein S. Co-operation with IFNAR leads to phosphorylation of STAT1, which 
translocates to the nucleus where it upregulates the expression of various negative regulators of TLR 
signalling including SOCS1 and 3. The ligand for TREM2 (Dark green, and signalling pathways in 
light green) is currently unknown. It is composed of an extracellular V-type IgG domain, a positively 
charged transmembrane domain, and a short cytoplasmic tail. Activation of this receptor leads to 
recruitment  and phosphorylation of the ITAM domain of adapter protein DAP12. Via recruitment 
of kinase Syk, this causes the phosprylation of ERK and subsequent alteration in Ca2+ signalling, as 
well as inhibiting NFκB translocation to the nucleus by as yet uncharacterised pathways. CD200R 
(purple, and signalling pathways in light purple) is composed of 2 extracellular IgG like domains, and 
a long cytoplasmic tail containing sites for phosporylation on ligation  of CD200 (expressed on 
epithelial cells, as well as other cell types). This leads to recruitment and phosphorylation of Dok1 
and 2, the recruitment of SHIP and RasGAP, and the subsequent regulation of ERK and Ras 
signalling pathways, ultimately altering the expression of genes controlled by transcription factors c-
Fos and c-Myc.
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1.3   Respiratory infections 
The World Health Organisation (WHO) estimates that respiratory lung infections, (excluding 
tuberculosis and pneumonias in patients with HIV/AIDS) cause more than 6 % of the global 
burden of disease, higher than any other disease category, equating to 3.9 million annual deaths 
worldwide and responsible for 100 million disability adjusted life years (DALYs) [44-46]. Lung 
infections disproportionately burden low income countries (20 fold increase in respiratory 
related DALYs compared to the rest of the world), where effective methods of prevention and 
primary care are underdeveloped or unavailable [46, 47]. The emergence of novel respiratory 
infections such as H1N1 swine „flu, SARS, and the continuing H5N1 influenza A virus epidemic 
in South East Asia as well as the increasing number of common agents of community and 
nosocomial acquired pneumonias acquiring antibiotic resistance ensures that respiratory 
infections will remain concerning in the future. In this thesis the respiratory viruses influenza 
and RSV will be studied in greater detail 
 
1.3.1  Influenza and RSV 
Influenza and RSV are both enveloped, negative strand RNA viruses which cause acute and 
normally self limiting respiratory disease. RSV infects all infants at least once within the first 
three years of life and in 2005 was estimated to cause 66,000–199,000 deaths in children under 5 
with 99% of these deaths occurring in developing countries [48, 49], whilst influenza epidemics 
can affect 10-20 % of the global population [50]. Re-infection throughout life is common to 
both viruses. Influenza induces strong long term immunity, but antigenic variation in the 
haemagglutinin (HA) and  neuraminidase (NA) epitopes allows evasion of pre-existing 
neutralising antibodies, causing seasonal epidemics due to antigenic drift and occasional 
pandemics due to antigenic shift. RSV re-infection is not well understood and occurs 
independently of strain variation and the presence of neutralising antibodies [51]. Influenza is 
significantly more pathogenic than RSV due to the cytopathic effect of high titre lytic burst 
from infected cells, which allows viral propagation. The lytic burst  of RSV occurs at lower titre, 
and the virus can spread through tight junctions and the formation of syncytia [51]. With the 
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important exception of pandemic influenza, severe infection from RSV or influenza is normally 
limited to the very young, old or immunocompromised. 
Table 1.1: Comparing the viral features and infectious routes of RSV and influenza 
virus  
References from [51] or as stated in the text.  
 
1.3.2  The immune response to respiratory infections 
Respiratory infectious agents include viruses, bacteria, fungi and parasites. Although the 
architecture of the immune response to each pathogen is distinct, in simplistic terms a similar 
cascade of events typically occurs.  
Firstly in order to initiate infection, respiratory pathogens must overcome both physical (cilial 
clearance, mucus, laryngeal particle size exclusion) and chemical (antimicrobial and 
immunomodulatory peptides) barriers. Once established in the respiratory tract, pathogens and 
Influenza RSV
Viral features and infection
Family Paramyxoviridae Orthomyxoviridae
Structure Enveloped, negative strand 
RNA virus, encoding 8 
genes and 10 viral proteins
Enveloped negative strand 
RNA virus, encoding 10 
genes and 11 viral proteins
Subtypes and subgroups 3 subtypes A (human and 
animals) B, C (human)
2 subgroups, A and B
Hosts Human, swine, avian Human (h RSV ), bovine (b 
RSV)
Infectious route Nose, mouth, eye Nose, mouth, eye
Transmission droplet droplet
Infects Epithelial cells Epithelial cells
Attachment protein HA, CD200? F-protein
Adheres to: Sialic acid Nucleolin? TLR-4?
Cellular release and spread Lytic burst at high titre Lytic burst at lower titre, 
and through tight junctions 
to form syncytea
Virulence factors Highly virulent avian strains 
display self cleaving HA, 
bypassing attachment to 
sialic acid, and allowing 
systemic infection.
Strain independent
Chapter 1: Introduction  30 
 
infected cells are detected by pattern recognition receptors (PRRs) expressed by innate immune 
and structural cells, principally epithelial cells, DCs and AMΦ. The mammalian immune system 
has evolved a number of effective anti-microbial strategies, (including phagocytosis and the 
lysis and engulfment of infected or dying cells, complement induction and the production of 
cytotoxic chemicals). Signalling through PRR signalling cascades results in the secretion of a 
specific cytokine milieu which ultimately dictates which cell types are recruited to the lung, 
and their differentiation/activation on arrival; thereby initiating the most effective immune 
clearance mechanism for a particular pathogen. Key classes of PRRs and the pathogen associated 
molecular patterns (PAMPs) they respond to are summarised in Table 1.2.  
Table 1.2: Pattern recognition receptors 
 
 
 
PRR PAMP responded to: Cellular location
TLRs TLR-1 Bacterial lipoproteins  Cell membrane
TLR-2 Lipoteichoic acid Cell membrane
TLR-3 dsRNA Endosome
TLR-4 Certain viral proteins, 
Lipopolysaccharide (LPS)
Cell membrane
TLR-5 Flagellin Cell membrane
TLR-6 Bacterial lipoproteins Cell membrane
TLR-7 ssRNA Endosome
TLR-8 ssRNA Endosome
TLR-9 CpG DNA Endosome
RLRs RIG-1 Short dsRNA, ssRNA Cytoplasm
MDA-5 dsRNA Cytoplasm
NLRS NOD-1 Peptidoglycan Cytoplasm
NOD-2 Muramyl dipeptide Cytoplasm
NLRC4 Flagellin Cytoplasm
NLRP3 Bacterial RNA, viral RNA and DNA, bacterial 
cell wall components
Cytoplasm
Pattern recognition receptors (PRRs) fall into three broad categories, Toll- like receptors 
(TLRs) Retinoid acid inducible gene (RIG)I like receptor (RLRs) and nucleotide 
oligomerisation domain NOD-like receptors (NLRs). These recognised conserved features 
of typical pathogens or pathogen associated molecular patterns (PAMPs)
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The negative regulation imparted on AMΦ during homeostasis is overcome by TLR 
ligation and their subsequent activation. Epithelial expression of CD200 is also reduced, which 
releases the airway macrophages from inhibition via CD200R [52]. The inhibition of T cell 
responses by alveolar macrophages is overcome by pro-inflammatory cytokines such as GM-
CSF and TNFα [53, 54]. Once activated, alveolar macrophages display a greater phagocytic 
capacity [55], with a higher oxidative burst and pro-inflammatory cytokine production [56].  
DCs are resident within the pulmonary interstitium below airway epithelial cells and 
extend dendrites between airway epithelial cells, making them strategically placed to sample 
airway antigen [57-59]. Four distinct subsets of respiratory DCs have been studied extensively 
in rodents [60]. Two resident mature respiratory DC subsets are defined as MHCII-hi, CD11c-
hi, and differentiated by the expression of CD103 and CD11b. Activated CD103+ respiratory 
DCs produce moderate levels of pro-inflammatory mediators, whereas CD103-CD11b-
hi respiratory DCs are major chemokine producers in response to pulmonary inflammation [61, 
62]. Monocyte derived DCs (CD11c-low, MHCII-low) are more abundant than mature DCs, 
they are poor activators of naïve T cells, but may serve as precursors to replenish the pool of 
mature respiratory DCs [63]. Plasmacytoid DCs (pDCs) are the fourth category of respiratory 
DCs. They are an unconventional population and are recognized as major producers of type I 
interferons (IFNs) during infection. Although they can also transport antigens from the infected 
lung to the draining lymph nodes, they are weak activators of naïve T cells due to low-level 
expression of co-stimulatory ligands [62]. 
Respiratory infection triggers antigen uptake and activation of APCs resulting in their 
mobilisation and migration out of the lung into the draining lymph node [64]. Primarily this 
process is undergone by DCs however recent evidence indicates that AMΦ can migrate from 
the lung to the draining lymph nodes at homeostasis and can also serve as antigen carriers 
following bacterial infection [65], although their role in the induction of adaptive immune 
responses in the draining lymph nodes is currently unclear [62]. 
The lymph node is designed to maximise the efficiency of specific cell interactions and 
concentrate viral antigens at a site where extremely rare virus-specific adaptive immune cells, 
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such as naïve and memory T cells can encounter their cognate antigens [66].  Following their 
encounter with APCs in the draining lymph nodes, naive (and memory) antigen specific T cells 
undergo a stepwise process of activation, proliferation and differentiation to become effector 
cells that can migrate to the lung and mediate pathogen clearance. Activation and propagation 
of lymphocyte populations can also occur in situ in the lung itself generating inducible 
bronchial associated lymphoid tissue (iBALT) [67]. Again, the specific cytokine environment 
that surrounds lymphocyte activation will dictate a differentiation pathway, to both maximise 
pathogen clearance by adaptive immune cells, and initiate effective memory against subsequent 
attacks.  
Excessive immune infiltrate causes immunopathology to the delicate structure of the 
lung, and for this reason the balance between initiating an effective immune response to clear 
the pathogen, and limiting excessive inflammation is particularly crucial in the airway. In this 
thesis the immune responses to influenza and RSV viral infections will be studied in more 
detail. 
1.3.2.1  The immune response to respiratory viruses: influenza and RSV  
Following challenge with either RSV or influenza virus the immune system mounts an 
immediate response to restrict viral replication and limit the associated cytopathology. Infected 
cells activate a host of transcription factors, including NFKB (nuclear factor-kb) IRFs 
(interferon regulatory factors) and NF-IL-6 (nuclear factor of interleukin-6), that co-ordinate 
the release of pro-inflammatory cytokines and chemokines that subsequently initiate antiviral 
defences [68]. Infected epithelial cells primarily release RANTES MCP-Q and IL-8, whereas 
monocytes/macrophages secrete MIP-1α, MIP-1β, RANTES, MCP-1&3 IFNα/β, TNFα IL-6 and 
IP-10 [69]. These soluble mediators activate adjacent CD45− parenchymal cells, such as 
fibroblasts and epithelial cells, and neighbouring innate immune cells. Following activation, 
these cells convert latent TGFβ to an active form, resulting in increased secretion of the 
chemokines CCL2 and CCL20 by parenchymal stromal cells and of cytokines such as IL-12 and 
TNF by inflammatory cells (reviewed in [62]).   
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The plethora of chemokines released ultimately favours the recruitment of blood 
mononuclear cells to the site of infection and their differentiation into phagocytotic 
macrophage. NK cells, in addition to their cytotoxic function, also contribute to the cytokine 
milieu releasing IFNγ TNFα and GM-CSF, all of which activate APCs [68]. Neutrophils are also 
recruited and their numbers reflect the virulence and dose of virus. In the early stages of the 
response IFNα/β is critical in the containment and resolution of influenza infection due to 
direct anti viral effects, and potential to mediate further recruitment of inflammatory cells [70, 
71]. A successful type I interferon response is absent from the immune response to RSV due to 
viral encoded NS1 and 2 proteins which inhibit downstream IFN signalling cascades [72].  
Anti-viral adaptive immune response is initiated by the uptake of antigen by respiratory 
DCs. Multiple mediators including CCL21, CCL5, CCL20 and CCL2 are involved in their 
activation and subsequent migration out of the lungs along chemokine gradients of CCL21 and 
sphingosine-1-phosphate (S1P) to the lymph nodes draining the infected lung [64, 73]. 
Migrating CD103+ respiratory DCs reach maximum numbers in the draining lymph nodes at 2-
4 days following viral infection and serve as the most potent APCs for naïve, virus-specific 
CD8+ T cells early in the response to an active infection [63, 74]. Once in the lymph nodes, 
these DCs participate in initiating adaptive immune responses to the respiratory virus [75, 76]. 
Three principal effector mechanisms are utilised by conventional CD4+ and CD8+ anti-
viral T cells. T cells can induce tumour necrosis factor receptor (TNFR) family-dependent 
apoptosis of infected cells by expressing CD95 ligand or TNF-related apoptosis-inducing ligand 
(TRAIL) Secondly, T cell-associated lytic mechanisms that promote the lysis of infected cells 
following the exocytosis of perforin- and granzyme-containing granules. Finally T cells can 
produce pro-inflammatory and regulatory mediators in response to encounter with virus-
infected cells which further propagate or restrain the immune response (reviewed in [62]). 
Unconventional T cell populations including γδT cells, Th17 cells, T regs and Th22 cells have 
all been shown to play a role in anti-viral immunity and immunopathology in the lung, but will 
not be discussed here.    
Additionally influenza infection results in a robust and multifaceted humoral immune 
response. Neutralising antibodies to key antigenic viral proteins (HA and NA) can suppress 
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early viral replication, help clear the infection, aid in tissue repair and are long lived preventing 
subsequent re-infection. Natural IgM antibodies can also assist in the initial prevention of 
infection (reviewed in [77]). The role of the humoral immune system in response to RSV 
infection is less clear. Motavizumab, humanised monoclonal antibodies directed against an 
epitope in the A antigenic site of the F (fusion) protein in RSV, can prevent viral cell entry and 
reduce hospitalization due to RSV by 50 % when given to vulnerable infants [78, 79]. This 
passive immune protection suggests that naturally produced neutralising antibodies should be 
efficient against RSV re-infection. However although primary infection seems to lead to robust 
antibody protection, re-infection is common. IgM protection against RSV is also thought to be 
poor [80].  
Table 1.3: Comparing the immune response to RSV and influenza virus 
 
 
Influenza RSV
Host immune response
Features of innate immunity High type 1 IFN response Low type 1 IFN response, 
due to encoded interference 
proteins
Features of adaptive 
immunity
Immunopathology 
associated with CD8 T cell 
recruitment
Immunopathology 
associated with TH2 T cell 
recruitment.
Long term immunity Immunity is long lasting, 
but antigenic variation in 
the dominant epitopes (HA 
and NA) allows evasion of 
pre-existing neutralising 
antibodies, causing seasonal 
epidemics and occasional 
pandemics
No long lasting immunity, 
poor IgM production
Symptoms of severe disease Fever and cough Cough, rhinorrhea, 
dyspnoea
Vaccine Vaccines against seasonal 
strains have high efficacy
None although passive 
immunity generated by pre-
emptive antibody treatment 
is effective 
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1.3.2.2  Balancing the immune response to viral infection: 
The careful balance between effective anti viral immunity and overzealous immunopathology is 
typified by the immune response to these viruses. Human studies show that immune 
deficiencies correlate with increased disease severity following either RSV of influenza 
infection. For example, a study looking at fatal cases of RSV and influenza, concluded that 
infants died as a result of uncontrolled viral replication, ineffectual innate responses and a 
failure to develop an adaptive immune response [81]. Additionally single nucleotide 
polymorphisms in genes involved in the innate immune response such as TLR4, IFNA5 and 
NOS2 are most associated with increased RSV disease severity [82, 83]. 
However in animal models of both infections, disease severity correlates closely with 
immune infiltrate into the airway, which peaks several days after peak viral load and often after 
viral clearance (Figure 1.3 - taken from [84]). This suggests that excessive immunopathology 
may contribute more to disease severity than viral cytopathology. Indeed many anti-
inflammatory strategies have proved successful in limiting disease severity without hindering 
viral clearance, or the induction of efficient immunological memory (influenza only). For 
example, OX40 signalling in T cells delivers a pro-survival signal that leads to clonal expansion 
of both CD4+ and CD8+ T cells. Blocking this interaction during an influenza infection reduces 
T cell proliferation in the airway, reducing immune infiltrate into the lung, and thereby 
reducing disease severity without preventing viral clearance [85]. Other anti-inflammatory 
strategies such as TNF blockade and antibody agonism of the CD200R regulatory signal during 
influenza infection similarly reduce disease severity [31, 86]. In models of RSV infection, 
weight loss (a good measure of disease severity) can be abrogated by depleting CD8+ T cells or 
NK cells during infection [87, 88]. Interestingly in RSV infection the nature of the adaptive 
immune response to the virus is also seen to play a role in immunopathology, with Th2 skewed 
responses associated with worse outcome (reviewed in [84]). 
 Although human experiments investigating anti-inflammatory strategies to respiratory 
viruses are yet to be realised, the role of immunopathology in human viral lung disease is now 
widely recognised with „cytokine storm‟ attributed as a significant cause of mortality during the 
influenza pandemic of 1918 and the 1997 H5N1 bird‟ flu outbreak [89]. 
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Figure 1.3: The murine immune response to RSV or influenza infection 
 
 
1.3.2.3  Resolution from viral infection: is homeostasis resumed? 
Following successful viral clearance the immune system initiates resolution and repair 
processes, aiming to clear inflammatory cells from the airway and orchestrate tissue repair to 
restore normal lung architecture. Extensive evidence in animal models suggests that the lung 
does not always return to its original homeostatic state, and differences in the cellular 
populations of the airway can persist for long periods after influenza infection. Few studies have 
characterised altered homeostasis following RSV infection, hence this is a key topic investigated 
in this thesis (see Chapters 4 and 5). 
AMΦ in resolution: For long periods following influenza infection AMΦ express higher levels 
of the negative regulator CD200R and also display broad TLR desensitisation with reduced or 
impaired NFκB translocation following TLR antagonism [31, 90]. The more regulated nature of 
AMΦ in resolution is in part attributed to their role in the efferocytosis of inflammatory cells 
during the contraction phase of the immune response to influenza infection. In contrast to the 
phagocytosis of pathogen, the ingestion of apoptotic cells causes anti-inflammatory changes to 
the phagocyte, for example the liberation of suppressive cytokines such as TGFβ, prostaglandin 
E2 (PGE2) and platelet activating factor (PAF), presumably to limit the induction of self-
Taken from Openshaw and Tregoning: 2005  
Days post infection
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directed inflammation. In the airway, clearance of apoptotic cells by AMΦ causes the release of 
TGFβ, IL-10 and prostaglandins, while reducing the production of pro-inflammatory cytokines 
and chemokines [91-93]. Subsequent to the efferocytosis of apoptotic cells the airway is less 
responsive to LPS challenge, and the ability of AMΦ to phagocytose invading bacteria is also 
diminished [94, 95]. Apoptotic cells express CD200, and their interaction with CD200R on 
AMΦ during efferocytosis could perhaps explain the downstream regulation of these cells in 
resolution [32].  
Other cell types in resolution: Elevated numbers of DCs remain in the lung for several weeks 
after influenza infection and have an altered phenotype- they are less efficient at presentation 
of antigens, but instead produce lymphotoxin-β and homeostatic chemokines that maintain the 
tertiary lymphoid tissue, iBALT [96]. Treg numbers are also elevated for prolonged periods 
following influenza infection. These cells secrete IL-10 (present at 50 fold higher levels in 
resolved airways [97, 98]) and limit the activity of effector cells via interference with the IL-2 
axis. The suppressive effects of T-regs on the airway environment are important in the 
resolution of inflammation, but may also impair the response to subsequent challenge. In 
humans T reg numbers are second only to underlying illness in predicting the onset of H1N1-
virus-related pneumonia [99]. 
Epithelial cell repair: Given the importance of epithelial cells in maintaining appropriate airway 
homeostasis, the second key event in lung resolution after clearance of inflammatory cells, is 
the replenishment of damaged epithelial cells. This is in part achieved by type II pneumocytes 
which serve as local stem cells and is facilitated by other airway cells which secrete 
proliferation inducing cytokines such as Macrophage-derived hepatocyte growth factor [100]. 
Given the changes to the cellular populations (listed above) which facilitate this process, it is 
perhaps unsurprising that replenishment and repair or epithelial cells is thought to impaired 
following influenza infection [3]. 
Altered immunity in resolution: Although the full extents of the airway alterations which occur 
in resolution remain to be fully characterised, plentiful studies exist describing an altered 
immune responsiveness following an inflammatory airway event. Changes in the quality of the 
innate immune response to subsequent challenge have been termed „innate immune imprinting‟ 
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[90, 101]. For example anti-viral responses to RSV are impaired following a previous influenza 
infection [102]. Additionally both viral and bacterial infections are exacerbated following non-
viral inflammatory events such as asthma or chronic obstructive airway disease (COPD). 
Relevant to this thesis, respiratory viral infections are known to predispose the lungs to the 
development of secondary bacterial complications.  
 
1.4:  Virus-induced susceptibility to secondary bacterial 
infection 
Viruses which infect the lung, including influenza and RSV, are increasingly recognised as 
triggers of secondary bacterial infection which inevitably worsens disease outcome [103, 104]. 
In the vast majority of cases the causative agents of secondary bacterial pneumonias are 
opportunistic bacteria, harboured as part of the normal commensal load, including 
Streptococcus pneumoniae, Haemophilus influenzae and Staphylococcus aureus [105, 106]. 
Despite the extensive epidemiological and experimental evidence supporting a strong 
association between pulmonary viruses and secondary bacterial infections (reviewed in [107]), 
the causality of the link is poorly understood. For many years it was believed that the loss of 
epithelial integrity during viral infection was the primary contributing factor [108]. However, 
unpublished studies using chemotherapy agents to replicate lung injury show that epithelial 
damage alone is unlikely to account entirely for the level of vulnerability to bacterial super-
infection seen after viral infection [109]. Many synergistic events between individual viruses 
and specific bacterial species have been investigated, (For example: rhinovirus causes up-
regulation of H. influenzae adherence factors whilst RSV causes a reduction in specific 
antimicrobial peptides [110, 111]), but fail to explain the universal nature of this phenomenon. 
Recently attempts have been made to address the problem from the perspective of an innate 
immunological rheostat, whereby viral infections qualitatively alter the ability of the immune 
system to respond to subsequent challenge [107]. 
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1.4.1:   The innate immune rheostat  
The threshold of activation of the innate immune system is site specific. As discussed 
previously, in order to avoid unnecessary inflammation to innocuous antigen, mucosal surfaces, 
such as the airway and gut, are more immunologically repressed than their sterile compartment 
counterparts like the spleen and blood [31]. These regulatory interactions must be overcome for 
inflammation to occur. During resolution from severe inflammation, in order to return to the 
regulated homeostatic state, there is a period of heightened regulation characterised by 
increased CD200R expression and TLR desensitisation on AMΦ, and a 50 fold increase in IL-10 
expression [31, 90, 98], potentially initiated by the suppressive effect of efferocytosis of 
apoptotic cells [95](Figure 1.4). This immunologically suppressive environment contributes to 
resolution of inflammation and prevents overzealous responses to subsequent infections but 
may also predispose the lungs to opportunistic secondary bacterial infection [107].  
Figure 1.4:  The innate immune rheostat 
 
At homeostasis, AMΦ are prevented from responding to innocuous antigen by regulatory 
receptors (IL-10 receptor, TGFβ receptor and CD200R) (A), which must be overcome for 
inflammation to occur (B). During resolution from inflammation, in order to return to the 
original homeostatic state, there is a period of heightened regulation characterised by 
increased IL-10 and CD200R expression and TLR desensitisation, perhaps due to the 
regulatory signals initiated by the efferocytosis of apoptotic cells (C).
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1.4.2:  Influenza and RSV: triggers of secondary bacterial complication 
With the important exception of pandemic influenza, severe infection from RSV or influenza is 
normally limited to the very young, old or immunocompromised. However it is increasingly 
recognised that when severe disease does occur, it is often complicated by secondary bacterial 
infection. A recent reanalysis of necropsies from victims of the 1918 influenza pandemic 
showed that only 2-7% were free of secondary bacterial infections, whilst in 20% of victims, 
two or more bacterial species were identified [112], suggesting that although pneumonia was 
the most prominent clinical feature of the epidemic, bacterial super infection was the primary 
cause of death (Figure 1.5- adapted from [113]). In addition, the majority of hospitalisations 
caused by more recent influenza outbreaks of 1957, 1968, and 1995 and recent cases of avian 
influenza were more frequently due to secondary bacterial pneumonia [114-117]. Whilst during 
the recent swine „flu pandemic bacterial co-infection was diagnosed in 20 to 24 % patients 
admitted to intensive care and in 26 to 38 % of patients who died [118].  
Limited invasive studies of neonates, (the demographic most susceptible to severe RSV 
infection), means that the true incidence of secondary bacterial complications following RSV 
are likely to be under-reported. Even in large epidemiology studies the causative agents of 
pneumonia are only identified in 20-50% of children [119]. However, in retrospective studies, 
1-3% of RSV bronchiolitis cases are complicated by bacterial super infection [106, 120, 121] and 
seroepidemiological studies demonstrate that of all hospitalised children with pneumococcal 
infection, 25-30% have evidence of concurrent RSV [120]. In addition both RSV and influenza 
infection pre-dispose children to recurrent and acute otitis media [122, 123].  
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Figure 1.5:  Influenza infection is followed by secondary bacterial complications 
 
Numerous in vivo animal models of influenza co-infection have highlighted several 
synergistic interactions between influenza virus and respiratory bacterial pathogens [109, 124]. 
The epithelial damage caused by the lytic nature of the replicating virus, is believed to allow 
bacteria access to otherwise inaccessible lung compartments. Histopathological studies during 
the 1957/59 Asian influenza pandemic suggested bacterial specifically adhered to areas of viral 
cytotoxicity [125].  
Another principle concept is the alteration of cell surface receptor profiles and adhesion 
proteins in response to influenza infection. Influenza viruses possess neuraminidase (NA), 
which cleaves terminal sialic acid residues on host cell glycoprotein‟s allowing the release of 
viral particles. Exogenously administered NA increases the adherence of S. pneumoniae in vitro 
[126], and administration of NA inhibitor prevents secondary bacterial infection [127]. 
Secondary bacterial pneumonia was the major cause of death during the 1918 Spanish „flu 
pandemic. The graph above is based upon medical records from an army camp in the UK. 
(Adapted from Brundage et al., 2006). 
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Resultantly it has been postulated that NA acts as a bacterial adhesion protein for S. 
pneumoniae. 
Preceding influenza infection also skews the immune system leading to immune 
dysfunction. Numerous models provide evidence for viral-induced leucopoenia and 
granulocytopenia in bacterial co-infection models [128, 129]. In contrast, other experimental 
models demonstrate viral-induced leukocytosis whereby large numbers of activated 
neutrophils, macrophages and inflammatory mediators in the lung exacerbate tissue damage, so 
although cellular infiltrate is increased the functional capabilities necessary for bacterial 
clearance may be altered [130, 131]. In recent research, secondary bacterial complications 
following influenza infection have been linked to reductions in neutrophilic chemotaxis, 
survival, phagocyte function, degranulation, respiratory burst, and intracellular killing of 
bacterial pathogens [128, 132-134], and reduced neutrophil recruitment [90] [135] due to a 
viral-driven type 1 IFN reduction of appropriate chemokines (reviewed in [3]). Furthermore, 
IFNγ induced during influenza infection decreases bacterial scavenger receptors such as 
MARCO on macrophages [136], clearance of apoptotic cells by macrophages reduces their 
bactericidal capacity [91, 92, 95], and influenza infection reduces NK cell responses and 
antibacterial IL-17 responses [137, 138].   
Fewer models exist of RSV co-infection, but in the chinchilla model of otitis media, RSV 
alters expression of anti-bacterial peptides leading to increased commensal carriage, and likely 
promotion of otitis media [111], whilst in the mouse model, RSV co-infection increases 
inflammation in the airway and alters neutrophil function [139]. 
Two causative agents of secondary bacterial pneumonia, H. influenzae (Hib) and S. 
pneumoniae will be studied in more detail in this thesis. 
1.4.3:   S. pneumoniae and Hib 
1.4.3.1:  S. pneumoniae and Hib epidemiology 
S. pneumoniae and Hib are both opportunistic, commensal organisms which primarily colonise 
the nasopharyngeal mucosa of the human respiratory tract [140, 141]. Carriage amongst the 
general population is high; 63% of under fives carry Streptococcal species [142], whilst 
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approximately 80% of healthy individuals in the general population carry Haemophilus species 
[143]. Carriage alone is not normally associated with detrimental pathology, but both species 
are opportunistic causing minor diseases such as otitis media and sinusitis, and severe disease 
including invasive pneumonia, septicaemia and meningitis. Despite the development of 
effective vaccines to both bacteria, severe disease burden remains high particularly in low 
income countries, with recent estimates suggesting that S. pneumoniae and Hib are responsible 
for as many worldwide child deaths as HIV/AIDS, malaria and tuberculosis combined [144, 
145].  
Whether carriage is a pre-requisite for the development of severe disease, or whether 
disease results from the acquisition of unseen bacterial serotypes, remains debatable [146-148]; 
however, the young, old and immunocompromised are at greater risk of developing severe 
disease, as are those with a proceeding viral trigger, of which influenza is the most studied.  In 
the 1918 influenza pandemic S. pneumoniae was present in 22 % of victim necropsies, whilst 
Haemophilus species were found in 11 % [112]. In fact the name „H. influenzae‟ is attributed to 
the fact that Hib was mistakenly thought to be the causative agent of „flu before influenza 
viruses were identified in the early 20th century [149].  
1.4.3.2:  Virulence and immunity to S. pneumoniae and Hib 
Whilst S. pneumoniae is gram positive and Hib gram negative, both bacteria rely on the 
presence of a polysaccharide capsule as their primary means of immune evasion by preventing 
opsonophagocytosis in the naive host [150, 151]. Unencapsulated S. pneumoniae is 100,000 
times less virulent [152], whilst unencapsulated H. influenzae strains (Non-typable 
Haemophilus influenza) are less pathogenic, and are more commonly found in the commensal 
flora of healthy individuals [153]. S pneumoniae also expresses an exotoxin, pneumolysin. Other 
virulence factors are summarised in Table 1.4. Components of the classical pathway of 
complement activation are essential for effective clearance of both S pneumoniae and Hib, 
whilst the expression of TLR-2 and TLR-4 (and NOD-1 for Hib), are essential for the 
development of a protective immune response [154-157]. In both bacterial infections the 
downstream consequences of TLR signalling, namely neutrophil recruitment, is important for 
clearance [158, 159], but also adds to the immunopathology associated with severe pneumonia 
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[160-162]. For both bacterial species the role of the adaptive immune system in primary 
infection remains to be fully elucidated.  
Table 1.4: Comparing S. pneumoniae and Hib infection, and the resultant host 
immune responses 
 
S. pneumoniae Typable H. influenzae
Bacterial features and 
infection
Gram stain Gram positive Gram negative
Shape Diplococcus Coccobacillus
Respiratory requirement Fermentative aerotolerant 
anaerobe
Facultative anaerobe
Encapsulated Yes
Multiple polysaccharides
Yes
Polyribosylribitolphosphate 
(PRP)
Serotypes 92 6 (A,B,C,D,E,F, with B being 
the most virulent)
Exotoxin production Yes - pneumolysin No
Other virulence factors Exoglycosidases 
(neurominidase, IgA 
protease), adhesion molecules
Exoglycosidases 
(neurominidase, IgA protease)
Adhesion to: Rpaf on epithelial cells, and 
extracellular matrix 
components Fibrinogen , 
Plasminogen
Carcinoembryonic Antigen 
Related Cell Adhesion 
Molecules (CEACAMs) on 
epithelial cells
Host immune response
PRRs TLR-2, TLR-4 TLR-2, TLR-4, NOD-1
Features of innate immunity Complement mediated 
(classical pathway) 
phagocytosis.
Neutrophil clearance strain 
dependant
Both classical and alternative 
complement pathways 
important.
Phagocytosis primarily by 
neutrophils
Features of adaptive 
immunity
Th1 cytokines (IL-12), CD4+ 
T cells important for bacterial 
clearance.
High level of CD4+ T cells and 
CD8+ T cells, early induction 
of both Th 1 and Th2 
responses.
Long term immunity Good, IL-1β, Il-6, TNFα, IL-
12, IFNγ individually regulate 
antibody production
Good
Vaccine Glycoconjugate vaccine 
against capsular 
polysaccharide, high efficacy
Glycoconjugate vaccine 
against capsular 
polysaccharide, high efficacy
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1.5: microRNA (miRNA) 
miRNA act as post transcriptional regulators of gene expression. They were discovered in 1993 
by Victor Ambros, Rosalind Lee and Rhonda Feinbaum during a study of developmental 
pathways in C. elegans [163]. Initially thought to be an idiosyncrasy of nematode gene 
expression, it was not until the discovery of let-7 in 2000 and the subsequent finding that this 
miRNA was conserved in higher life forms that their global importance was realised [164]. 
Current estimates suggest miRNAs account for greater than 3 % of all human genes, which 
together regulate a large fraction of the transcriptome [165].  
1.5.1:  miRNA biogenesis and control of gene expression 
miRNA are transcribed as primary transcripts (pri-miRNAs) by RNA polymerase II. Within the 
cell nucleus, their distinctive hairpin containing secondary structure is recognised by Drosha, 
an RNaseIII type endonuclease and its partner DGCR8. This microprocessor complex cleaves 
the pri-miRNA to form a 70-nucleotide stem loop known as the precursor miRNA (pre-
miRNA). Pre-miRNAs are then actively exported to the cytoplasm by exportin 5. In the 
cytoplasm pre-miRNA are recognised by Dicer, another RNase III type endonuclease and TAR 
RNA-binding protein (TRBP). Dicer cleaves the pre-miRNA generating a 15-22 nucleotide 
mature miRNA duplex. In general only one strand is selected as the biologically active miRNA 
and the other is degraded. The mature miRNA is loaded into the RNA-induced silencing 
complex (RISC), which contains the mature miRNA and Argonaut (Ago) proteins. Target 
recognition is achieved through partial sequence complementarity between the seed sequence 
(2nd to 8th nucleotide) of the mature miRNA and the seed match sequences in the 3‟ untranslated 
region (UTR) of target mRNAs ([165] and references therein). 
 The binding of RISC to target mRNA can inhibit the expression of target mRNA through 
two main mechanisms Firstly deadenylation which involves removal of the polyA tail of target 
mRNA by fostering the activity of deadenylases like CCR4-NOT. This leads to mRNA 
degradation. Secondly the blockade of translation either at the initiation step or the elongation 
step; for example by inhibiting eukaryotic initiation factor 4E (EIF4E) or causing ribosome 
stalling. RISC bound mRNA can be localised to sub cytoplasmic compartments, known as P-
bodies, where they are reversibly stored or degraded ([165] and references therein). 
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Additionally in certain situations, particularly in cell cycle arrest, as opposed to active 
proliferation, certain miRNA such as let-7 will act as activators of gene translation rather than 
repressors [166]. miRNA biogenesis and control of gene expression is summarised in Figure 1.6.  
 The degree of target down-regulation imposed by miRNA tends to be quantitatively 
modest, even over expressed miRNA typically only down-regulate targets by less than 50 % 
[167]. However regulation imposed by miRNA tends to be sharply dose dependant and each 
miRNA has the potential to control the expression of vast number of genes (let-7b has over 
8000 putative targets in the human genome [168]). For this reason they are well placed to affect 
the global responsiveness of cells to signalling molecules. As such they can act as „fine tuners‟ or 
act as nodes of signalling networks to carry out multifaceted outputs like maintaining 
homeostasis, or regulating developmental pathways.  
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Figure 1.6:  miRNA biogenesis and regulation of gene expression 
 
 
 
 
 
miRNA are transcribed 
as hairpin containing 
primary miRNA (pre-
miRNA). Processing by 
Drosha and DGCRB 
produces precursor 
miRNA (pre-miRNA). 
These are exported into 
the cytoplasm by 
Exportin 5, where they 
are processed further by 
DICER and TRBP to 
form mature miRNA. 
These combine with 
Agonault proteins to 
form the RNA-induced 
silencing complex 
(RISC). Complementary 
pairing between the 
mature miRNA and 
target sequences in the 
3‟ UTR of potentially 
hundred of mRNA leads 
to regulation of their 
expression by 
deadenylation, blocking 
translation initiation or 
elongation, by targeting 
to P-bodies, or 
increasing their stability. 
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1.5.2:   miRNA regulation of inflammation 
Recent studies highlight the importance of post transcriptional control of gene expression in 
orchestrating the immune response. For example differential mRNA stability imparts temporal 
control on the immune response to TNF stimulation (Figure 1.7- taken from [169]).  
Figure 1.7: Intrinsic mRNA stability helps compose the inflammatory symphony 
 
It is unsurprising that miRNAs are increasingly shown to have unique expression 
profiles in cells of the innate and adaptive immune systems and have pivotal roles in the 
regulation of both immune cell development and in directing the immune response (reviewed 
in [170]). Although the story is far from complete, many direct roles have been identified for 
particular miRNAs and some pathways such as the TLR signalling pathway have been 
particularly investigated. For example miR-146, miR-9, miR-21 and miR-155, are induced by 
TLR signalling and then negatively regulate the activation of inflammatory pathways in 
myeloid cells (reviewed in [170, 171]). miR-146 directly represses several signalling molecules 
that are down stream of TLRs including IL-1R-associated kinase (IRAK1), IRAK2, and TNFR-
associated factor 6 (TRAF6). Whilst miR-9 represses NFκB and helps maintain a constant level 
In response to TNF, fibroblasts and macrophage transcribe mRNAs that encode proteins 
which regulate the initiation, propagation and resolution of inflammation. These transcripts 
are in three distinct classes that differ in their induction kinetics: those in class I (pink) are 
expressed early and disappear rapidly; those of class II (blue) are expressed later and disappear 
slowly; and those of class II (purple) are expressed even later and persist. The proteins encoded 
by these transcripts are involved in early, intermediate and late events in inflammation. These 
differences in expression kinetics are due mainly to different rates of mRNA decay. Figure 
taken from Paul Anderson, Nature Immunology, News and Views 2009.
49  Chapter 1: Introduction 
 
of NFκB protein expression during TLR-4 mediated activation of monocytes and neutrophils 
[171]. A summary of the current understanding of miRNA control of TLR signalling is 
presented in Figure 1.8, taken from [171]. 
Figure 1.8: miRNA control of TLR signalling 
 
TLR activation induces the sequential expression of specific miRNA that control the strength 
and longevity of the resultant inflammatory response.  miR-155 is strongly induced upon TLR 
signalling, and is proposed to enhance pro-inflammatory responses by the inhibition of negative 
regulators such as Src homology 2 (SH2) domain containing inositol-5 phosphatase 1 (SHIP1) 
and suppressor of cytokine signalling 1 (SOCS1), the promotion of cytokine signalling and the 
subsequent induction of an adaptive immune response. The down-regulation of let-7i and miR-
125b could contribute to this effect owing to a lack of repression of their respective targets TLR4 
and tumour necrosis factor (TNF) (A). Later, the induction of miR-146a and miR-9 resolves the 
pro-inflammatory response by targeting TNFR-associated factor 6 (TRAF6) and IL-1R-associated 
kinase 1 (IRAK1), which are key components of TLR signalling pathways, and the nuclear 
factor-κB (NF-κB) subunit p50, respectively. miR-132 expression has also been shown to be 
increased by TLR signalling and would limit the antiviral response by targeting p300 (B). At 
later times, miR-21 is induced and increases IL-10 expression by repressing programmed cell 
death 4 (PDCD4), which might contribute to the induction of an anti-inflammatory response 
through the inhibition of miR-155. miR-147 also promotes an anti-inflammatory response by 
repressing cytokine production (C). Figure taken from Luke O'Neill et al., 2011. Nature Reviews 
Immunology [171].
A   Immediate early response
C   Late response
B   Early response
•Repression of negative regulators (SHIP1, SOCS1)
•Promotion of cytokine expression
•Initiation of adaptive immune response
Pro-inflammatory response
•Repression of 
TLR signalling
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•Repression of 
NFκB p50
Negative regulation of inflammation
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cytokine production
Anti-inflammatory response
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1.6  Thesis objectives  
1)   Develop and characterise viral induced bacterial complication models in mice; using 
influenza or RSV as viral triggers, and assessing their differential effects on co-infection with 
Hib, S. pneumonia or endogenous bacteria. 
In particular to identify: 
a)  Common and divergent features of different infectious models and mouse strains 
b) The longevity of viral induced susceptibility to bacterial complication  
c) To confirm the importance of CD200R and the innate immune rheostat in predisposing the 
lung to secondary complications 
 
2)  Investigate the possible causes of susceptibility to secondary bacterial complication by 
characterising   
a) The longevity and extent of damage following a viral infection. 
b) The cellular changes that occur following viral infection, with particular emphasis on 
changes to the AMΦ population. 
 
3)  Investigate the phenotypic and genetic changes that occur to the AMΦ population 6 
weeks after viral infection and using these findings to manipulate the AMΦ to turn a naïve 
macrophage phenotype into one resembling resolved macrophage and vice versa 
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Chapter 2: Materials and Methods 
2.1:   Mouse strains 
6 to 8 week old female BALB/c and C57BL/6, and for some experiments pregnant females were 
purchased from Harlan Olac Ltd, Bicester UK. The CD200R-/- strain was a kind gift from R. 
Williams (Kennedy Institute of Rheumatology, Imperial College, London). All mice were 
maintained in specific pathogen free conditions ay Bio Safety Level 2 and kept in accordance 
with institutional and UK Home Office guidelines. 
2.1.1:   Plethysmography  
Measurements of dynamic resistance and compliance were performed using a Flexivent system 
(Scireq, Montreal, Canada). After induction of anaesthesia with an intraperitoneal injection of 
sodium pentobarbital (Sigma-Aldrich, UK) at a dose of 50 mg/kg in saline and intramuscular 
injection of ketamine (90 mg/kg), mice were tracheostomized and connected to the flexivent 
ventilator via a blunt-ended 19-gauge needle. Mice were ventilated using the following settings; 
tidal volume of 10 ml/kg body weight, 150 breaths/minute; positive end-expiratory pressure 
approximately 2 cm H2O. Mice were initially ventilated for 5 minutes. Standardization of the 
lung volume history was done by performing two deep inflations. Subsequently, measurements 
of airway function were made. Measurements of resistance and compliance were determined 
from a user defined protocol using the snapshot-150 perturbation, which is a single frequency 
sinusoidal wave at a frequency equivalent to ventilation rate (i.e., 2.5 Hz). Resultant data was 
fitted using multiple linear regression to the single compartment model in the form: pressure = 
resistance × flow + elastance × volume + fitting constant. Fitting the data to this model provides 
readings of resistance and compliance. Changes in resistance and compliance were measured in 
response to increasing concentrations of nebulised methacholine (MCh) from 3–100 mg/ml, 
delivered into the inspiratory line of the flexivent ventilator. 
2.2:  Tissue recovery and sample preparation 
Mice were culled by intraperitoneal (I/P) injection of 3 mg pentobarbitone and exsanguinations 
via the femoral artery. Bronchoalveolar lavage (BAL), lung tissue, spleen, inguinal lymph nodes, 
lung lymph nodes and nasal wash were harvested by methods described previously [172].  
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2.2.1:   Whole blood and serum 
For serum collection, whole blood was allowed to clot at 4 °C. The resultant clot was 
centrifuged at 5000 x g for 8 minutes and the supernatant stored at -80 °C for future analysis. 
Whole blood was collected into tubes containing 50 U heparin/ 80 µl blood. For single cell 
analysis the cell suspension was centrifuged for 5 minutes at 240 x g and red blood cells lysed by 
resuspension of the pellet in ACK buffer (0.15 M ammonium chloride, 1 M potassium hydrogen 
carbonate, 0.01 mM EDTA, pH 7.2) for 8 minutes at room temperature. The final pellet was 
resuspended in R10F (RPMI medium [PAA laboratories] containing 10 % vol/vol foetal calf 
serum (FCS) Sigma-Aldrich, UK), 50 μg/ml streptomycin and 50 U/ml penicillin [both Sigma-
Aldrich, UK]). Cell viability and number was assessed using a haemocytometer with Trypan 
Blue exclusion. 
2.2.2:  Whole organ extraction and isolation of single cell suspensions 
Lung, spleen, inguinal lymph node and mediastinal lymph node were dissected and either:  
1) Frozen immediately in liquid nitrogen for future analysis. 
2)  Collected into R10F, and passed through a 100 µm sieve (BD labware, New Jersey, USA) 
when single cell suspensions were required. 
3)  Finely chopped and incubated for 30 minutes at 37 °C with 2.5 mg/ml Liberase (Roche, 
Switzerland) and DNAse grade II (Sigma-Aldrich, UK) in R10F before passage through a 100 µm 
sieve (BD labware, New Jersey, USA) for high cell recovery to allow analysis of rare cell 
populations. 
4)  For isolation of lung endothelial cells 0.13 mg/ml collagenase and 1.25 mg/ml dispaseII 
in 1 ml HBSS (Hanks Basic Salt Solution [PAA laboratories]) was introduced into the lungs via 
an intratracheal cannula. Lung lobes were collected into 2 ml R10F supplemented with 0.13 
mg/ml collagenase and incubated at 37 °C for 30 minutes. 15 ml of sterile PBS was added and 
the suspension vortexed for 30 seconds, before passing through a 100 µm sieve (BD labware, 
USA).   
For 2) 3) and 4), the resultant cell suspension was centrifuged for 5 minutes at 240 x g and red 
blood cells lysed by resuspension of the pellet in ACK buffer (0.15 M ammonium chloride, 1 M 
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potassium hydrogen carbonate, 0.01 Mm EDTA, pH 7.2) for 3 minutes at room temperature. 
Cells were centrifuged again for 5 minutes at 240 x g and the pellet resuspended in R10F. Cell 
viability and number was assessed using a haemocytometer with Trypan Blue exclusion. 
2.2.4:   BAL 
BAL was obtained by inflating the lungs of each mouse 6 times via an intratracheal cannula 
with 1.5 ml Hanks Basic Salt solution (HBSS) with 1 mM EDTA. BAL was centrifuged for 5 
minutes at 240 x g and the supernatant removed and stored at -80°C for further analysis. BAL 
cell pellet was resuspended in R10F for further analysis. Cell viability and number was assessed 
using a haemocytometer with Trypan Blue exclusion. 
2.2.5:   Nasal wash 
Nasal wash was obtained by removal of the lower jaw, and insertion of a nasopharygeal 
cannula. The nasopharyngeal cavity was then washed with 200 µl sterile PBS. 
2.3:   Pathogen stocks 
2.3.1:   Influenza  
Influenza A, Puerto Rico/8/34 (PR8), H1N1 stocks propagated in chicken eggs [173] and stored  
in single use aliquots at <-196 °C, were a kind gift from W. Barkley (National Heart and Lung 
Institute, St Mary‟s hospital, Imperial College London).  
2.3.2:   RSV 
Plaque purified RSV A strain was a kind gift from P. Openshaw (National Heart and Lung 
Institute, St Mary‟s Hospital, Imperial College London).  Viral stocks were generated by 
infecting HEp-2 cell monolayers in 125 ml culture flasks at an MOI of 0.1. 48 hours post 
infection virus was liberated from infected cells by triple freeze thawing. Resultant cell debris 
and supernatant were then stored at < -196 °C.  
2.3.3:  Streptococcus pneumoniae 
Wild type S pneumoniae (serotype 2)strain D39 (NCTC 7466, National Collection of Type 
Cultures, London, UK), a kind gift from J. Brown (Centre for respiratory Research, UCL, 
London) was cultured at 37 °C in 5 % CO2 on blood agar plates or in Todd-Hewitt broth 
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(OXOID) supplemented with 0.5 % yeast extract (OXOID, UK) (THY broth) to an OD600 of 0.4 
(approximately 1 x 108 CFU/ ml) and stored at -80 °C in 10 % glycerol as single use aliquots. 
2.3.4:   Hib  
Hib Eagan strain was a kind gift from P. Langford (Faculty of Medicine, St Mary‟s Hospital, 
Imperial College London). Bacteria were cultured at 37°C in 5 % CO2 in Brain heart Infusion 
(BHI) broth (OXOID) supplemented with 10µg/ml of both Hemin (10ug/ml) and Nictinamide 
adenine dinucleotide (NAD) (Sigma-Aldrich, UK) or on BHI agar (OXOID) supplemented with 
4 % Levinthals when agar was <50 °C. Levinthals was made by adding 50 % horse blood (TCS 
Biosciences) to BHI broth and heating to 70 °C for 45 minutes. On cooling to 50 °C, 0.7 mg/ml 
NAD was added and the supernatant stored at –80 °C. Bacteria were cultured to an OD600 of 0.3 
(approximately 1 x 109 CFU/ml) and stored at -80 °C in 10 % glycerol as single use aliquots. 
 
2.4:   Murine infection models 
2.4.1:   Single infection Models 
Mice were lightly anaesthetised with isoflourane and intranassally (I/N) inoculated with 50 µl 
volumes of either 100 plaque forming units (PFU) PR8, 5x106 - 5 x 105 PFU RSV (as stated in the 
text), 1 x 106 (BALB/c) or 1 x 104 (BL/6) CFU S. pneumoniae, or 1 x 107 CFU Hib. Disease 
severity and weight loss was assessed daily. Mice were culled at pre-determined time points 
post infection, or when deemed to have become moribund (as defined by Home Office awarded 
license requirements) by I/P injection of 3 mg pentobarbitone and exsanguinations via the 
femoral artery. 
2.4.2:   Co-infection models 
Mice were lightly anaesthetised with isoflourane and inoculated I/N with either RSV or 
Influenza (as stated above). At designated time points post viral infection, mice were 
intranasally inoculated with either S. pneumoniae or Hib (as stated above). Mice were culled at 
pre-determined time points post infection or when deemed to have become moribund (as 
defined by Home Office awarded license requirements) by I/P injection of 3 mg pentobarbitone 
and exsanguinations via the femoral artery. 
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2.5:    Determining infectious load 
2.5.1:   Bacterial CFU assay and bacterial identification 
Nasal wash, BAL, single cell lung suspension and whole blood were prepared as in 2.2. Serial 
dilutions of each fluid were transferred to appropriate agar plates (Columbia blood agar plates 
for S. pneumoniae and commensal bacteria, BHI agar with 4 % Levinthals (see 2.24) for Hib, 
and grown overnight at 37 °C with 5 % CO2. Resultant colonies were counted manually. S. 
pneumoniae was confirmed by optochin sensitivity. Hib was confirmed by no growth on BHI 
agar without Levinthals. Crude identification of commensal bacteria was carried out by Gram 
stain, growth on MacKonkeys agar (OXOID), and catalase test (assessing bubble formation by 
bacteria placed on a drop of hydrogen peroxide).  
2.5.2:   Viral PFU assay 
2.5.2.1  Influenza PFU assay 
Influenza titre was assessed from triple freeze-thawed lung homogenate titrated on a Madine 
Darby canine kidney (MDCK) cell monolayer in 96-well, flat bottom plates. 3 hours after 
incubation at room temperature a 1 % methyl cellulose overlay was placed over the cells, before 
incubation for a further 72 hours at 37 °C with 5 % CO2. Cell monolayers were washed with 
PBS, permeabilised with 0.5 % Triton-X-100 (Sigma-Aldrich, USA) and incubated with anti-
influenza antibody (Serotec), followed by incubation with  anti-mouse-horse radish peroxidise 
(HRP [Dako]). Infected cells were detected with 3-amino-9-ethylcarbazole substrate and 
infectious units enumerated by light microscopy. 
2.5.2.2:   RSV PFU assay 
RSV titre was assessed from lung homogenate by titration on a Human Epithelial Type 2 (HEp-
2) cell monolayer in 96-well, flat bottom plates. 24 hours after infection, monolayers were 
washed with PBS, fixed with methanol and incubated with peroxidise-conjugated goat anti-
RSV antibody (Biogenesis, UK). Infected cells were detected with 3-amino-9-ethylcarbazole 
substrate and infectious units enumerated by light microscopy.  
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2.6:   Reagents used for in vivo studies 
2.6.1:  In vivo use of TLR ligands 
Mice were lightly anaesthetised with isoflourane and challenged I/N with 1 µg LPS (Sigma-
Aldrich, USA). 
2.6.2:   In vivo use of fluorescent dextrans 
Mice were lightly anaesthetised with isoflourane and administered I/N with 2 mg of 4 kd 
(FITC) and 70 kd (RhoB) fluorescently labelled dextrans (Sigma-Aldrich, USA) in 50 µl volumes 
sterile PBS. 1 hour post challenge serum, BAL cells, BAL supernatant and nasal wash were 
collected as in 2.2, lung homogenate was also collected by homogenising lung lobes and 
collection of supernatant following centrifugation at 5000 x g for 5 minutes.  For each animal 50 
or 100 µl of serum, nasal wash, BAL fluid, BAL supernatant, and lung homogenate were added 
to 96-well, round bottom microtitre plates and fluorescence measured against a 3 fold standard 
curve using a FLOUROstar OPTIMA fluorescence plate reader (BMG Labtech, Germany). The 
following Excitation/Emission wavelengths (nm) were utilised:  FITC 485/520, RhoB 540/580. 
Sigmoidal variable slope standard curves were drawn using GraphPad Prism version 5.04 for 
Windows, (La Jolla, California, USA), and used to interpolate dextran concentration for 
experimental samples.  
2.6.3:   In vivo use of fluorescent albumin 
Mice were injected intravenously (I/V) with 200 µL of 7.5 mg/mL FITC labelled albumin 
(Sigma-Aldrich, USA). 1 hour later, BAL and serum were collected as in 2.3, and fluorescence 
measured using a FLOUROstar OPTIMA fluorescence plate reader (BMG Labtech, Germany). 
The following Excitation/Emission wavelengths (nm) were utilised:  FITC 485/520. Sigmoidal 
variable slope standard curves were drawn using GraphPad Prism (GraphPad Software, USA), 
and used to interpolate albumin concentration for experimental samples.  
2.6.4:   In vivo use of antibiotics 
Mice were injected I/P with Ampicillin (200 mg/kg/day) or Azithromycin (5 mg/kg/day) in two 
doses given at 12 hour intervals, both antibiotics from Sigma-Aldrich, USA. 
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2.6.5:  In vivo use of macrophage dye 
Mice were lightly anaesthetised with isoflourane and administered I/N with 0.5 Nm (or as 
stated) PKH26 Red Fluorescent Cell Linker [Sigma-Aldrich, UK].  
 
2.7:    Ex vivo and in vitro techniques 
AMΦ were isolated for ex vivo analysis via BAL (as described previously-2.2) AMΦ were 
further concentrated by adherence to plastic for 2 hours at 37 °C in 5 % CO2 or by Florescence 
activated cell sorting (see-2.8). AMΦ were cultured ex vivo in R10F. 
In vitro studies of macrophage function were carried out on RAW cells, a murine 
leukaemic monocyte macrophage cell line, and MH-S cells [174], a murine AMΦ cell line. Both 
cell lines were cultured in R10F, and maintained at 30-70 % density. 
 
2.7.1:   Phagocytosis assay 
Phagocytic activity was determined by phagocytosis assay using pHrodo dye conjugated to 
Staphylococcus aureus (Invitrogen, USA). pHrodo florescence depends on the environmental 
pH; hence it acts as a sensor for internalisation into the acidic phagosome. 96-well flat bottom 
plates were seeded with 1x105 cells. 2 hours were allowed for adhesion of the cells to the plate, 
before media was aspirated and replaced by pHrodo (2 mg of pHrodo dye dissolved in 10 ml 
RPMI containing 10% FCS and sonicated for 5 minutes). As a negative control, parallel wells 
were pre-treated with Cytochalasin D (2.5µM per well) (Sigma-Aldrich, UK). Cells were 
incubated in non-CO2 enriched incubator at 37 oC for 1-24 hours. After incubation, cells were 
placed immediately on ice, to halt further phagocytosis and fixed before pHrodo incorporation 
was assessed by flow cytometry (see 2.8).  
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2.7.2:   TLR challenge 
96-well flat bottom plates were seeded with 1x105 cells. 2 hours were allowed for adhesion of 
the cells to the plate, before media was aspirated and replaced by media containing TLR 
agonists according to manufacturers‟ instructions (Invivogen, USA).   
 
2.7.3:   siRNA 
96-well flat bottom plates were seeded with 1x105 cells and incubated at 37 °C in 5 % C02. 2 
hours were allowed for adhesion of the cells to the plate, before media was aspirated and 
replaced by media containing 50 pM Mercury LNA microRNA Power Inhibitors (Exiqon, 
Denmark) and 0.25 μl Lipofectamin (Invitrogen, Life Technologies, USA)/well, in OptiMEM 
Reduced Serum Medium (Invitrogen, Life Technologies, USA) prepared in accordance with 
manufactures instructions. After 16 hours media was aspirated and replaced with R10F. 
 
2.8:   Flow cytometry 
Antibodies specific for markers of interest, conjugated directly or indirectly to either FITC, PE, 
PerCP (Pe-Cy5.5), Pe-Cy7, APC, APC-Cy7 or PB were arranged into panels at optimised 
concentrations (see Table 2.1 for detailed list of antibodies).Gating plans for specific cell 
populations are described where relevant in results chapters. 
Flow cytometric assessed expression data was acquired on a BD FACS CantoII or BD 
LSRFortessa. Fluorescence-activated cell sorting (FACS) of specific cell populations was carried 
out using a BD FACSARIAIII (All machines from BD Biosciences, Belgium). Subsequent data 
analysis was conducted using FlowJo analysis software (Tree Star, USA) following previously 
published guidelines [175].  
2.8.1:   Cell number by flow cytometry 
Cell number was assessed using CountBrightTM Absolute Counting Beads (Invitrogen, Life 
technologies, USA) according to manufactures instructions. 
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2.8.2:   Live dead determination 
When assessing fixed cells live and dead cells were distinguished by prior staining with 
LIVE/DEAD Fixable Cell stain kits (Invitrogen, Life technologies, USA) according to 
manufactures instructions. For assessing unfixed cells, propidium iodide (1:200 dilution) was 
added 10 minutes before flow cytometric analysis. 
2.8.3:   Staining for extracellular surface markers 
Cell suspensions at a minimum of 2 x 105 or maximum of 1 x 106 cells were incubated with the 
optimised extracellular antibody panels for 30 minutes at 4 °C in PBA (PBS containing 1% 
BSA/0.05 % sodium azide). Indirectly conjugated antibodies required a second incubation step 
with the appropriate secondary antibody. After incubations cells were washed in PBA and 
centrifuged for 2 minutes at 240 x g. For cell sorting or acquisition of live cells data acquired as 
above (section 2.8). For infected cells, or delayed acquisition, cells were first fixed for 20 
minutes at room temperature with 2 % formaldehyde/PBS, washed in PBA, and stored at 4 °C, 
before data acquisition.  
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Table 2.1: Antibody reagents 
 
Name Clone Conjugation Company 
CD11c N418 F, P, P5, P7, A eBioscience 
CD11b M1/70 P5, PB eBioscience 
Ly6G 1A8 F, A eBioscience 
F4/80 BM8 F,P,P5,P7,A eBioscience 
MHCII M5/114.15.2 P, P7 eBioscience 
AXL H-124 - SantaCruz 
Tyro-3 X12-3 - SantaCruz 
MerTK polyclonal - SantaCruz 
CD200R OX110 A eBioscience 
TREM2 237920 A R&D Biosystems 
TREM1 174031 P R&D Biosystems 
ST2L D8 F MabTechnologies
PPARγ E-8 - SantaCruz 
LXRαβ C-20 - SantaCruz 
Ronβ G-20 - SantaCruz 
CX3CR1 polyclonal - eBioscience 
GR M-20 - SantaCruz 
MannoseR MR5D3 F AbDserotec 
Relmα polyclonal - Peprotech 
YM1 281926 - R&D
TLR-2 T2.5 P eBioscience 
TLR-4 UT41 A eBioscience 
CD3 17A2 F,A eBioscience 
CD4 GK1.5 F,P,P5,A eBioscience 
CD8 53-6.7 F,P,P5,A eBioscience 
B220 RA3-6B2 F,P eBioscience 
NKp46 29A1.4 P eBioscience 
IFNγ XMG1.2 P eBioscience 
TNFα MP6-xt22 F eBioscience 
Il-10 JES5-16E3 P eBioscience 
Il-17 eBio17B7 A eBioscience 
Il-22 1H8PWSR P eBioscience 
FoxP3 FJK-16s F eBioscience 
γδ UC7-13D5 F eBioscience 
CD31 390 F,P,P5 eBioscience 
CD45 30-F11 P7,P5,P eBioscience 
E-Selectin UZ7 - SantaCruz 
PAF-R M16 P SantaCruz 
CAR N17 P eBioscience 
Caveolin Polyclonal - abCam 
EGF-R ICR-10 - abCam 
CD200 OX90 A eBioscience 
ICAM-1 3.00E+02 - BD 
ZO-1 ZO1-1A12 - Invitrogen 
Conjugation abbreviations: F=FITC, P=PE, P5=PerCY5.5, P7=Pe-Cy7, A=APC and PB. 
AlexaFlor equivalents were also used where available. A dash indicates a purified , 
unconjugated antibody, for which secondary antibodies from Invitrogen were used for 
detection. 
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2.8.4:   Staining for intracellular surface markers 
When analysing T cell populations, 1 x 106 cells/ml were incubated with 50 ng/ml PMA, 500 
ng/ml ionomycin (Calbiochem, UK), and 10 µg/ml brefeldinA for 4 hours at 37°C. When 
analysing macrophage populations identical conditions were used excluding PMA and 
ionomycin. Cells were then stained for extracellular markers and fixed as above (section 2.8.3). 
After permeabilisation with saponin buffer (PBA containing 1 % saponin) for 10 minutes, cells 
were stained with optimised intracellular antibody panels at room temperature for 30 minutes 
in saponin buffer. Cells were washed in saponin buffer and then in PBA and acquired as above 
(section 2.8). 
2.8.5:   Fluorescence minus one (FMO) controls 
Slight but significant shifts were identified in the fluorescence of cell populations as measured 
by flow cytometry, particularly when comparing different time points following an infection. 
These differences were due to slight variations in laser power of the cytometer over time, and 
for AMΦ in particular, changes in the auto-fluorescence of the cells as they became activated. 
The fluorescence of AMΦ on the PE and APC channels over a six week time course following 
RSV infection is shown in Figure 2.1. Slight but consistent variation was observed in both the 
percentage of fluorescence positive cells (numbers to the right of flow cytometry plots) and the 
fluorescence geometric mean of the AMΦ population (numbers to the left of flow cytometry 
plots). In order to accurately measure the expression of cell markers by fluorescent antibody 
detection these intrinsic variations in fluorescent levels were controlled for by including a FMO 
control for each fluorescent marker at each time point. Expression of a particular marker was 
then calculated by subtracting FMO fluorescence values from fluorescent antibody levels. To 
control for variations in the performance of the flow cytometer and in the staining procedure a 
naïve control group was included at each time point after RSV infection. Time points where the 
fluorescence of a particular marker on naïve controls varied significantly from average were 
excluded. 
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Figure 2.1: Fluorescence Minus One (FMO) controls 
 
2.9:    Immunohistochemistry 
Lung lobes taken were fixed in 10 % formalin for 24 hours then stored in 70 % ethanol. Lung 
tissue was mounted in paraffin blocks and 4 µM sections mounted onto glass slides. Slides were 
de-waxed through three changes of Histoclear (National Diagnostics, USA), then rehydrated 
through 100, 90 and 70 % ethanol and water. Antigen retrieval was carried out with 2 mg/ml 
proteinase K for 10 minutes at 37 °C. Slides were blocked using an Avidin/Biotin blocking kit 
(Vector Laboratories, USA) according to manufacturer‟s instructions, then further blocked for 1 
hour with 5 % donkey serum. Slides were then incubated overnight at 4 °C with 5 µ/ml rabbit 
anti-ZO-1 primary antibody (Invitrogen, USA) or a rabbit isotype control. Slides were washed 
in PBS with 0.1 % Tween-20, and then incubated with biotinylated anti-rabbit secondary 
antibody for 45 minutes at room temperature. Slides were washed again then incubated with 
Streptavidin-PE complex tertiary antibody for 30 minutes at room temperature. Slides were 
washed a final time, immersed in water then cover slips mounted with Prolong Gold Anti-fade 
1.00% 1.00%99189.7
1.93% 10.5%74636.6
4.86% 4.86%53217.2
2.04% 6.08%5354.03
2.69% 4.51%84628.3
7.6% 4.84%90629.4
Day0
Day3
Day7
Day15
3weeks
6weeks
PE APC
BALB/c mice were infected with RSV and at various time points post infection (day 
0-red, day 3-orange, day 7-yellow, day 15-green, 3 weeks-blue, and 6 weeks-
purple) AMΦ were identified by flow cytometry, and their intrinsic fluorescence on 
the PE channel (A) and the APC channel (B) of the flow cytometer assessed. 
Representative plots from each time point are shown, with the geometric mean of 
the AMΦ population displayed on the left and the percentage of cells appearing 
fluorescence positive displayed on the right of the flow plots. 
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(Invitrogen, USA). Stained lung lobes were visualised using a Carl Zeiss LSM-510 inverted 
confocal microscope (Carl Zeiss, Germany). 
 
2.10:   Soluble mediator detection 
2.10.1:   Luminex 
Mouse cytokine 20-Plex Panel (Invitrogen, USA) measuring FGF, IP-10, MCP-1, MIG, MIP-1α, 
IFN-γ, KC, IL-17, IL-1α, GM-CSF, VEGF, IL-1β, IL-2, IL-4, IL-5, IL-6, TNF-α, IL-10, IL-12 and 
IL-13 was used on BAL supernatant according to manufacturer‟s instructions. 
2.10.2:   ELISA 
IFN-γ, TNF-α, soluble TREM, KC and MIP-1α (OptEIA kits, Pharmingen, USA); albumin 
(Bethyl Laboratories, UK) were quantified from either BAL supernatant, lung homogenate or ex 
vivo/in vitro cellular supernatants by ELISA following manufactures instruction‟s. 
2.10.3:  Other soluble mediator measurements 
Pierce BCA total protein assays (Thermo Fisher Scientific, USA) and lactate dehydrogenase 
activity assays (Sigma-Aldrich, USA) were carried out according to manufacturer‟s instructions. 
 
2.11:   RNA analysis 
2.11.2:   RNA extraction 
miRNA and mRNA were extracted from AMΦ using miRNeasy miRNA micro kit (QIAGEN). 
Where necessary RNA samples were further cleaned and concentrated using RNeasy MinElute 
Cleanup Kit (QIAGEN). 
2.11.3:   mRNA microarray 
Sample quality control:  RNA was quantified using the nanodrop spectrophotometer (Thermo 
Scientific). 100 ng of total RNA was measured for quality using the Agilent Bioanalyser RNA 
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nano chip (Agilent), samples with an RNA Integrity Number (RIN) greater than 7.5 were passed 
for processing on the array.  
Sample labelling: 250 ng of total RNA were labelled as per the manufacturer‟s instructions using 
the Illumina® TotalPrep™-96 RNA Amplification Kit (Illumina, Life Tech).  Samples were 
again assessed for quality using a nanodrop spectrophotometer (Thermo Scientific) and Agilent 
Bioanalyser RNA nano chip (Agilent).  
Array:  750 ng of labelled cRNA was hybridised overnight to the Illuimina mouse ref 8 bead 
chip array and visualised on the iScan (Illumina).  Data was analysed using Illumina‟s 
GenomeStudio package with Quantile normalisation. 
Statistics: Statistically significant expression patterns between transcriptomes were assessed by 
ANOVA with Bonferroni correction. 
2.11.4:   miRNA RT-PCR panel 
Sample Quality Control: RNA was quantified using the nanodrop spectrophotometer (Thermo 
Scientific). 100 ng of total RNA was measured for quality using the Agilent Bioanalyser RNA 
nano chip (Agilent), samples with an RNA Integrity Number (RIN) greater than 7.5 were passed 
for processing on the array  
cDNA: Each RNA sample was reverse transcribed (RT) into cDNA (RNA was reverse 
transcribed in 40 μl reactions and diluted 50 fold). Where possible, 4 ng of RNA was used per 
reaction. Samples were incubated at 42 °C for 1  hour, and then heat inactivated at 95 °C for 5 
minutes with reagents supplied by Exiqon cDNA synthesis kit, according to manufactures‟ 
instructions. 
miRNA RT-PCR panel: The miRCURY LNATM Universal RT miRNA PCR (Rodent panel I) 
(Exiqon, Denmark) contains 375 miRNA assays and a range of positive and negative controls. 
Each PCR panel contained a PCR control (three replicates of an inter-plate calibrator) and 3 
primer sets for reference genes. One enzyme control (reverse transcriptase replaced with water) 
in the RT step was included as a negative control. Pools of all samples were used for this 
control.  
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Melting curve analysis: An additional step in the real-time PCR analysis was performed to 
evaluate the specificity of the assays by generating a melting curve for each reaction. The 
appearance of a single peak during melting curve analysis is an indication that a single specific 
product was amplified during the qPCR process. The appearance of multiple melting curve 
peaks correspondingly provides an indication of multiple qPCR amplification products and is 
evidence of a lack of specificity.  
Normalization: Normalization was performed based on the geomean of the assays detected in all 
8 samples. Normalized Cp = Geomean – assay Cp. A higher value thus indicates that this 
miRNA is more abundant in this sample. 
Statistics: Statistically significant expression patterns between transcriptomes were assessed by 
ANOVA with Bonferroni correction. 
 
2.11.5:   Confirmation of miRNA RT-PCR panel results by individual RT-
PCR reactions 
cDNA synthesis was carried out as before (2.11.4).  cDNA was pipetted onto 384 well plates 
using EpMotion Robotics (Eppendorf, Germany) to ensure accuracy. RT-PCR reagents: SYBR 
green master mix (Exiqon, Denmark) LNA PCR primer mix (Exiqon, Denmark) and passive 
reference dye (ROX – Affymetrix, USA) were also added using EpMotion Robotics according to 
manufactures instructions (Exiqon, Denmark). RT-PCR amplification followed by melting 
curve analysis was carried out on ABI 7900HT (ABI) RT-PCR machine, with 40 amplification 
cycles at 95 °C for 10 seconds, and 60 °C for 1 minute with a ramp rate of 1.6 °C/second. Data 
was analysed using GenEx free trial software (GeneEx, MultiD).  
 
2.12:   Bioinformatics 
Pathway analysis on transcriptome data was carried out using Ingenuity (free trial) software. 
Canonical pathway analysis identified pathways from the Ingenuity Pathways library that were 
most significant to the data set. The significance of the association between the data set and the 
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canonical pathway was measured in two ways. First, a ratio of the number of molecules from 
the data set that mapped to the pathway divided by the total number of molecules that mapped 
to the canonical pathway. Secondly, Fisher's exact test was used to calculate the probability that 
the association between the genes in the dataset and the canonical pathway could be explained 
by chance alone. For this purpose, p=< 0.05 was set as a threshold. 
Predicted interactions between miRNA and mRNA were assessed using Ingenuity (free 
trial) software. Ingenuity Pathways microRNA target filter was used to associate the miRNAs 
assessed as differentially expressed between naïve and resolved AMΦ with experimentally 
observed and predicted mRNA target information provided from the Ingenuity Knowledge Base 
using predicted relationships from TargetScan database and experimentally observed 
relationships from TarBase database. This information was then filtered to reveal targets from 
our mRNA microarray dataset only. 
2.13: Statistics 
GraphPad Prism version 5.04 for Windows, (La Jolla, California, USA) was used for all statistical 
calculations. Statistical significance was calculated using the most suitable test depending on the 
experiment and the datasets to be compared. For multiple dataset analysis ANOVA with either 
Bonferroni or Dunnett‟s correction was applied. For comparing data sets with low n numbers or 
when data was not normally distributed a Kruskal-Wallis test with Dunn correction was used. 
To compare two datasets two tailed Mann Whitney test was applied. For survival experiments 
Log rank Mantel-Cox test was applied. Data are presented as the mean ± standard error of the 
mean (SEM). P values < 0.05 were considered significant (*p<0.05, **p<0.01, ***p<0.001). 
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Chapter 3: Modelling co-infections 
3.1: Introduction 
3.1.1: The need to study secondary bacterial complications 
It is commonly accepted that outside the highly controlled laboratory setting, the clinical and 
pathophysiological characteristics of most infectious diseases are more complex than implied by 
a simple one pathogen one disease model. Unlike most animal models used to study infectious 
diseases, humans are never free from previous or concurrent infections. This is particularly 
apparent with upper respiratory tract viral infections and their associated bacterial 
complications. Although influenza virus is most commonly thought of in this context, many 
other respiratory viruses including RSV, measles virus, and rhinovirus as well as non infectious 
triggers, such as COPD and allergic asthma predispose to secondary infections (reviewed in 
[176]).  
Secondary bacterial infections are best documented following pandemic viral infection, 
perhaps when awareness is high and diagnostics are more routinely applied to hospitalised 
pneumonia cases. During the 1918 influenza pandemic secondary bacterial infection was the 
most common cause of death, and similarly hospitalisations and deaths during the influenza 
outbreaks of 1957, 1968, 1995 and 2009-10 were frequently due to secondary bacterial 
pneumonia or exacerbations of underlying conditions [112, 114-117]. Resultantly empiric 
antibiotics are strongly advised in all patients hospitalised with severe influenza infection [177], 
and mathematical models of future 1918 scale pandemics, suggest that bacterial vaccination and 
antibiotic treatment will significantly reduce mortality rates [178]. Outside of pandemic 
situations, it is likely that the incidence of secondary bacterial infection is grossly under-
estimated not least because viral clearance may precede the development of bacterial 
pneumonia preventing reliable detection and since in most cases viral triggers are not routinely 
screened for in patients presenting with bacterial pneumonia. Bacterial pneumonias remain a 
significant global health burden with S. pneumoniae and Hib responsible for as many 
worldwide child deaths as HIV/AIDS, malaria and tuberculosis combined [179]. Given that both 
bacterial species are opportunistic and form part of the normal commensal load, it seems 
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feasible that many cases of invasive bacterial pneumonia are preceded by a viral trigger or 
underlying condition.  
In an era of increasing antibiotic resistance, and continuing concern over influenza 
pandemics, understanding the mechanisms and genetic basis underlying susceptibility to 
secondary bacterial infection in the lung is important.  
 
3.1.2:  The need for small animal models 
The multi-organ complexity of the immune system means that in vitro models currently lack 
the sophistication to fully characterise an immune response to a particular pathogen.  
 The genes involved in the immune response are the most numerous and diverse in the 
human genome, indicating the evolutionary advantages of a varied immunological response to a 
wide range of infectious pathogens [180]. Despite the identification of numerous SNPs which 
correlate with disease susceptibility, there remains a large gap in our understanding of how 
genetic variation influences individual outcomes following pathogen exposure [181]. Given the 
complex interplay between genetic and environmental factors which governs susceptibility to a 
specific pathogen, it is unsurprising that the role of an individual gene can be indistinguishable 
from background noise in the out bred human population without large scale, expensive, 
systems-biology approaches. Small animal models in inbred strains represent an easily 
controllable platform to investigate the whole-body immune response to a particular pathogen. 
Additionally, the use of knock-out mice allows the role of an individual gene to be indentified 
in a particular infectious setting. Similarly comparing susceptibility to infection between 
different inbred strains allows the identification of potentially important genotypes within a 
context of limited and predictable genetic diversity. Animal models are well suited to the initial 
identification of important genes and pathways, which can then be corroborated in humans. 
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 3.1.3: The need for animal models of respiratory co-infection 
Despite the extensive epidemiological evidence supporting a strong association between 
pulmonary viruses and secondary bacterial infections (reviewed in [109]), the causality of the 
link is poorly understood. Potential hypotheses can be classed into three main categories. 
Firstly, synergy between host, virus and bacteria, for example the viral-induced up-regulation 
of adhesion factors for a specific bacteria. Secondly, physical effects, such as viral induced 
reductions in cilial clearance, and increased mucus production as well as epithelial damage as a 
result of cytopathological or immunopathological processes. These result in the generation of 
hospitable environments for bacterial growth, and increased bacterial access to sterile sites. 
Thirdly, viral induced alterations in the effectiveness of the immune response to subsequent 
bacterial challenge (reviewed in [107, 109]). These hypotheses are not mutually exclusive and it 
is likely that susceptibility to secondary bacterial infection is a multifactorial process.  
Given the complexity of the interactions, animal models provide the only means to 
dissect in detail the importance of these different processes. To date no human co-infection 
studies have been attempted.  
 
3.1.2:  Existing respiratory co-infection models 
The first documented study of secondary bacterial infection was conducted by M. V. de 
Terregosa et al., in 1945. They reported that S. pneumoniae, H. influenzae, and S. aureus all 
caused fatal pneumonia in an intranasal co-infection model with the mouse adapted influenza 
virus A/Puerto Rico/8/34 (PR8) [182]. Since then many models have been presented, most 
numerously murine models of influenza induced bacterial super-infection with S. pneumoniae 
for example [108]. During the duration of this PhD a detailed murine model of influenza 
triggered Hib co-infection was also published [183]. Fewer models exist of RSV co-infection, 
but in the chinchilla model of otitis media, RSV is seen to alter expression of anti-bacterial 
peptides leading to increased commensal carriage, and likely promotion of otitis media [111], 
whilst in the mouse model, RSV co-infection with S. pneumoniae increases inflammation in the 
airway and alters neutrophil function [139]. 
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The variety of mechanisms underlying susceptibility to secondary infection presented in 
these studies are testament to the probable multifactorial nature of susceptibility, with 
differences in the timing of secondary co-infection, doses and strains of both virus, bacteria and 
mouse, likely to explain differing outcomes.  However given the universality of the 
phenomenon it is likely that general mechanisms can be described which remain to be fully 
elucidated.  
 
3.1.3: The use of antibiotics in respiratory viral infection and co-
infection 
Antibiotics are routinely prescribed for both hospitalised and community respiratory infections 
often without initial diagnostics. Recently antibiotic treatment was shown to have a deleterious 
effect on subsequent influenza infection in mice, due to the suggested importance of commensal 
load in maintaining effective mucosal immunity [184]. In antibiotic treatment of bacterial 
pneumonia in animal models of influenza co-infection with S. pneumoniae the choice of 
antibiotic was important; with bacteriostatic prophylactics proving more effective than 
bactericidal antibiotics, due to the detrimental inflammatory response to bacterial lysis [185].  
3.1.4:  Hypothesis  
This chapter tests the hypothesis that common immunological alterations exist following 
disparate respiratory viral infection that predispose to bacterial super-infection and that this 
situation can be manipulated by therapeutic immune intervention.   
Aims:   1)      Develop and characterise murine (BALB/c and BL/6) models of viral-induced 
(Influenza and RSV) bacterial (S. pneumoniae and Hib) super infection. 
   2)      Characterise and manipulate specific elements of the innate immune 
rheostat in the above models to assess their contribution towards bacterial super-infection. 
   3)      Determine the efficacy of specific antibiotics on viral-induced bacterial 
super-infection derived from commensal microorganisms  
73  Chapter 3: Modelling co-infections 
 
3.2: Results 
3.2.1: Modelling co-infections 
Two clinically relevant bacterial species, Streptococcus pneumoniae (D39 strain) and 
Haemophilus influenzae (Eagan strain, serotype B (Hib)) were chosen to establish murine 
models of secondary bacterial pneumonia following viral infection in mice. Consistent stocks 
were generated, and their doubling rates in culture established as 43 minutes for Hib (Figure 
3.1A) and 29.3 minutes for D39 (data not shown). To establish a dose which mirrored as 
accurately as possible the human situation; colonisation of the nasopharynx without 
dissemination and the induction of invasive disease following viral infection, dose response 
experiments were designed to compare the pathology of primary Hib infection in both BALB/c 
and BL/6 mouse strains. 
3.2.1.1:   Modelling murine Hib single infection 
 Both strains of mice were resilient to infection with Hib, showing minimal signs of infection at 
low doses (data not shown), and effective clearance following intra-nasal (I/N) infection with 
1x107 Colony forming units (CFU)/mouse, the highest dose administered. To fully map the 
clearance kinetics in the two mouse strains, recoverable CFU were examined for 3 weeks post 
infection with 1x107 CFU Hib/mouse. Both strains initially lost weight following infection 
(Figure 3.1B) but regained weight (compared to naive), within 3 days for BL/6, and 6 days for 
BALB/c, and no mortality was observed. The delayed regain of weight in BALB/c mice was 
reflected in higher bacterial titres recovered from the nasal cavity, BAL and lung tissue 
compared to BL/6 at 12 hours post infection. However both strains achieved full clearance from 
the lungs and BAL by 1 week post infection (Figure 3.1D and E). Hib was never recovered from 
the blood at any time point (Figure 3.1F). In BL/6 mice, clearance was also achieved from the 
nasopharynx by 1 week post infection, whereas in BALB/c mice clearance was delayed, with 
Hib recovered from the nasopharynx of 60 % of these mice even at 3 weeks post infection 
(Figure 3.1C) .  
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Figure 3.1: Primary Hib infection characterisation in BALB/c and BL/6 
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Hib doubling rates were determined in vitro (A). BALB/c (grey circles) and BL/6 mice 
(black diamonds) were infected with 1e7 CFU Hib/mouse (closed shapes)and weight loss 
followed compared to naive controls (open shapes) (B). At 12 hours, 1 week and 3 weeks 
post infection, bacterial titres in the nasal wash (C) , BAL (D), lung tissue (E) and blood 
(F) were measured by CFU assay, comparing BALB/c (white) to BL/6 (black) with 
respective naive controls (time point 0). The presence of Hib was confirmed by lack of 
growth on –NAD –haem agar. Data representative of one experiment with 5 mice per 
group and are presented as the mean  standard error of the mean (SEM). p values by 
ANOVA < 0.05 were considered significant  (*p<0.05, ** p<0.01, *** p<0.001). 
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The higher bacterial burden in BALB/c mice was associated with a more vigorous 
immune response. At 12 hours post infection cellular infiltrate into the airway was significantly 
elevated in BALB/c mice (Figure 3.2A), whilst cellular infiltrate into the lung tissue remained 
elevated even at 1 week and 3 weeks post infection (Figure 3.2B). Soluble triggering receptor 
expressed on myeloid cells (TREM-1), a diagnostic marker used to denote bacterial infection in 
patients [186], was found to be significantly higher in both the BAL and lung homogenate of 
BALB/c mice (Figures 3.2C and D). The cellular infiltrate into the BAL and lungs was 
dominated at the 12 hour time point by neutrophils, which made up 75% of BAL cells in 
BALB/c. This percentage was significantly lower in BL/6 mice (Figure 3.2E). Not only did 
BALB/c mice have a greater number and proportion of neutrophils (Figures 3.2F, E), but they 
appeared to be more activated, expressing higher levels of integrins CD11b and Ly-6G (data not 
shown). Additionally alveolar macrophages from BALB/c mice expressed higher levels of the 
scavenger receptor, MARCO and the activation marker OX40L (data not shown).  
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Figure 3.2: Comparing Hib primary infection in BALB/C and BL/6 
 
At 12 hours, 1 week and 3 weeks post infection with 1e7 CFU Hib/mouse, cell 
number in the BAL (A)and lung homogenate (B) was assessed by haemocytometer, 
in BALB/c (white) and BL/6 mice (black) compared to naive controls (time point 0). 
At the same time points soluble TREM levels in the BAL supernatant (C)and lung 
homogenate (D) were measured by ELISA. (ELISAs kindly performed by Gang Xin). 
Flow cytometry was used to calculate  the percentage of neutrophil present in the 
BAL (E) and the total number of neutrophil was inferred from total cell numbers (F). 
Data representative of one experiment with 5 mice per group and are presented as 
the mean  SEM. p values by ANOVA < 0.05 were considered significant (* p<0.05, ** 
p<0.01, *** p<0.001). 
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3.2.1.2 Modelling murine influenza and Hib co-infection 
In order to model secondary Hib infection following influenza infection, BL/6 mice were 
chosen, due to the availability of knock outs (KO) in this background. Mice were infected with 
influenza (or given PBS control) and then co-infected with the non-lethal dose of Hib 
characterised in Figures 3.1 and 3.2 (or given PBS control), at the peak of viral disease severity 
(as determined previously [32]) (Experimental design, Figure 3.3A). As seen previously, control 
mice administered with PBS prior to Hib infection, lost little weight. Control mice infected 
with Influenza and then PBS, showed the typical weight loss profile associated with influenza 
infection in mice with weight loss peaking between day 6 and 8, followed by a recovery period, 
such that by day 16 post influenza, weight was completely regained. Mice infected with 
influenza and then co-infected with Hib, showed a pronounced loss of weight following Hib 
infection, which they were unable to regain (Figure 3.3B). By 48 hours post Hib infection there 
was 100% mortality in the co-infected group, whilst influenza or Hib alone control mice 
showed 100% survival (Figure 3.3C).  This difference in mortality was reflected in the bacterial 
titres recovered from the nasal cavity, BAL and lung tissue 12 hours post infection, which were 
significantly higher in the co-infected group, compared to bacteria alone controls (Figure 3.3D). 
Interestingly even at later time points, (48 hours post bacteria) Hib was never recovered from 
the blood of the co-infected group, suggesting that the mortality in this group may have 
resulted from pneumonia, rather than septicaemia.  
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Figure 3.3: Prior influenza infection dramatically increases the severity of Hib 
infection 
 
The increased bacterial titres recovered from the co-infected group were associated with 
significantly higher cell numbers in the BAL and lung compared to single infection controls 
(Figure 3.4A, B). The different infections had dramatically different cellular infiltration profiles. 
Lymphocytes dominated at day 9 post influenza infection alone, whilst neutrophils dominated 
at 12 hours post Hib infection. The BAL of co-infected mice was dominated by both 
lymphocytes and neutrophils, which in both cases were therefore at a significantly lower 
proportion than the respective single infections (Figure 3.4A pie charts). For this reason, 
although there were more neutrophils in co-infected mice (Figure 3.4B), they were at a lower 
proportion than seen in bacterial alone infections, and there was a significantly lower number 
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of neutrophils per bacteria in the BAL (figure 3.4C). Additionally neutrophils from co-infected 
mice showed significantly lower levels of integrin activation markers such as CD11B (Figure 
2.4D). The total number of alveolar macrophage was similar in the three groups (Figure 2.4B). 
However a significantly lower proportion of alveolar macrophage expressed the scavenger 
receptor MARCO in co-infected mice compared to either single infection control. Additionally 
the expression level of MARCO was significantly lower on macrophages from co-infected mice 
compared to bacteria alone controls (Figure 3.4E).  
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Figure 3.4: Prior influenza infection dramatically increases the severity of Hib 
infection 
 
3.2.1.3:  Susceptibility to Hib co-infection does not extend into resolution  
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at day 14 post influenza (Experimental design-Figure 3.5A). Delaying co-infection to day 14 
resulted in 100% survival. At 12 hours post co-infection there was a significant increase in the 
number of bacteria recovered from the BAL and lung of co-infected mice compared to bacteria 
alone controls (figure 3.5C), and this difference was accompanied by a decrease in the number 
of neutrophils per bacteria in the BAL (data not shown). By 48 hours post co-infection 
differences in the recovery of bacteria from the BAL and lung had dissipated (figure 3.5D).  
Figure 3.5: Susceptibility to Hib during resolution from influenza 
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3.2.1.4:  CD200R-/- are protected from secondary Hib infection 
 CD200R-/- mice are protected from secondary S. pneumoniae infection following influenza 
infection [32]. This suggests that susceptibility to bacterial infection following influenza 
infection is not merely a consequence of viral replication. We wished to determine whether 
lack of CD200R could also protect mice from the high mortality seen following secondary Hib 
infection (see Figure 3.4). WT and CD200R-/- mice were infected with influenza, and at day 8 
co-infected with Hib (experimental plan – Figure 3.6A). Influenza and Hib alone controls were 
also included for both groups. As seen in Influenza and S. pneumoniae co-infection models, 
CD200R-/- mice were significantly protected from secondary Hib infection following influenza. 
Whilst there was 100% mortality in WT mice by 48 hours post Hib infection, there was 100% 
survival in CD200R-/- mice (Figure 3.6B).  Despite this dramatic difference in survival, at the 
harvest point included in this study (12 hours post bacterial infection), in both groups there 
were significantly more bacteria recovered from the BAL and lungs of co-infected mice 
compared to bacteria alone controls. However, no differences were observed between co-
infected WT and KO mice (Figures 3.6C and D). Improved outcome in co-infected mice could 
also not be attributed to differences cellular recruitment to the BAL (Figure 3.6E). There was a 
significant decrease in the cellular recruitment to the lungs in the KO co-infected groups 
compared to WT controls, although there was also a significant increase in the number of cells 
present in the lung after Hib alone in KO compared to WT (Figure 3.6F). 
 
 
 
 
 
 
 
 
83  Chapter 3: Modelling co-infections 
 
Figure 3.6: CD200R-/- mice are protected from lethal secondary Hib infection  
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3.2.2 Modelling co-infections following RSV 
RSV is another clinically important respiratory virus that infects respiratory epithelium. It is 
less cytopathic than influenza virus and is less often associated with secondary bacterial 
complications [103]. RSV was plaque purified and expanded in HE-p2 cells and concentrated for 
infection in a murine model. In agreement with previous studies [187], it was found that 
BALB/c mice were significantly more susceptible to infection with RSV than BL/6 mice (Figure 
3.7) Whilst a 5x106 PFU/mouse dose of RSV led to 100% mortality in BALB/c mice, it led to 
only minor weight loss in BL/6.  
Figure 3.7: RSV titration in BALB/c and BL/6 mice 
 
3.2.2.1: RSV and Hib co-infection  
To assess the influence of RSV infection on susceptibility to Hib, BALB/c mice were infected 
with RSV and co-infected with a non lethal dose of Hib at either peak weight loss (day 7) or 
during recovery (day 14) (experimental plan-Figure 3.8A). As seen following influenza 
infection, co-infection at day 7 resulted in high mortality (Figure 3.8C), and significantly higher 
bacterial recovery from the BAL, and lung tissue (Figure 3.8D). Similarly the number of 
neutrophils present in the BAL per bacteria was significantly decreased in co-infected mice 
(data not shown). In contrast, co-infection at day 14 did not result in mortality (Figure 3.8E), 
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of mice co-infected with Hib compared to those given Hib alone (Figure 3.8F). There was also 
no significant difference in susceptibility to co-infection with Hib at 6 weeks post RSV 
infection (data not shown).  
Figure 3.8: Modelling RSV co-infection with Hib 
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3.2.2.2: RSV and S. pneumoniae co-infection 
In order to assess susceptibility to S. pneumoniae following viral infection a bacterial dose 
which mirrored as accurately as possible the human situation; colonisation of the nasopharynx 
without dissemination and the induction of invasive disease following viral infection was 
determined in both BALB/c and BL/6 mice (data not shown). A model of susceptibility to 
secondary S. pneumoniae infection in BL/6 mice following influenza infection was already well 
established in the lab [32]. However, bacterial susceptibility following RSV infection has not 
been examined. 
3.2.2.2.1: Comparing RSV infection in BALB/c and BL/6 
 BALB/c or BL/6 mice were infected with either high (3x106 plaque forming units (PFU)/mouse) 
or low (1x106 PFU/mouse) doses of RSV. As anticipated, BALB/c mice lost considerable weight 
when given a high dose of RSV, and significantly less when administered the low dose. In each 
case weight loss peaked between day 6 and 8 (Figure 3.9A). In contrast BL/6 mice showed no 
significant weight loss at either high or low doses of RSV (Figure 3.9A). The cellular infiltrate 
into the BAL at day 7 post infection was dose dependant, with BALB/c mice recruiting 
significantly more cells than BL/6 mice in response to RSV infection (figure 3.9B). Although 
BL/6 mice showed no significant weight loss in response to RSV, there was a significant increase 
in cellular infiltrate into the BAL at day 7, suggesting an immune response was initiated (Figure 
3.9B).  
3.2.2.2.2: Comparing RSV and S. pneumoniae co-infection in BALB/c and BL/6 
BALB/c and BL/6 mice were then co-infected with S. pneumoniae 7 days after RSV infection at 
a dose already established to be non lethal when administered as a single infection 
(experimental plan-figure 3.9C). Susceptibility to secondary S. Pneumoniae infection was 
dependent on RSV induced disease severity. BL/6 mice administered with either high or low 
doses of RSV, showed no mortality following secondary S. pneumoniae infection (Figure 3.9D). 
These mice showed a non significant trend for higher recovery of bacteria from the nasal cavity 
and BAL, compared to bacteria alone controls (data not shown) and bacteria were never 
recovered from the lungs or blood of BL/6 mice following co-infection (Figure 3.9E and F). 
BALB/c mice given a low dose of RSV also showed 100% survival following secondary S. 
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pneumoniae infection (Figure 3.9D), but were more susceptible to infection, with higher titres 
of S. pneumoniae recovered from the BAL (data not shown) and lung, compared to bacteria 
alone controls (Figure 3.9E). However, BALB/c mice co-infected with S. pneumoniae, following 
the highest dose of RSV, showed 100% mortality by 48 hrs post bacterial infection (Figure 
3.9D), and far higher bacterial titres were recovered from the lung and blood of these mice 
compared to bacteria alone controls or to BALB/c mice administered with the lower dose of 
RSV (Figure 3.9E and F). S. pneumoniae therefore disseminates following a viral infection 
unlike Hib. 
 
3.2.2.3: Susceptibility to S. pneumoniae co-infection is prolonged into resolution 
from RSV 
Given the dependence of susceptibility to secondary S. pneumoniae infection on the viral 
induced weight loss at the time of co-infection (Figure 3.9), the susceptibility to secondary 
infection at various time points post RSV infection was next assessed, with particular interest in 
resolution, when weight loss was recovered. BALB/c mice were infected with low dose RSV 
(1x106 PFU/mouse), and weight loss followed for 6 weeks. Weight loss peaked 6 days post 
infection, and had returned to naïve levels by 10 days post infection (figure 3.10A).  At 0, 3, 8, 
14, 22 or 44 days post infection, groups of mice were co-infected with S. pneumoniae and the 
recovery of bacteria from the BAL, lung and blood was assessed by CFU assay (Figures 3.10 B, C, 
and D). Despite a mild RSV infection, and the recovery of weight loss by day 13, mice remained 
more susceptible to co-infection even 6 weeks post infection.  
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Figure 3.9: Susceptibility to S. pneumoniae secondary infection is dependent on 
the severity of the initial RSV infection 
 
 
 
 
BALB/c or BL/6 mice were administered with either PBS (O), high (H) or low (L) doses of 
RSV and weight loss followed for 7 days (A). Cellular infiltrate into the BAL was measured 
by haemocytometer with Trypan blue exclusion at 7 days post infection (B). In a parallel 
experiment, mice were co-infected with S. pneumoniae at day 7 post RSV- Experimental 
model (C).Mortality was measured for 15 days post bacterial co-infection (D). Bacterial 
recovery from the lung tissue (E) and blood (F) was measured by CFU assay at 24 hours post 
bacterial co-infection. Data representative of 2 separate experiments with 4-5 mice per group 
and are presented as the mean  SEM. p values were calculated Kruskal-Wallis ANOVA with 
Dunns correction , or Mantel Cox test for survival graphs. (* p<0.05, ** p<0.01, *** p<0.001). 
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Figure 3.10: Susceptibility to S. pneumoniae co-infection is prolonged into 
resolution from RSV 
 
 
 
 
 
 
 
BALB/c mice were infected with low dose RSV, or given PBS control. Weight loss was 
followed for six weeks (A). At either day 0, 2, 7, 14, 21 or 43 post RSV mice were infected 
with S. pneumoniae (SP-red arrows, experimental plan-A).  24 hours after bacterial 
infection, mice were culled and the recovery of bacteria from the BAL (B), lung (C) and 
blood (D) was measured by CFU assay. N=5-10 for all time points. This data is 
representative of one complete time course and individually repeated time points. 
Significance compared to mice infected with S. pneumoniae at time point 0 post RSV, was 
assessed by Kruskal-Wallis with Dunns correction (black significance stars), and also by 
Log Rank Mantel Cox (red significance stars).
BAL
0 3 8 15 22 44
101
103
105
107 ***
**
***
***
***
*
**
Days post RSV infection
C
F
U
 p
e
r 
m
o
u
s
e
Blood
0 3 8 15 22 44
101
102
103
104
105
106
*
*
*
Days post RSV infection
C
F
U
 p
e
r 
m
l
Lung
0 3 8 15 22 44
101
103
105
107
**
*
***
**
***
**
Days post RSV infection
C
F
U
 p
e
r 
m
o
u
s
e
B C D
7 14 21 28 35 42
90
100
110
120
PBS
RSV
Days post RSV
%
 o
ri
g
in
a
l 
w
e
ig
h
t
SP SP SP
SP
SP
SP
Chapter 3: Modelling co-infections  90 
 
To investigate the prolonged susceptibility to S. pneumoniae co-infection into resolution 
from RSV, the immune response to bacterial infection was assessed at each time point post 
infection. The cellular recruitment of cells into the BAL following S. pneumoniae co-infection 
was significantly higher when co-infection was administered 3 and 8 days post RSV infection 
(Figure 3.11A). RSV infection alone leads to cellular recruitment to the BAL, (see Chapter 4 for 
full analysis). Cell number to RSV alone was subtracted at each time point to estimate the 
number of cells infiltrating into the BAL as a result of bacterial co-infection. This number did 
not significantly change during the RSV infection (Figure 3.11B).  
Figure 3.11: Cell number during prolonged susceptibility to S. pneumoniae co-
infection 
 
 
 
BALB/c mice were infected with low dose RSV, or given PBS control. At either day 0, 3, 
8, 15, 22 or 42 post RSV mice were co-infected with S. pneumoniae. 24 hours post 
bacterial co-infection mice were culled and cellular recruitment to the BAL measured by 
haemocytometer with Trypan blue exclusion (A). At identical time points cellular 
recruitment into the BAL of mice infected with RSV alone was also calculated (data not 
shown). The number of cells infiltrating into the BAL following co-infection was inferred 
by subtracting the average number of cells in the BAL of RSV alone groups from co-
infected groups (B). N=5-10 for all time points. This data is representative of one complete 
time course and individually repeated time points. Significance was calculated by ANOVA 
with Dunnett‟s multiple correction (* p<0.05, ** p<0.01, *** p<0.001). 
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Neutrophils are essential for successful clearance of S. Pneumoniae infection [158] and 
their proportion and total number were reduced in co-infected mice at all time points post RSV 
infection (Figure 3.12A, B). This was particularly significant given that the number of bacteria 
present in the BAL was higher at these time points, such that the ratio of neutrophils to bacteria 
was significantly reduced (Figure 3.12C). 
 
Figure 3.12: Neutrophil deficiency in prolonged susceptibility to S. pneumoniae 
co-infection 
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BALB/c mice were infected with low dose RSV, or given PBS control. At either day 0, 3, 
8, 15, 22 or 42 post RSV mice were infected with S. pneumoniae. 24 hours post bacterial 
co-infection mice were culled  and the percentage (A) and number (B) of neutrophil in 
the BAL was determined by flow cytometry. The number of neutrophil per bacteria in 
the BAL was calculated (C) using CFU data from figure 3.10. N=5-10 for all time points. 
This data is representative of one complete time course and individually repeated time 
points. Significance was calculated by ANOVA with Dunnett‟s multiple correction (* 
p<0.05, ** p<0.01, *** p<0.001). 
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Both neutrophils and AMΦ produce NO in response to TLR challenge [188] which 
assists in the phagocytosis and killing of a number of microorganisms including S. pneumoniae. 
The expression of NO by neutrophils and AMΦ following co-infection with S. pneumoniae was 
significantly reduced compared to mice infected with S. pneumoniae alone (Figure 3.13) and 
did not return to naïve levels, even 6 weeks post RSV infection. 
 
Figure 3.13: Nitric oxide in prolonged susceptibility to S. pneumoniae co-infection 
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BALB/c mice were infected with low dose RSV, or given PBS control. At either day 0, 3, 
8, 15, 22 or 42 post RSV mice were infected with S. pneumoniae. 24 hours post bacterial 
co-infection mice were culled and the expression of NO on neutrophil (A) and AMΦ was 
assessed by 4-Amino-5-Methylamino-2',7'-Difluorofluorescein Diacetate (DAF-FM 
[Invitrogen, USA]) which becomes fluorescent on binding to NO. Fluorescence levels 
were measured by flow cytometry. N=5-10 for all time points. This data is representative 
of one complete time course and individually repeated time points. Significance was 
calculated by ANOVA with Dunnett‟s multiple correction (* p<0.05, ** p<0.01, *** p<0.001). 
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To investigate the activation status of AMΦ further, the expression of two negative 
regulators of macrophage function (CD200R and TREM2) were assessed at each time point post 
co-infection. The expression of both negative regulators was significantly elevated on AMΦ at 
all time points post bacterial infection as measured by geometric mean of fluorescence, and as 
the percentage of AMΦ expressing each marker (Figure 3.14). 
Figure 3.14: Negative regulator expression in prolonged susceptibility to S. 
pneumoniae co-infection 
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BALB/c mice were infected with low dose RSV, or given PBS control. At either day 0, 3, 
8, 15, 22 or 42 post RSV mice were infected with S. pneumoniae. 24 hours post bacterial 
co-infection mice were culled the expression of CD200R (A and B)and TREM2 (C and 
D)on AMΦ was assessed by the geomean of expression (A and C) and the percentage of 
AMΦ expressing each marker above FMO control (B and D). N=5-10 for all time points. 
This data is representative of one complete time course and individually repeated time 
points. Significance was calculated by ANOVA with Dunnett‟s multiple correction (* 
p<0.05, ** p<0.01, *** p<0.001). 
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The finding that susceptibility to S. pneumoniae co-infection was prolonged to 6 weeks 
following a low dose RSV infection (Figures 3.10-14) was confirmed following a high dose RSV 
infection. BALB/c mice were infected with 3x106 PFU/mouse of RSV or given PBS control. 6 
weeks later they were co-infected with a non lethal dose of S. pneumoniae and bacterial 
recovery assessed at 6 hours and 24 hours after the bacterial infection (experimental plan and 
weight loss-Figure 3.15A). At 6 hours post infection, there was no difference in the recovery of 
bacteria from the lung of PBS or RSV treated mice. However by 24 hours, PBS mice had cleared 
the bacterial infection from the lungs. In contrast RSV infected mice showed persistent 
bacterial infection of the lungs, and the development of septicaemia (Figures 3.15B and C). 
Despite the higher bacterial load in RSV infected mice, they showed a reduction in both the 
percentage and total number of neutrophils migrating into the BAL (Figures 3.15 E and F). 
There was no difference in the number of neutrophils in the lung or circulating in the blood 
between the two groups (Figures 3.15H and I). There was also no difference in the recruitment 
of other early inflammatory cells such as NK cells into the BAL or lung (data not shown).  
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Figure 3.15: Susceptibility to S. pneumoniae co-infection is prolonged into 
resolution from high dose RSV 
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BALB/c mice were infected with high dose RSV (red), or given PBS control (white) and 6 
weeks later infected with S. pneumoniae (experimental plan and weight loss-A). At 6 hours 
and 24 hours post bacterial infection, mice were harvested and the recovery of bacteria from 
the lung (B)and blood (C) assessed by CFU assay. The number of infiltrated cells in the BAL 
(D) and lung (G) was measured by haemocytometer and confirmed by flow cytometer using 
CountBrightTM Absolute counting beads (Invitrogen).The percentage of neutrophil in the 
BAL (E) was ascertained by flow cytometry, and the total number of neutrophil in the BAL 
(F) lung (H) and blood (I) was measured by flow cytometer using CountBrightTM Absolute 
counting beads (Invitrogen). N=5-10 for all time points. This experiment was not repeated. 
Significance was calculated by ANOVA with Bonferroni correction or Log Rank Mantel Cox 
test for B and C (* p<0.05, ** p<0.01, *** p<0.001). 
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As seen following a low dose RSV infection, AMΦ from the BAL of RSV infected mice 
displayed different expression profiles for a number of positive and negative regulators of 
macrophage function following bacterial co-infection, For example AMΦ from RSV treated 
mice expressed higher levels of CD200R, TREM2, and MHCII compared to PBS treated controls 
(Figure 3.16). 
Figure 3.16: Susceptibility to S. pneumoniae co-infection is prolonged into 
resolution from high dose RSV 
 
3.2.3 Endogenous secondary bacterial complications 
Since RSV infection led to a viral-severity dependant decrease in the ability of mice to control 
exogenous secondary bacterial infection, we hypothesised that viral infections might also alter 
the ability of mice to control endogenous commensal bacteria. The commensal burden of the 
nasopharyngeal cavity was assessed by CFU assay throughout high and low dose RSV infections 
in BALB/c mice (Figure 3.17A). The titre of bacteria recovered increased as the infection 
progressed, and at the higher dose, commensal bacteria were culturable from the BAL. This data 
is consistent with commensal load increases seen following influenza infection [32]. 
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BALB/c mice were infected with high dose RSV (red), or given PBS control (white) and 6 
weeks later infected with S. pneumoniae (experimental plan and weight loss-A). At 6 
hours and 24 hours post bacterial infection, mice were harvested  expression of CD200R 
(A) TREM2 (B) and MHC2 (C) by AMΦ was assessed by flow cytometry. Percentage 
expression was calculated by subtracting FMOs for each sample. This experiment was not 
repeated. Significance was calculated by ANOVA with Bonferroni correction (* p<0.05, ** 
p<0.01, *** p<0.001). 
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 At an even higher dose of RSV (5x106 PFU/ mouse) BALB/c mice continued to lose 
weight beyond day 6, and by day 7 had become moribund, and were culled. The weight loss 
profile of such a severe RSV infection was similar to the weight loss profile generated by 
infecting BALB/c mice with a high dose of influenza (4x105 PFU/influenza per mouse) (Figure 
3.17B). In this lethal viral model, commensal bacteria were again elevated in the 
nasopharyngeal cavity (data not shown), and could also be recovered from the airway at 
significantly higher titres, and interestingly were also culturable from the lung tissue (Figure 
3.17C - representative CFU assays shown in Figure 3.17D). Although the relative doses of RSV 
and influenza used in this experiment were not comparable, the disease severity as measured by 
weight loss was comparable, and the resultant reduction in antibacterial defence against 
commensal bacteria was also similar. These data suggest that during viral infections, there is a 
severity dependant increase in the level of commensal bacteria in the upper respiratory tract. 
Beyond a certain threshold of severity, these bacteria are able to gain access to the lower 
respiratory tract, and in extremely severe viral infections, bacteria are also able to invade lung 
tissue.  
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Figure 3.17: Commensal burden increases as viral disease severity increases 
 
It was noted that recovery from influenza infection was significantly enhanced in 
CD200R-/- mice. Weight loss peaked earlier at day 6 rather than day 7 in WT mice, and 
remained significantly less severe for five days during the recovery period (Figure 3.18A). The 
less severe weight loss coincided with a reduction in epithelial permeability, with CD200R-/- 
mice showing significantly lower albumin levels in the airway at day 9 post influenza infection, 
than wild type controls (Figure 3.18B). In both WT and KO mice, the commensal burden of the 
nasopharyngeal cavity at this time point, was significantly elevated compared to naive controls, 
but there was no significant difference between WT and KOs (Figure 3.18C). However WT 
mice consistently showed commensal colonisation of the airway, whilst commensal bacteria 
The commensal burden of the nasopharyngeal cavity was assessed by CFU assay  
following infection with either high or low dose RSV in BALB/c mice (A). The weight 
loss profile of a lethal influenza infection (blue squares) is similar to that generated 
following a lethal RSV infection (grey diamonds) (B). Commensal colonisation of the 
BAL and lung tissue of mice following lethal RSV or influenza infections, compared to 
naive controls as measured by CFU assay (C). Representative CFU assays (D)of naive 
BAL (i), BAL following lethal RSV infection (ii) and lung tissue following lethal RSV 
infection (iii). Data representative of  3 separate experiments for A and 1 experiment  
for B-D with 3-5 mice per group and are presented as the mean  SEM. 
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were never recovered from the airway of CD200R-/- mice (Figure 3.18D). This supports the 
hypothesis that the more severe the viral infection, the greater the complication with bacteria, 
but also suggests that less regulated AMΦ from CD200R-/- are more capable of clearing 
endogenous bacterial complications following viral infection. 
Figure 3.18: CD200R-/- recover faster from influenza infection, and are less prone 
to endogenous secondary bacterial infection 
 
 
 
WT (white circles) or CD200R-/- (red diamonds) were infected with influenza and 
their weight loss followed until they regained original weight (A). WT mice showed 
greater weight loss during the recovery period (day 7-day 12). At day 9 post 
infection  the epithelial integrity was measured by albumin ELISA (B) and the 
commensal burden of the nasal cavity (C) and airway (D) was analysed by CFU assay. 
Data representative of 1 experiment with 4 mice per group and are presented as the 
mean  SEM. p values by Mann Whitney test < 0.05 were considered significant 
(* p<0.05, ** p<0.01). 
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3.2.4: Antibiotic treatment during influenza infection 
To assess the contribution of endogenous commensal outgrowth to disease severity during viral 
infection, antibiotics were administered I/P throughout an influenza infection. Azithromycin 
and ampicillin were chosen since both are commonly used in human pneumonia [189], and the 
contrast between a bacteriostatic (azithromycin) and bactericidal (ampicillin) antibiotic was 
considered important given recent findings that the latter leads to increased disease severity in 
bacterial super-infection models [185].  
Firstly the effect of administrating these antibiotics on homeostasis was considered. 
Following a weekly treatment regime, neither azithromycin nor ampicillin were found to have 
any effect on BAL or lung cell number (Figures 3.19A and B). There was also no significant 
difference in the cellular populations of these compartments or to the expression of various 
AMΦ activation markers (data not shown). The responsiveness of AMΦ to TLR challenge was 
also not altered by antibiotic treatment (Figure 3.19C). The commensal burden of the 
nasopharyngeal cavity tended to be lower in both antibiotic treated groups; however this 
difference was only significant following azithromycin (Figure 3.19D).  
Figure 3.19: Antibiotic treatment at homeostasis 
 
 
BALB/c mice were treated I/P twice daily with either PBS (grey circles), azithromycin 
(blue diamonds) or ampicillin (purple triangles).  After 1 week of treatments, the 
number of cells in the BAL (A), and lung  (B)was assessed by haemocytometer. The  
responsiveness of AMΦ to TLR antagonism was measured by TNF production 
following overnight LPS stimulation on sorted AMΦ (C). The commensal load of the 
nasal cavity was assessed by CFU assay (D). Data representative of 1 experiment with 
5 mice per group. Statistical significance was  measured by Kruskal Wallis ANOVA     
** p<0.01.
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Having ascertained that antibiotic treatment had no obvious effects on the cellular 
environment of the lung at homeostasis, these antibiotics were then administered during an 
influenza infection (experimental plan Figure 3.20A). Antibiotic treatment had no significant 
effect on the disease severity parameters tested (weight loss, epithelial permeability, or viral 
titre (Figures 3.20B, C and D)).  
Figure 3.20: Antibiotic treatment during influenza 
 
As expected, influenza led to an increase in the commensal load of the nasopharyngeal 
cavity and sporadically led to colonisation of the BAL. When pooling 7 separate experiments, 
treatment with antibiotic reduced commensal outgrowth particularly at day 4 and 7, and 
azithromycin treatment resulted in a more significant reduction than ampicillin (Figure 3.21A). 
BALB/c mice were infected with influenza and treated I/P twice daily with either PBS 
(grey circles), azithromycin (blue diamonds) or ampicilin (purple triangles) 
(experimental plan-A).  Weight loss was followed for 15 days (B). At 4, 7 and 15 days 
post influenza mice were culled epithelial permeability of the lung assessed by 
measuring albumin in the BAL fluid by ELISA (C). Viral titre was measured by plaque 
assay at day 4 post influenza (D). Statistical significance was  measured by ANOVA 
with Dunnet‟s multiple correction.
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The degree to which antibiotics reduced the commensal load was very variable between 
experiments, and individual mice. By growing culturable bacteria on antibiotic medium and 
carrying out basic identification, it was apparent that antibiotic treatment altered the microbial 
diversity in the nasopharyngeal cavity, favouring species that were naturally more resistant to 
antibiotics without affecting the ability of these species, if present, to outgrow and colonise the 
respiratory tract during the early stages of an influenza infection (Figure 3.22). Basic screening 
for bacterial phenotype identified an E.coli like species that dominated following azithromycin 
treatment, and proteus spp following ampicillin treatment. Despite the variable efficacy of 
antibiotic treatment, overall reductions in commensal load were mirrored by a reduction in 
cellular infiltrate into the BAL (Figure 3.21B). Irrespective of antibiotic treatment, a positive 
correlation was seen between commensal load and cellular infiltrate into the BAL at day 4 and 
day 7 post infection (Figure 3.21C). This suggests that endogenous bacterial infection can 
contribute to inflammation during the early stages of influenza infection in mice.  
Figure 3.21: Antibiotic treatment during influenza 
 
 
 
 
BALB/c mice were infected with influenza and treated I/P twice daily with either PBS (grey), 
azithromycin (blue) or ampicillin (purple).  At 4, 7 and 15 days post influenza mice were culled 
and the commensal load of the nasopharyngeal cavity assessed by CFU assay  (pooled data from 7 
separate experiments) (A). The cellular infiltrate into the BAL was measured by 
haemocytometer (B). Statistical significance was  measured by Kruskal Wallis ANOVA with 
Dunn multiple correction- * p<0.05, ** p<0.01, *** p<0.001. Irrespective of antibiotic treatment 
correlations between commensal load and cellular infiltrate into the BAL were assessed by linear 
regression at day 4 (black), day 7 (red) and day 15 (green) (C). 
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Figure 3.22: Antibiotic treatment during influenza 
Bacteria recovered from mice treated with PBS, ampicillin (Amp), or 
azithromycin (Azi) during influenza infection, were tested for antibiotic 
resistance by growth on antibiotic containing agar plates. Basic bacterial 
identification was carried out using selective growth plates for example 
Maconkey agar (Mck). 
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3.3: Discussion 
In this chapter murine models of co-infection were established. RSV and influenza were used as 
viral triggers, and the subsequent response to co-infection with either Hib or S. pneumoniae 
was assessed. In addition the commensal burden following viral infection was measured, as was 
the effect of antibiotic treatment on viral disease severity. Given the different viral, bacterial 
and mouse strains used in these models, several interesting points of comparison emerge.  
 
3.3.1: RSV and Influenza as triggers of bacterial complications 
Our data suggests that susceptibility to secondary bacterial complications is dependent on the 
severity of the preceding viral infection determined by the dose of the initial virus, and also 
temporally, such that peak susceptibility correlated with the peak of viral disease severity. Thus 
reducing the dose of virus, or using a mouse strain less susceptible to viral infection reduced 
secondary bacterial complications (Figure 3.9). As in humans, in mice influenza is more 
pathogenic than RSV since a 2 log lower titre was needed to establish similar weight loss. 
However when given doses of the two viruses that established similar weight loss profiles, their 
ability to trigger secondary bacterial infection was similar (Figure 3.17). Thus, although RSV is 
less virulent, at sufficient titre it causes bacterial outgrowth in the airway and lung similar to 
influenza virus. This argues against a simple loss of barrier function by virulent viruses causing 
bacterial access to deeper tissues, or specific synergies between influenza and S. pneumoniae 
[108]. 
These results may explain why RSV, which in the majority of cases causes only mild 
upper-respiratory tract infection, is only infrequently associated with secondary bacterial 
complications compared to more pathogenic viruses like influenza. Similarly, this observation 
may explain why particularly virulent strains of influenza, such as avian influenza and the 1918 
influenza pandemic strain were associated with extensive bacterial complications [112].  
3.3.1.1 Endogenous bacterial infection 
Whether secondary bacterial infections are caused by an outgrowth of commensals or by 
exposure to novel bacterial serotypes during viral seasons when the rate of coughing, sneezing 
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and bacterial transmission is increased, is a subject of much debate within the field [190]. Mice 
are poor models to address questions of transmissibility since they are unable to cough. 
However during viral infection there appears to be a viral-severity dependent increase in the 
level of commensal bacteria in the upper respiratory tract. Beyond a certain threshold of 
severity these bacteria are able to gain access to the lower respiratory tract, and in extremely 
severe viral infections, bacteria were able to invade lung tissue (Figure 3.17). 
The diversity of bacterial species in the respiratory tract is dynamic and affected by co-
existing pathologies. The laboratory has previously shown that mice harbour an extensive range 
of bacterial species in the lower respiratory tract that synchronises to various species during 
influenza infection.  Such synchronisation leads to a dominance of species typically found in 
patients with bacterial pneumonia following influenza infection [32].  Furthermore, asthmatic 
and COPD patients experience periods of disease exacerbation that are associated with similar 
bacterial species [191, 192]. Although the chronology of the multiple infections is a subject of 
debate, it is possible that lung inflammation causes an altered or heightened bacterial carriage 
(possibly as a consequence of immune dysregulation -see Chapters 4 and 5), recently referred to 
as a dysbiosis [193]. Secondary bacterial complications therefore represent an aberrant response 
to the new dominant bacterial species. Bacterial commensals in those with asthma or COPD 
may already be skewed toward particular species such that viral infection leads to a more 
pronounced clinical outcome (Figure 2.23). The determinants of viral disease severity which 
pre-dispose to secondary complications will be investigated in the following chapter. 
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Figure 3.23: The hypothetical clinical bacterial threshold 
 
3.3.2: Hib and S. pneumoniae as causative agents of secondary 
complications 
Mice co-infected with either Hib or S. pneumoniae following a viral infection had a worse 
outcome than those given either bacteria alone, confirming that both bacterial species can cause 
secondary complications. However three key differences between S. pneumoniae and Hib co-
infections were observed. Firstly Hib was significantly less pathogenic to mice than S. 
pneumoniae, with a 2-3 log higher dose needed to establish colonisation. Secondly, whilst both 
bacteria when administered as secondary infections were capable of causing mice to become 
moribund, only S. pneumoniae was capable of causing septicaemia. Thirdly mice remained 
susceptible to secondary S. pneumoniae infections for prolonged times following resolution of 
infection whereas Hib complications were only observed during peak viral disease severity. 
Hypothetically, at homeostasis the commensal burden is kept at equilibrium by 
host innate immune responses (purple). Mild respiratory diseases like RSV (blue) 
or more severe infections, like influenza cause a temporary increase in bacterial 
carriage (green). Very severe viral infections, such as pandemic influenza strains, 
cause a greater increase in bacterial carriage, which leads their outgrowth, invasion 
of tissue, and death. Asthmatic or COPD sufferers may have heightened bacterial 
carriage (possibly as a consequence of immune dysregulation). These individuals 
may therefore be more susceptible to secondary bacterial infection following mild 
viral infections
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 These differences can be most easily explained due to the suitability of the mouse as a 
host for specific pathogens. S. pneumoniae is a natural pathogen of mice and is commonly found 
in laboratory rodent colonies, where more than 80 strains have been reported (reviewed in 
[194]). As in humans the organism is considered a commensal under normal conditions but can 
cause invasive disease typically related to the presence of specific virulence factors. Athymic 
mice are not more susceptible to disease since host innate immunity is of primary importance in 
clearing these bacteria [195-197].  In contrast naturally acquired disease caused by H. influenzae 
seems only to occur in humans. In our murine models Hib infection did not cause septicaemia, 
however in humans, invasive bacteraemia, pneumonia and acute bacterial meningitis are 
reported following Hib infection [198]. Mice are not commonly used to model Hib infection, 
with the pig > cotton rat models considered the most physiologically relevant.  In murine 
experimental models of S. pneumoniae infection, it is possible to utilise less virulent strains, 
[199] which do not cause septicaemia, but are restricted to pneumonia and lesser pathologies.  
This difference in susceptibility is likely to be clinically relevant but beyond the scope of 
this thesis to dissect here.  However, the following parameters are likely to be involved:  
A) Hib contains PAMPS for TLR2 and TLR4, whereas S. pneumoniae predominantly 
stimulates TLR2. Perhaps the reduced TLR responsiveness seen following viral infection [90] is 
compensated for if more than one TLR is ligated. It is possible that signalling pathways 
activated by one TLR are more affected than other or that TLR-responsiveness to Hib returns 
quicker.  
B) Influenza is known to reveal binding sites for S. pneumoniae [126], perhaps this 
alteration is maintained whereas binding receptors for Hib are not. 
  C) Anti-bacterial immune cells and peptides may be critical for Hib clearance and return 
more quickly than those for S. pneumoniae 
D) Hib may rely more on loss of tissue integrity for colonisation and replication and so 
once repaired the bacterium is excluded   (reviewed in Figure 3.24).  
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Figure 3.24: Causes of secondary bacterial infection, and their temporal 
relationships 
 
3.3.3: BALB/c and BL/6 murine models of single and co-infection 
BALB/c and BL/6 mice responded differently to every pathogen tested in this thesis. The 
differences were not specific to viral or bacterial immune responses, since BALB/c mice were 
more susceptible to RSV but less susceptible to influenza compared to BL/6, whilst BALB/c 
were less susceptible to S. pneumoniae, but more susceptible to Hib infection compared to BL/6. 
Several suggestions have been made to explain these phenomenon, for example the 
susceptibility to RSV in BALB/c mice is  linked to a more Th2 skewed immune response [84], 
whilst the greater susceptibility of BALB/c mice to Hib is linked to a reduction in the levels of 
naturally occurring antibody levels [200]. The presence of bacterial adhesins, anti-bacterial 
peptides and the mechanisms mentioned in section 3.3.2 are also likely to be important. Given 
that the full genome sequence of both mouse strains is well annotated, a more thorough genetic 
Hypothesised causes of bacterial complications can be divided into three main categories, 
synergy between virus, host and bacterium, physical damage resulting from cytopathology and 
immunopathology, and immune dysfunction. At peak viral disease severity, all these factors 
contribute, explaining why susceptibility to secondary infection is highest at this point (less 
virulent Hib can cause secondary complication at this point). In resolution, fewer factors 
contribute to secondary complications, so susceptibility to secondary infection is less 
pronounced, however virulent bacteria such as S. pneumoniae are still able to cause 
complications.
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explanation of susceptibility is feasible, and may shed light on the genes responsible for 
divergent individual responses to these pathogens in human infection; however this is beyond 
the bounds of this thesis.  
3.3.4:  Immune dysregulation 
Irrespective of mouse strain utilised, several features of immune dysregulation following viral 
infection were noted in this chapter which are hypothesised to increase susceptibility to 
secondary bacterial complications. 
3.3.4.1:  Neutrophil responses to co-infection 
Following viral infection there was a reduction in the number and effectiveness (as measured 
by NO production) of neutrophils recruited to the airway following bacterial co-infection. 
Neutrophil transmigration to the airway and subsequent activation is essential for bacterial 
clearance, and is a multistep process. Briefly, up-regulation of endothelial integrins and 
selectins L, E and P, captures circulating neutrophils causing them to roll and adhere to the 
endothelium. Transmigration into the airway and activation is supported by a number of 
chemokines and cytokines including in humans IL-8, GRO, and CXCL5 and in mice KC and 
MIP2α. The dominant source of neutrophil attracting chemokines in the airway is AMΦ 
(reviewed in [201]). In previous studies the recruitment of neutrophils towards I/N 
administered KC or MIP2α was unaffected following influenza infection but effected following 
TLR challenge, or pathogen challenge [90] suggesting that neutrophil deficiencies were caused 
by cells producing neutrophil attracting chemokines rather than deficiencies in neutrophils 
themselves. Here we show that this effect is common to all co-infection models studied, and as 
well as recruiting fewer neutrophils to the airway following bacterial co-infection, the 
neutrophils are hypothesised to be less effective at bacterial killing due to reduced NO 
production. Deficiencies in neutrophil recruitment and effectiveness following viral infection 
will be considered in greater detail in Chapter 5. 
3.3.4.2:  AMΦ response to co-infection 
Notable differences in the AMΦ population following bacterial co-infection were also observed. 
Firstly the production of NO by AMΦ was significantly reduced in co-infected mice compared 
to those given bacteria alone (Figure 3.13). Since NO is essential for the effective killing of 
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engulfed bacteria [188], this is likely to impact the ability of AMΦ to clear secondary bacterial 
infections. Additionally the expression of negative regulators of AMΦ function, CD200R and 
TREM2, was significantly elevated following bacterial co-infection compared to mice given 
bacteria alone. TREM2 signalling dampens TLR signalling via MyD88 and MAL [35] whereas 
loss of CD200R results in spontaneous AMΦ activation [31]. The more regulated AMΦ seen in 
resolution to viral infection are likely to be unable to mount as effective an immune response to 
subsequent bacterial challenge. This hypothesis is strengthened by my observation that 
CD200R-/- mice are protected from mortality associated with co-infection with Hib following 
influenza infection, as has been previously shown following co-infection with S. pneumoniae 
[32]. Interestingly we found that viral induced changes to AMΦ extended far into resolution, 
and were still apparent 6 weeks after viral infection. Further differences between naïve and 
resolved AMΦ will be considered in Chapter 5. 
3.3.5:  Use of antibiotics during viral infection 
Antibiotics are routinely prescribed for both hospitalised and community respiratory infections 
often without initial diagnostics. Recently antibiotic treatment was shown to have a deleterious 
effect on subsequent influenza infection in mice, due to the suggested importance of commensal 
flora in maintaining effective mucosal immunity [184]. Interestingly this study assumed that 
antibiotic treatment reduced commensal load, without actually measuring a reduction. In our 
studies, we found that antibiotic treatment altered the microbial diversity in the 
nasopharyngeal cavity, favouring species that were naturally more resistant to antibiotics 
without affecting the ability of these species, if present, to outgrow and colonise the respiratory 
tract during the early stages of an influenza infection. Therefore we question the exclusion of a 
measurement of commensal load in the assumptions of Ichinohe et al., 2011. In addition we saw 
that on average antibacterial treatment reduced cellular recruitment to the airway therefore 
suggesting that outgrowth of endogenous bacteria contributes to disease severity in murine 
models of influenza infection. The timing of antibiotic treatment may explain the differences 
between our findings (antibiotic treatment started simultaneously with influenza infection) and 
those of Ichinohe et al., 2011, (antibiotic treatment given 1 week before influenza infection). 
The use of antibiotics for respiratory infections has long been debated. Our conclusion is that by 
the time patients are hospitalised, viral infection may be contained by innate immunity and that 
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bacterial complication following severe damage to tissue integrity may pose a more serious 
threat.  A thorough trial of antibiotic treatment during severe viral infection in different patient 
cohorts is long overdue. 
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Chapter 4: Characterising RSV infection 
4.1:  Introduction 
Forward 
In chapter 3 we developed animal models of secondary bacterial complications, and showed 
that respiratory viruses (both RSV and influenza) acted as triggers for secondary complications. 
Interestingly we found temporal differences in this predisposition. Susceptibility to S. 
pneumoniae extended far into resolution, with mice remaining predisposed to secondary 
infection even 6 weeks after an initial RSV infection. In contrast susceptibility to Hib was 
limited to peak viral disease severity, at 1 week after RSV infection.  
It is likely that susceptibility to secondary bacterial infection is a multifactorial process, 
and that different factors carry different significance depending on the time post viral infection. 
In this chapter we attempt to characterise the changes that occur in the lung following RSV 
infection, to try and identify key factors which may determine susceptibility to bacterial co-
infection at different time points.  In particular we investigate the extent and duration of viral 
induced epithelial and endothelial damage, and changes that occur to the resident cellular 
populations in the BAL.  
4.1.1:  Altered lung function following RSV infection 
Severe RSV infection has long been linked with a number of predispositions to subsequent 
disease and altered lung function. As previously discussed RSV infection correlates with the 
development of secondary bacterial pneumonias, and also with an increased risk of acute and 
recurrent otitis media. In a recent study, RSV was linked to 56 % of hospitalisations with acute 
otitis media [202]. 
As well as increasing the risk of bacterial infection, severe RSV infection in the first 6 
months of life correlates with recurrent childhood wheezing, and significantly higher rates of 
asthma with 37 % of RSV bronchiolitics diagnosed with asthma compared to 5.4 % of age and 
sex matched controls [203]. Whether this association is causal is not yet fully determined 
however administration of anti-RSV immune globulin to children at high risk of RSV improves 
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asthma scores and reduces atopy [204]. In murine models, RSV infection provokes airway 
remodelling in animals that would otherwise not develop structural airway changes upon sole 
exposure to allergen via the airway [205].  
In this chapter, changes that occur in the lungs following RSV infection which may play 
a role in these various susceptibilities will be investigated. In particular we investigate the 
extent and duration of viral induced epithelial and endothelial damage, and changes that occur 
to the resident cellular populations in the BAL.  
 
4.1.2:  Lung damage following respiratory viral infection 
Of the multitude of possible factors that govern susceptibility to secondary bacterial infection 
after a viral trigger, damage to the lung epithelial and endothelial barrier integrity is perhaps 
the most obvious, but also the least studied. Unpublished claims by Jon McCullers suggest that 
viral damage alone is not sufficient to explain susceptibility to secondary bacterial infection, 
since mice treated with bleomycin, to replicate influenza induced lung damage, were not 
susceptible to secondary bacterial infection [109]. Additionally influenza virulence factors such 
as PB1F2 are associated with increased susceptibility to secondary infection, without effecting 
viral disease severity [206]. In contrast recent studies following the 2009 H1N1 influenza 
pandemic show a direct correlation with the degree of viral induced lung damage and 
subsequent susceptibility to secondary complication [207].  
Damage to the integrity of the epithelial and endothelial barrier during viral infection is 
caused by cytopathogical factors and immunopathologic effects of cell infiltration.  
4.1.2.1:  Cytopathological causes of lung damage.  
Both influenza and RSV predominantly infect epithelial cells. Direct infection can induce cell 
lysis, which releases new virions together with potentially inflammatory or harmful cellular 
contents into the extracellular space at around 20–40 h after infection [208]. Both viruses may 
also induce apoptosis of epithelial cells via classical programmed cell death pathways (reviewed 
in [209]). These processes cause significant damage to the integrity of the airway epithelium, 
potentially allowing bacteria to penetrate regions of the lung previously protected by the 
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epithelia such as the basement membrane [109]. This denudation of the airway also results in 
decreased cilial beating, hindering clearance of bacteria from the mucosa [210, 211]. 
Additionally RSV infection induces oxidative stress in the epithelium by modulating the 
expression of antioxidant enzymes [212]. 
4.1.2.2:  Immunopathological causes of lung damage. 
As previously discussed, in animal models of both RSV and influenza infections, disease severity 
correlates closely with the infiltration of inflammatory cells into the airway, which peaks 
several days after peak viral load and often after viral clearance. This suggests that excessive 
immunopathology may contribute more to disease severity than viral cytopathology.  
 Pro-inflammatory cytokines are linked with lung damage and disease severity following 
viral infection, and in particular in the development of cytokine storm [213]. Anti-TNF 
treatment reduces lung damage during influenza infection [86], whilst blocking IL-17 reduces 
epithelial damage following RSV or influenza infection [214, 215]. Similarly infiltrating 
inflammatory cells such as neutrophils, monocytes and lymphocytes secrete large quantities of 
matrix metalloproteinases (MMP) that damage and degrade the basement membranes of both 
the epithelium and the endothelium, resulting in the destruction of the micro-architecture of 
the conducting airways and alveoli [62]. Epithelial lysis is also mediated by CD8+ T-cells that 
recognise viral peptides presented on MHC class I cells via FAS ligand trimerizing FAS or 
secretion of perforin and granzyme [216]. Blocking the entry of CD8+ T-cells, or NK cells 
reduces RSV disease severity [87, 88], whilst reducing T cell proliferation in the airway via 
OX40 blockade, minimises disease severity following influenza infection [85].  
4.1.3: Changes to resident cellular populations in the BAL following 
RSV infection 
4.1.3.1: AMΦ 
At homeostasis the airway is dominated by AMΦ, which make up over 90 % of the cellular 
population [7]. Given the importance of AMΦ in orchestrating an immune response to bacterial 
challenge (see introduction), it seems likely that RSV induced changes in the number and 
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effectiveness of AMΦ may have a crucial role in the ability to combat secondary bacterial 
infection.  
AMΦ are particularly important in the early stages of RSV infection. Depleting AMΦ via 
clodronate administration causes a profound inhibition of early inflammatory cytokines into the 
airways after RSV infection and lessens the activation and recruitment of NK cells. However, 
despite the virtual abolition of early inflammatory mediator release and a rise in viral load at 
day 4, removing AMΦ has no effect on weight loss, lung function deterioration, or T-cell 
recruitment that characterizes the later stages of RSV infection [217].  
4.1.3.1.1:  Alternative activation and RSV  
Mounting evidence suggests that multiple macrophage phenotypes exist with the capability to 
carry out different functions and elicit divergent effects on surrounding cells and tissues; of 
these phenotypes „alternatively activated‟ and „classically activated‟ macrophage are the best 
characterised.  Classically activated macrophage (M1), promote inflammation, extracellular 
matrix destruction, and apoptosis. They are associated with chronic inflammation and tissue 
injury. Alternatively activated macrophage (M2), promote extracellular matrix construction, 
cell proliferation and angiogenesis. Alternatively activated macrophage tend to resolve 
inflammation and facilitate wound healing [218]. Previous murine studies suggest that RSV 
promotes the beneficial differentiation of AMΦ into alternatively activated macrophage [219].  
3.1.2.3: Negative regulators of AMΦ 
As previously described (see introduction), CD200R, a negative regulator of AMΦ function, is 
up-regulated on AMΦ during influenza infection, and this increases susceptibility to secondary 
bacterial infection [32]. The expression of CD200R during a less cytopathic infection, RSV is not 
currently known.  In this chapter we delve deeper into macrophage polarisation before, during 
and after lung viral infection. Following a literature review 9 negative regulators were selected 
for further study:   
TAM: (tyrosine-based activation motif) receptors: TAM receptors, Tyro3, Axl and MerTK, are 
involved in the regulation of macrophage via interference with NF-κB pathways and 
subsequent broad desensitisation of TLRs [42], the induction of suppressor of cytokine 
signalling 1 and 3 (SOCS-1 and 3) [43]. The main agonist/ligand for TAM receptors is GAS6, 
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which is involved in bridging phagocytic cells with externalised phosphatidyl serine on 
apoptotic cells [220].  
RONβ: The Ronβ receptor tyrosine-kinase has a regulatory role in acute lung injury [221]. Upon 
activation by macrophage stimulating protein (MSP), Ronβ reduces the production of 
inflammatory cytokines such as TNF-α and IL-12 [222] by disrupting the enzymatic cascade in 
NF-κB pathways [223]. 
ST2L: ST2L is a membrane bound form of ST2 [224] and its natural ligand is IL-33 [225]. Upon 
IL-33 binding, ST2L desensitises TLR2, 4 and 9 signalling by interference with adaptor 
molecules MAL and MyD88, downstream of TLR signalling cascade [226].  
EP2: EP2 is a receptor for Prostaglandin E2 (PGE2) and upon activation it significantly 
suppresses the phagocytic ability and production of reactive oxygen species by alveolar 
macrophage by inducing cyclic AMP (cAMP) generation and subsequent activation of cAMP 
effector molecules [227].   
LXR: (Liver X receptors) LXR (two isoforms, LXR-α and β) are nuclear receptors expressed by 
various cell types including macrophage [228, 229]. LXR forms a heterodimer with Retinoid X 
receptors (RXR) upon activation by low density lipoprotein derive oxysterols, and suppresses 
genes involved in inflammatory responses by antagonism of NF-κB [229].  
PPAR-γ (Peroxisome Proliferator-activated Receptor gamma): PPAR-γ is a nuclear receptor 
which, like LXR, forms a heterodimer with RXR [230]. PPAR- γ plays an important role in 
regulation of inflammatory responses via a process called trans-activation. PPAR- γ antagonises 
NF-κB and therefore inhibits the expression of various genes involved in inflammatory 
responses [231].    
GRK2 (G-protein coupled receptor kinase-2): GRK2 is involved in the negative regulation of 
macrophage chemotaxis. Up-regulation of GRK2 is known to be induced by high levels of MIP-
2 [232], which is a chemo-attractant secreted primarily by infiltrating leukocytes such as 
monocytes in the airway [233]. 
NO (nitric oxide): NO is thought to play several roles in AMΦ, acting in both pro-inflammatory 
and anti-inflammatory pathways [234]. In rodents, NO causes immunomodulation of AMΦ by 
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inhibiting phosporylation of the kinases involved in the production of IL-2 [235]. In vitro 
infection of AMΦ with influenza virus increases NO expression [236]. However, pre-term lamb 
in vivo models of RSV infection, show reduced NO expression by AMΦ, which correlates with 
worsened outcomes [237].  
TREM2: (Triggering Receptor Expressed on Myeloid cells): TREM2 dampens TLR signalling and 
has an anti-inflammatory role. Initial work suggests that TREM-2 suppresses macrophage TNF-
α and IL-6 production and promotes an anti-inflammatory state (Hamerman et al., 2006). 
4.1.4  Hypothesis  
This chapter characterises changes that occur in the airway following RSV infection, with 
particular emphasis on the extent and duration of lung damage and changes to the resident cell 
populations of the BAL. We hypothesise that peak lung damage will correlate with cellular 
infiltration into the BAL, and may determine susceptibility to secondary complications at this 
time point. In resolution, we hypothesize that lung damage will resolve, but that long lasting 
changes to the resident cell populations may persist and predispose to bacterial complications. 
We also hypothesise that due to the specific microenvironment in the airway, alveolar 
macrophages will display a regulatory or wound healing phenotype in naïve and inflammation 
resolved mice.  
Aims:    
1)      Develop protocols for investigating the duration and extent of epithelial and endothelial 
damage following RSV infection. 
2)      Characterise the cellular infiltration into the BAL following RSV infection, and assess the 
duration of inflammation.  
3)      Determine changes that occur in the resident T cell and AMΦ populations during and 
after RSV infection, with particular emphasis on the turnover of AMΦ, and their expression of 
negative regulators. 
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4.2 Results 
We chose a plaque purified RSV-A strain to characterise RSV infection in mice. Supporting 
previous murine RSV models, we found that live virus was detectable at day 4 post RSV 
infection, but virus was cleared from the lungs by day 8 (Figure 4.1).  
Figure 4.1: Viral titre 
 
4.2.1 Damage 
Three groups of mice were infected with different doses of RSV and weight loss followed daily 
(Figure 4.1A). As seen in chapter 3, during a high dose infection (3 x 106 pfu/mouse-red), weight 
loss peaked at day 8, but had returned to original levels by 3 weeks post infection. In lower dose 
infections (2 x 106 PFU/mouse –pink, 1 x 106 PFU/mouse-grey), weight loss peaked slightly 
earlier, and recovery to original weight was faster. To assess the level of damage in these 
different dose infections, the level of oedema and epithelial and endothelial permeability was 
BALB/c mice were infected with 3 x 106 PFU/mouse of RSV, UV inactivated 
RSV or given PBS control. At 4 and 8 days post infection lung lobes were 
harvested and the viral titre assessed by quantifying the number of plaque 
forming units (PFU) formed following infection of a monolayer of Hep-2 cells 
with lung homogenate. n=5 for each group, this experiment was not repeated. 
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inferred by measuring BAL albumin, the most abundant plasma protein,  by ELISA (Figure 
4.2B), and also total protein levels (Figure 4.2C). Protein infiltrate into the BAL closely 
mirrored weight loss, peaking 1 week post infection, and returning to naïve levels by 3 weeks in 
a dose dependant fashion. Lactate dehydrogenase is released during tissue damage and 
haemolysis and is therefore a measure of tissue damage [238]. The level of lactate 
dehydrogenase in the BAL also peaked at 1 week post infection, returning to naïve levels by 2 
weeks (Figure 4.2D). 
  In order to ensure that albumin present in the BAL was exudate from the serum, mice 
were infected with RSV, and at various time points intravenously administered with 
fluorescently labelled albumin. One hour later, mice were euthanized and the amount of 
fluorescent albumin in the BAL was measured by fluorescent reader (experimental plan – 
Figure 4.2E). Fluorescent albumin passing into the BAL was significantly increased at one week 
post RSV infection compared to naïve levels (Figure 4.2F) and by 2 weeks was reduced, but still 
significantly higher, than naïve levels.  
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Figure 4.2: Disease severity during RSV infection 
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BALB/c mice were infected with RSV high dose (3x106 PFU/mouse-RED) medium dose 
(2x106 PFU/mouse-PINK) or low dose (1x106 PFU/mouse-GREY) and weight loss 
followed daily (A). At various time points after RSV infection, BAL S/N was collected 
and the level of albumin (B) total protein (C) and lactate dehydrogenase (D) were 
measured by ELISA. The ability of albumin to travel from the blood into the airway 
was further measured using fluorescent albumin. BALB/c mice were infected with RSV, 
at various time points post infection, mice were administered I/V with fluorescent 
labelled albumin (experimental plan-A).( One hour after administration, mice were 
culled, and the level of fluorescent protein in the BAL was measured by fluorescent 
plate reader (B).  In figures A-D n=5 at each time point, and graphs for high dose RSV 
are representative of  3 separate experiments.  In figures E and F  n=5 at each time 
point. This experiment was not repeated. Statistical significance was calculated by 
ANOVA Kruskal-Wallis with Dunn’s multiple comparison test, p < 0.05 were 
considered significant (* p<0.05, ** p<0.01, *** p<0.001). 
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To achieve a more detailed visualisation of epithelial and endothelial permeability during RSV 
infection, a series of experiments were devised to measure the movement of different sized 
fluorescently labelled dextrans from within the air space into the lung tissue and serum.  
In order to optimise the concentration and size of dextran, mice were administered I/N 
with 1 or 2 μg of fluorescently labelled dextrans of 40 kDa, 70 kDa or 150 kDa (experimental 
design - Figure 4.3A). One hour later the recovery of these dextrans from the nasal wash, BAL 
supernatant, lung tissue and serum was measured by fluorescent reader (Figure 4.3B-E). There 
was no appreciable difference in the amount of the different sized dextrans recovered from the 
BAL and lung homogenate, although the amount recovered did increase with dose (Figure 4.3B, 
C). In the blood, whilst all sizes were detectable, the 4 kDa dextran was more abundant (Figure 
4.3E). This indicates that the lungs of naive mice have a low level intrinsic permeability to 
molecules that are 4 kDa or less in size, which is greatly reduced for molecules over 70 kDa. 2 
μg was found to give a higher signal, and the movement of 4 kDa and 70 kDa dextrans were 
chosen for further investigation (only 2 dextrans could be considered simultaneously in the 
same mouse, as only 2 fluorescent colours were available). Since the recovery of dextrans from 
the serum was low, a time course experiment was devised to test whether a higher reading 
would be achieved at later time points. Mice were administered simultaneously with 4 kDa and 
70 KDa dextrans, and their recovery from the nasal wash, BAL (whole and cell free), lung and 
serum measured by fluorescent reader 1 or 5 hours later (Figure 4.3F-K). The one hour time 
point was found to be optimal since although dextran recovery from the nasal wash, BAL and 
lung did not significantly change during the time course, recovery of dextrans from the serum 
was significantly reduced 5 hours after administration compared to the earlier time point. The 
recovery of dextrans from BAL compared to cell free BAL at 5 vs. 1 hour possibly suggests 
cellular take up and phagocytosis of dextrans (Figure 4.3I). 
 
 
 
 
 
123  Chapter 4: Characterising RSV 
 
Figure 4.3: Fluorescently labelled dextran optimisation 
 
Having optimised the size, concentration and duration of dextran administration, an 
experiment was devised to visualise the movement of these dextrans from the air space into the 
lung and serum during a high dose RSV infection. BALB/c mice were infected with RSV in a 
staggered fashion so that by 6 weeks different groups of mice were 6, 3, 2, 1 and 0.5 weeks post 
infection. These groups were administered I/N with fluorescently labelled dextrans. 4 and 70 
kDa dextrans were administered simultaneously (experimental plan Figure 4.4A-with weight 
loss data from the staggered RSV infections shown in shades of red) and recovery from the nasal 
wash, BAL, lung and serum assessed at 1 hour (Figure 4.4B-G).  
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Dextrans of differing molecular weights (4 kDa and 150 kDa with FITC label, and 70 kDa 
with a PE label) were administered individually I/N to BALB/c mice at a concentration of 
1mg or 2mg per mouse (Experimental plan: A). 1hour later mice were culled and the level 
of dextran present in the nasal wash (NW), BAL SN, Lung tissue and serum was measured 
by  fluorescence reader (B,C,D,E).  The 2mg dose and the 4 kDa and 70 kDa dextrans gave 
a stronger and more informative signal and were chosen for further optimisation 
experiments.  BALB/c mice were administered I/N with 2mg of both the 4 kDa and 70 kDa 
dextran simultaneously. Either 1 hour or 5 hours later mice were culled and the level of 
each dextran in the NW, BAL, BAL SN, BAL minus BAL SN (a measure of fluorescence in 
BAL cells), Lung tissue and Serum were measured by fluorescence reader (F,G,H,I,J,K).  
For figures B-K n=2-3. These experiments were not repeated. Significance was measured 
by Mann Whitney test. These experiments were carried out with the assistance of 
Master‟s student Tom Bell.
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The recovery of the larger 70 kDa dextran from the serum was not altered during the 
RSV infection (Figure 4.4F). This was surprising given the abundant movement of albumin 
from the serum into the air space (Figure 4.2B). Albumin is a 67 kDa protein and therefore a 
comparable size to the 70 kDa dextran. This suggests that movement from the blood into the 
airway is more affected during an RSV infection and possibly hinders movement in the opposite 
direction. Fluid exudate is common in respiratory infections; however the results imply that 
bacteria are unlikely to passively transfer via this route. The smaller 4 kDa dextran was 
consistently found at higher levels in the serum than the larger dextran, showing the low level 
intrinsic permeability of the lungs to molecules that are 4 kDa or less. However, during the RSV 
infection the recovery of the 4 kDa dextran increased, peaking at 1 week post infection, and 
returning to naïve levels by 3 weeks post infection (Figure 4.4F), closely mirroring the weight 
loss and damage patterns seen in Figure 4.2.  
Both the 4 and 70 kDa dextran entered the submucosal tissue of the lung. Rather than 
mirroring weight loss, we saw that recovery of both dextrans from the lung peaked 3 weeks 
after infection, returning to naïve levels after 6 weeks (Figure 4.4E). In naïve mice and at 6 
weeks post infection there was no difference in the recovery of 4 and 70 kDa dextrans from the 
lung tissue, however during peak disease severity there was an accumulation of 70 kDa dextran 
in the lung, perhaps mirroring the reduced passage of this sized molecule into the serum.   
Lower levels of the 4 and 70 KD dextran beads were observed 0.5 and 1 week after viral 
infection in BAL and BAL supernatant, compared to 2, 3 and 6 weeks post RSV (Figure 4.4 B, 
C), reflecting movement of these dextrans out of the airway during peak disease. Again, this 
pattern mirrors the weight loss and damage patterns seen in Figure 4.2. The fluorescence of 
clarified BAL supernatants differed slightly from BAL fluid containing cells; and this small 
difference may reflect uptake of dextrans by phagocytic cells. Although only detected at low 
levels, these results indicate impairment in phagocytosis at 3 and 6 days post RSV infection.  
There was no change in the recovery of dextrans from the nasal wash during infection (Figure 
4.4G). 
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Figure 4.4: Measuring lung permeability during RSV with fluorescently labelled 
dextrans 
 
Dextran penetration into lung tissue indicates epithelial/basement membrane 
permeability whereas penetration into the blood indicates further endothelial permeability. To 
assess how the severity of RSV infection affected permeability and speed of recovery, the 
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BALB/c mice were infected with RSV in a staggered fashion so that by 6 weeks different groups 
of mice were 6,3,2,1, and 0.5 weeks post infection (Experimental plan: A). These groups were 
intranasally administered with 2 mg of both 4 kDa and 70 kDa fluorescently labelled dextrans. 
1 hour later mice were culled and the level of each dextran present in the whole BAL, BAL SN, 
BAL cells (calculated by subtracting fluorescence in BAL SN from whole BAL levels), lung, 
serum and NW was measured by fluorescence reader (B, C, D, E, F, G). For this experiment 
n=5, this experiment was not repeated. Statistical significance was calculated by ANOVA 
Kruskal-Wallis with Dunn‟s multiple comparison test , p < 0.05 were considered significant (* 
p<0.05, ** p<0.01). This experiment was carried out with the assistance of Master‟s student Tom 
Bell.
------------------RSV-----------------------
4KD&70KD dextran
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amount of dextran found in lung homogenate and blood was correlated with weight loss at the 
time of sample collection and also against peak weight loss during infection as a measure of past 
disease severity. The concentration of 4 kDa dextran in the blood increased as final mouse 
weight decreased (p=0.037, Figure 4.5A), whilst no correlation was seen for the 70 kDa dextran 
in blood (Figure 4.5A), or for either dextran in the lung (data not shown). Thus, mice that were 
sicker at the end of the experiment had more 4 kDa dextran in their blood.  
When correlating against maximum weight loss, a correlation was only observed with the 70 
kDa dextran in the lung (p=0.026, Figure 4.5B). Therefore endothelial permeability, (the 
amount of dextran in the blood) closely correlated with disease severity at the time of sampling, 
whereas epithelial permeability (the amount of dextran in the lung tissue), correlated with peak 
disease severity. This indirectly indicated that during an RSV infection, damage to epithelium 
was longer lasting than endothelial damage.  
Figure 4.5: Endothelial and epithelial damage following RSV infection 
 
BALB/c mice were infected with RSV in a staggered fashion so that by 6 weeks different 
groups of mice were 6,3,2,1, and 0.5 weeks post infection (Experimental plan: figure 
4.3A). These groups were intranasally administered with 2mg of both 4 kDa and 70 kDa 
fluorescently labelled dextrans. 1 hour later mice were culled and the level of each 
dextran present in the lung and serum measured by fluorescence reader (Figure 4.4). 
Correlations between epithelial/ endothelial permeability and current or prior weight loss 
were investigated by plotting the level of dextran in the serum against final mouse weight 
(A), and by plotting the level of dextran in the lung against peak weight loss (B). For this 
experiment n=5 for each time point. Significance was determined by  linear regression. 
This experiment was not repeated and was carried out with assistance from Master‟s 
student Tom Bell. 
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4.2.1.2: Endothelial and epithelial damage by flow cytometry 
An in situ enzymatic digestion technique was optimised that maximised the recovery of 
endothelial cells (optimisation experiments not shown). Mice were euthanized, and 1 ml of 
Hank‟s Buffered Salt Solution (HBSS) with 0.13 mg/ml collagenase and 1.25 mg/ml dispaseII 
introduced into the lungs via the trachea. Lung lobes were collected into 0.13 mg/ml 
collagenase and processed as per standard methods. Cell suspensions were stained to 
differentiate endothelial cells (Figure 4.6). Dead cells and doublets were first excluded (Figures 
4.6A-D), then endothelial cells were defined as CD45 negative CD31 positive (Figures 4.6 E-F).  
Figure 4.6: Identifying endothelial cells by flow cytometry 
 
 
 
Living cells: 60.3 % Singlets1: 94.5 % Singlets 2: 93.8 %
Size selection: 98 % Endothelial cells: 8.25 %
Living cells were selected using a fixable live dead marker (Invitrogen USA) (A). Single 
cells were selected against FSC-width (B) AND SSC-width (C). Cells of the approximate 
size were selected against FSC/SSC (D). Endothelial cells were identified as CD45 
negative, CD31 positive (E, F). 
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In order to investigate endothelial damage mice were infected with RSV and at various 
time points post infection endothelial cells were isolated and stained for a panel of endothelial 
damage markers including Caveolin-1, VCAM and ICAM. 
Caveolin-1 is the major structural component of a subset of lipid rafts known as 
caveolae, which are involved in both signal transduction and receptor-mediated transcytosis of 
macromolecules from the vascular lumen [239, 240]. Caveolin-1 also directly inhibits eNOS 
activity, reducing the endothelial NO concentration and increasing vascular permeability [241].  
Up-regulation of endothelial caveolin-1 expression is proposed as a mechanism of increased 
vascular permeability in the lung in response to bacterial lipopolysaccharide [242, 243].  
Caveolin-1 expression increased from 5.73 ±0.74 % in naive mice to 18.4 ±1.3 % 1 week 
post RSV infection (Figure 4.7A-B) and had returned to that of naive mice by 6 weeks post RSV. 
Expression of ICAM-1, an intercellular adhesion molecule characteristic of endothelial cells, is 
up-regulated 72 hours post RSV infection in vitro [244]; however no increased ICAM-1 
expression was observed in our in vivo RSV model (data not shown). Endothelial VCAM-1 is 
responsible for the recruitment of wound healing epithelial progenitor cells (EPCs) to inflamed 
areas [245]; however in our model endothelial expression of VCAM-1 (vascular cell adhesion 
molecule-1) was unchanged during RSV infection (data not shown). 
As well as looking at markers for endothelial damage and repair, expression of molecules 
with an immunomodulatory function was also assessed. CD200R is a negative regulator 
expressed by AMΦ (and other myeloid cells) which ligates to CD200 ligand expressed on airway 
epithelium and lymphocytes [31]. We observed that 97.5 ±0.29 % of endothelial cells from 
naive mouse lung homogenate expressed CD200 that increased in percent (Figure 4.7C) and 
mean fluorescence intensity (Figure 4.7D) fractionally during RSV infection. CD200 expression 
is therefore ubiquitous on endothelial cells as has been reported for airway epithelial cells [31]. 
However the function of CD200 on endothelium is not known.   
 
 
 
129  Chapter 4: Characterising RSV 
 
Figure 4.7: Expression of Caveolin-1 and CD200 by endothelial cells 
 
 
 
 
 
 
 
 
 
 
BALB/c mice were infected with RSV, and at various time points post infection, mice were 
culled and endothelial cells identified from the lung homogenate and the expression of 
various markers assessed by flow cytometry. The percentage of Caveolin-1 positive 
endothelial cells (white) compared to isotype control (black) (A). The percentage of CD200 
positive endothelial cells (white) against isotype controls (black) (B). An indication of the 
expression levels of CD200 on endothelial cells was inferred by measuring the geometric 
mean of fluorescent staining of CD200 on endothelial cells (white) compared to isotype 
controls (black) (C). n=5 for each time point. 2-3 naïve mice were culled at each time point 
post infection, to ensure reliability of processing and FACS staining. Time points where 
significant variation in naïve staining was observed were excluded. This experiment was not 
repeated and was carried out with assistance from master‟s student Tom Bell. Statistical 
significance was calculated by ANOVA with Dunnett‟s multiple comparison test, p < 0.05 
were considered significant (** p<0.01, *** p<0.001). 
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Epithelial integrity was investigated by staining lung sections for ZO-1. ZO-1 is a key 
component of intercellular tight junctions required for the normal barrier function of epithelial 
and endothelial tight junctions. In vitro depletion of ZO-1 results in increased permeability 
[246]. Naïve lung displayed an intricate, extensive pattern of ZO-1 staining (Figure 4.8B). At 
peak weight loss, 1 week after infection, this expression was severely disrupted (Figure 4.8C). 
By 2 and 6 weeks post infection ZO-1 expression was repaired so as to be indistinguishable from 
naïve lung (Figures 4.8E-F). 
Figure 4.8: ZO-1 staining during RSV infection 
 
Naïve: isotype
1 week: isotype
Naïve: ZO-1 1 week: ZO-1
2 weeks: ZO-1 6 weeks: ZO-1
BALB/c mice were infected with RSV and at various time points post infection lung lobes 
were fixed in formalin and processed for immunohistochemistry. Lung sections were 
stained to visualise nuclei with DAPI [Invitrogen, USA) (blue). Tight junctions were 
visualised by staining with fluorescently labelled antibodies against ZO-1 (red) or an 
isotype control (A). Autofluorescence was visualised in green. Representative sections 
from naïve mice (B), 1,3, and 6 weeks post RSV infection (C, D, E). Representative of two 
separate experiments where n=5 per time point. Immunohistochemistry was carried out 
with assistance from master‟s student Tom Bell. 
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Despite all of the cellular and pathological changes that occur in RSV infection there 
was no significant difference between the lung function of naïve mice and those at 6 weeks post 
RSV infection by any measurement parameter assessed by plethysmography (Figure 4.9A-D). 
Figure 4.9: Lung function at 6 weeks post RSV infection 
 
 
4.2.2: Characterising cellular changes during RSV infection 
RSV propagates without causing host cell lysis, since virus buds from the host membrane or 
migrates through cells causing syncytia [51]. Disease severity has been attributed in the past to 
cellular recruitment and resultant immunopathology [84]. To assess whether cellular 
BALB/c mice were infected with RSV (resolved, red) or treated with PBS (naïve, 
white). 6 weeks post infection mice were anaesthetised and subjected to lung function 
testing which measured the resistance (A), compliance (B), tissue dampening (C) and 
elastic properties (D) of the lungs. For this experiment n=5, this experiment was not 
repeated. Plethysmography measurements were carried out with the assistance of 
Simone Walker. 
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recruitment correlates with the damage parameters previously described cellular changes that 
occur in the lung and BAL were next characterised throughout an RSV infection.  
 In the BAL, cell numbers increased 7 fold peaking 1 week post RSV infection. Cell 
numbers fell in resolution, but remained significantly elevated compared to naïve mice even 6 
weeks post infection (Figure 4.10A). Cellular infiltration into the lung tissue followed a similar 
pattern, peaking 1 week post infection (Figure 4.10B). However by 6 weeks post infection the 
number of cells in the lung had returned to pre-infection levels. In contrast lung weight 
remained significantly elevated even 6 weeks post infection (Figure 4.10C). This likely reflected 
changes in fibroblasts, epithelial and possibly endothelial cells in the repairing lung.  
Figure 4.10: Changes to BAL and lung cell number and lung weight during RSV 
infection 
 
 After restricting analysis to single (Figures 4.11A-B) live cells (Figure 4.11C), AMΦ were 
defined as CD11c high (Figure 4.11D), neutrophils as CD11c low, LY6G positive and CD11b 
positive (Figure 3.11E) and lymphocytes by back-gating CD3 positive and B220 positive cells on 
FSC vs. SSC plots (Figure 4.11F). Remaining cells which were CD11c negative and CD11b 
positive were defined as infiltrating monocytes, although this definition is not exclusive. 
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BALB/c mice were infected with RSV (resolved, red) or treated with PBS (naïve, white). 
At 3 days, 1 week, 2 weeks, 3 weeks and 6 weeks post infection mice were culled and the 
number of cells in the BAL assessed by trypan blue exclusion using a haemocytometer (A). 
Whole lung was removed and weighed (C). Lung cell numbers were assessed by trypan 
blue exclusion using a haemocytometer, following enzymatic digestion (B). Significance 
was calculated by ANOVA with  Dunnett‟s Multiple Comparison Test. p < 0.05 were 
considered significant (* p<0.05, ** p<0.01, *** p<0.001). (A) represents combined data from 
2 separate experiments. (B) and (C) represent data from 3 separate experiments where n=6 -
10. 
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Figure 4.11: Cellular identification by flow cytometry 
 
 In naïve BAL the vast majority (90%‡1.3) of the cells were AMΦ (Figure 4.12). The 
remaining 10% of cells were predominantly lymphocytes. During RSV infection AMΦ percent 
dropped reflecting an increase in the proportion of infiltrating lymphocytes > monocytes > 
neutrophils. All effects peaked 1 week post infection mirroring weight loss (Figure 4.2). By 6 
weeks post infection there was no significant difference in the proportion of any cell type in the 
BAL compared to naïve mice; the BAL was again dominated by AMΦ, with the majority of 
remaining cells defined as lymphocytes (Figure 4.12).  
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Figure 4.12: Changes in cellular populations of the BAL during RSV infection 
 
 
 
 
 
 
 
 
 
 
BALB/c mice were infected with RSV, at various time points post infection ,BAL cells 
were stained and identified by flow cytometry  as defined in figure 4.10. At each time 
point the percentage  of  AMΦ (red), lymphocytes (grey) ,neutrophils (dark red) and 
monocytes (black)  in the BAL was calculated and displayed graphically and as a pie 
chart. Significance was calculated by ANOVA with  Dunnett’s Multiple Comparison 
Test. p < 0.05 were considered significant (* p<0.05, ** p<0.01, *** p<0.001). This 
experiment is representative of two separate experiments where n=4/5 for each time 
point post RSV and n= 24 for naïve group.  Additionally individual time points were 
repeated  in separate experiments with similar results. 
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4.2.2.1: Lymphocyte population in resolution 
To understand whether lymphocytes remaining in the lung at 6 weeks were different to those 
prior to infection we used flow cytometry to identify lymphocyte subsets. The proportion 
(Figure 4.13A) and number (data not shown) of B cells was increased in resolution. This was 
mirrored by a decrease in proportion (Figure 4.13B) but not number (data not shown) of T cells. 
Within the T cell population, there was an increase in the proportion and number of cells 
expressing γδ TCR in resolution (Figure 4.13C); however there was no difference in the 
percentage of γδ T cells producing IFNγ, IL-17 or IL-22 (Figures 4.13 D-F). Within αβ TCR 
subgroups, there was an increase in the proportion expressing CD8 (Figure 4.13L) and decrease 
in those expressing CD4 (Figure 4.13G). Of CD4 cells there was increase in the percentage and 
number of IFNγ + cells (Figure 4.13 H), but no difference in the proportion expressing IL-17, 
IL-22 or IL-10 (Figures 4.13 I-K). Within the CD8 T cell population IL-17 production was 
increased (Figure 4.13N), with a trend for higher expression of IFNγ (Figure 4.13M) but no 
significant difference in the production of IL-22 or IL-10. Treg cell numbers and the proportion 
producing either IL-10 or IL-17 were no different in naïve and resolved BAL (Figures 4.13 Q-S). 
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Figure 4.13: Lymphocyte populations in resolution from RSV 
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3.2.2.2: AMΦ during RSV infection 
During early stages of RSV infection, the AMΦ proportion in the BAL dropped due to the 
recruitment of other inflammatory cells, however total AMΦ numbers were relatively stable 
(Figure 4.14G). Despite no significant change in the number of AMΦ in early time points post 
infection, expression of the phagocytotic receptor CD11B, (MAC-1) by AMΦ increased as the 
cells became activated (Figure 4.14 A-F). In resolution from infection (from 2 weeks post 
infection) the total number of AMΦ in the BAL increased compared to naïve levels, whilst the 
expression of CD11B returned to naïve levels (Figure 4.14 A-G). To understand the stability of 
the AMΦ population during RSV infection, dye experiments were designed to track the 
resident population in vivo.  
 A dose of macrophage dye (PKH26 Red Fluorescent Cell Linker [Sigma, UK]) which 
stained the majority of AMΦ in the BAL, but not other cell types in the airway, lung or blood 
was optimised (Figure 4.15). This chosen dose was 0.5nM, administered I/N. We then ensured 
that this concentration of dye would not be taken up by recruited phagocytic cells during 
inflammation by administering different concentrations of PKH26 Red Fluorescent Cell Linker 
[Sigma, UK] and one week later infecting with S. pneumoniae and analysing the resultant 
cellular infiltrate by flow cytometry. Only AMΦ and CD11c+ macrophages in the lung (which 
repeated experiments show are residual macrophages not washed out by BAL) expressed the 
dye to any extent (Figure 4.16). Having chosen 0.5nM dye/mouse, the total number of cells in 
the BAL, lung, inguinal and lung lymph nodes were assessed in dye treated and untreated mice 
to ascertain that dye treatment alone did not lead to detectable inflammation (Figure 4.17). 
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Figure 4.14: AMΦ during RSV infection 
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BALB/c mice were infected with RSV. At various time points post infection BAL cells were 
isolated and live cells stained with CD11C and CD11B. to identify AMΦ. Representative 
flow cytometry plots for each time point displayed as gradient plots (A-F), with the CD11C+  
AMΦ population gated.  From flow cytometry plots the percentage of AMΦ in the BAL was 
calculated for each time point (red line  -G). The number of AMΦ was then calculated from 
total BAL counts carried out by trypan blue exclusion using a haemocytometer (grey line –
G). Statistical significance was calculated by ANOVA with Dunnett‟s Multiple Comparison 
Test. p < 0.05 were considered significant (* p<0.05, ** p<0.01, *** p<0.001). These data are 
representative of 2 separate experiments n=5 for each time point and n=24 for naïve group. 
Additionally individual time points were repeated  between 2-8 times further as part of less 
extensive time courses.  
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Figure 4.15: Optimising dye administration to stain AMΦ in vivo 
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PKH26 Red Florescent Cell linker (Sigma, UK) was administered I/N to BALB/c mice at 
either 5, 0.5, 0.25, 0.1, 0.05, 0.025 or 0.01nM / mouse. 6 hours later, the incorporation of dye 
into  different cell types in the BAL, lung and blood (as labelled) was assessed by flow 
cytometry (dye positive-red, no dye control-black).  The average percentage of each cell type 
staining positive for dye is labelled in the right hand corner of each flow plot. These flow 
cytometry plots are representative of  one experiment where n=3. 
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Figure 4.16: Optimising dye administration to stain only AMΦ in an inflammatory 
scenario in vivo
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BALB/c mice were administered I/N with either 0.5, 0.25 or 0.1nM of PKH26 Red 
Florescent Cell linker (Sigma, UK). One week later mice were challenged with 1x10 6
CFU of S. pneumoniae I/N. 6 hours later, the incorporation of dye into  different cell 
types in the BAL, lung and blood (as labelled) was assessed by flow cytometry. (dye 
positive-red, no dye control-black). The average percentage of each cell type staining 
positive for dye is labelled in the right hand corner of each flow plot. These flow 
cytometry plots are representative of one experiment where n=3. 
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Figure 4.17: Ensuring dye administration did not cause inflammation 
 
Having optimised a suitable dose of dye to stain resident AMΦ in vivo, experiments were 
carried out to investigate the turnover of AMΦ at homeostasis and during RSV infection 
(Experimental plans Figures 4.18A, 4.19A). Consistent with previous reports [7] the turnover of 
AMΦ at homeostasis was slow. The majority of CD11c+ AMΦ (gated) were stained, and 
remained dye positive (red) throughout the 6 week experiment (Figure 4.18B-H).  
The same analysis was performed in RSV infected mice (experimental plan Figure 
4.19A). By 6 weeks post infection, less than 50 % of the original dye positive macrophage 
remained in the airway and reflected a linear increase in dye negative AMΦs infiltrating into 
the BAL (Figure 4.19H). By considering the CD11b vs. CD11c plots generated at various time 
points post infection (Figure 4.19B-G), it appeared that newly generated (dye negative-grey) 
AMΦ were initially CD11b-high (most clearly seen in figure 4.19C) and became progressively 
CD11c+ with time. Furthermore, resident dye+ AMΦ gained expression of CD11b in the Th1 
environment of the RSV infected lung and returned to naïve phenotype after 6 weeks (Figure 
4.19G). During the 6 week period following RSV or PBS administration, the turnover of dye 
positive AMΦ can be visualised as histograms in Figure 4.20.  
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BALB/c mice were administered I/N with 0.5nM PKH26 Red Florescent Cell linker 
(Sigma, UK) (red n=19) or PBS (grey n=5). At various time points after administration, 
ranging from 1 week to 6 weeks, the  number of cells in the BAL (A), lung (B), lung 
lymph nodes (C) and inguinal lymph nodes was measured by trypan blue exclusion using 
a haemocytometer. Significance was calculated by Mann Whitney test. 
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Figure 4.18:  AMΦ turnover at homeostasis 
 
 
 
BALB/c mice administered with 0.5nM PKH26 Red Florescent Cell linker (Sigma, UK) . One 
week later mice were administered with PBS. At various time points after PBS 
administration mice were culled and the incorporation of dye into AMΦ was assessed by 
flow cytometry (experimental plan A). Live cells in the BAL are shown as representative 
CD11C vs. CD11B flow cytometry plots from naive mice (B), 3 days (C) 1 week (D), 2 weeks 
(E), 3 weeks (F) and 6 weeks (G) after PBS administration. Dye positive cells are shown in 
red, and dye negative cells are shown in grey. AMΦ were identified using a CD11C+ gate as 
shown on each flow cytometry plot. The percentage of dye positive AMΦ at each time point 
was calculated, (red line H). From the percentage of dye negative AMΦ, and the total BAL 
cell counts determined by haemocytometer using Trypan blue exclusion; the number of dye 
negative AMΦ entering the BAL was calculated (grey line – H). Statistical significance was 
calculated by ANOVA with  Dunnett‟s Multiple Comparison Test. These data are 
representative of one experiment where n=4. In subsequent experiments individual time 
points were assessed with similar results.
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Figure 4.19:  AMΦ turnover during RSV infection 
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BALB/c mice administered with 0.5nM PKH26 Red Florescent Cell linker (Sigma, UK) . One 
week later mice were administered with RSV. At various time points after RSV infection, 
mice were culled and the incorporation of dye into AMΦ was assessed by flow cytometry 
(experimental plan A). Live cells in the BAL are shown as representative CD11C vs. CD11B 
flow cytometry plots from naive mice (B), 3 days (C) 1 week (D), 2 weeks (E), 3 weeks (F) 
and 6 weeks (G) after PBS administration. Dye positive cells are shown in red, and dye 
negative cells are shown in grey. AMΦ were identified using a CD11C+ gate as shown on 
each flow cytometry plot. The percentage of dye positive AMΦ at each time point was 
calculated, (red line H). From the percentage of dye negative AMΦ, and the total BAL cell 
counts determined by haemocytometer using Trypan blue exclusion; the number of dye 
negative AMΦ entering the BAL was calculated (grey line – H). Statistical significance was 
calculated by ANOVA with  Dunnett‟s Multiple Comparison Test. These data are 
representative of one experiment where n=4. In subsequent experiments individual time 
points were assessed with similar results.
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Figure 4.20:  AMΦ turnover at homeostasis or following RSV infection 
 
4.2.2.2.1: Development of alternative activation during RSV 
Previous studies suggest that RSV infection leads to the differentiation of „Alternatively 
Activated Macrophage‟ (M2) [219]. However, we show that two markers of alternative 
activation YM1 and Mannose Receptor were highly expressed on naïve AMΦ (Figure 4.21), 
which reduced on RSV infection and returned to almost pre-infection levels 6 weeks later 
(Figure 4.21). 
 MHCII is a key component of the antigen presentation machinery on APCs. Expression 
of MHCII is used as a measure of macrophage activation, and down regulation of MHCII is 
associated with an „alternatively activated,‟ M2 phenotype [247]. As previously described [248], 
20% of naïve AMΦ expressed MHCII (Figure 4.22). During an RSV infection levels of MHCII 
expression significantly increased. And remained significantly elevated even 6 weeks post 
infection (Figure 4.22). 
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BALB/c mice were administered with 0.5nM PKH26 Red Florescent Cell linker (Sigma, 
UK). One week later mice were treated with PBS (A) or RSV (B). At various time points 
afterwards, mice were culled and the incorporation of dye into AMΦ was assessed by flow 
cytometry. Representative flow cytometry plots for each time point are shown as 
histograms of the entire AMΦ population measuring fluorescence on the PE channel .
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Figure 4.21: Alternatively activated AMΦ during RSV 
 
 
 
 
 
At various time points post RSV infection AMΦ were identified by flow cytometry and 
the expression of Mannose R (A+B) and YM1 (C+D) on AMΦ calculated by subtracting 
the FMO fluorescence for each sample. Representative flow cytometry plots for each 
time point are shown in B and D, and the percentage of positive AMΦ for each marker 
shown in A and C. Significance was calculated by ANOVA Kruskal-Wallis with Dunn‟s 
multiple comparison test, p < 0.05 were considered significant (* p<0.05, ** p<0.01, *** 
p<0.001). N=5 for each time point. These data are representative of two separate 
experiments, as well as individually repeated time points. 
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Figure 4.22: MHCII expression on AMΦ during RSV infection 
 
3.2.2.2.2: Negative regulators of AMΦ during RSV:  
Similar to our previous findings during influenza infection [31] CD200R expression on AMΦ is 
high prior to infection but is expressed at even higher levels during resolution from 
inflammatory disease (Figure 4.23).  (It should be noted that since the high dose and low dose 
experiments in Figure 4.23 were carried out under different flow cytometry settings, the 
absolute expression values cannot be directly compared, however the relative expression at each 
time point compared to naïve levels is directly comparable). 
 
 
 
 
 
At various time points post RSV infection AMΦ were identified by flow cytometry and 
the expression of MHCII on AMΦ calculated by subtracting the FMO fluorescence for 
each sample. Representative flow cytometry plots for each time point are shown in A, 
and the percentage of positive AMΦ shown in B. Significance was calculated by 
ANOVA Kruskal-Wallis with Dunn‟s multiple comparison test, p < 0.05 were 
considered significant (* p<0.05, ** p<0.01, *** p<0.001). n=5-10 for each time point. 
These data are representative of two separate experiments, as well as individually 
repeated time points. 
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Figure 4.23: CD200R expression on AMΦ during RSV infection 
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BALB/c mice were infected with either high dose (3x106PFU/mouse – red) or low dose 
(1x106PFU/mouse – grey) and weight loss followed daily for 6 weeks (A). At various 
time points post infection AMΦ were identified by flow cytometry and the expression 
of CD200R was calculated by subtracting the FMO fluorescence for each sample (high 
dose B, low dose D). Representative flow cytometry plots showing CD200R expression 
on FMO (black) naïve AMΦ (red) and AMΦ taken from 6 weeks post high dose RSV 
infection (purple). Significance was calculated by Kruskal-Wallis ANOVA with 
Dunn‟s multiple comparison test,  n=5 for each time point. p < 0.05 were considered 
significant (* p<0.05, ** p<0.01, *** p<0.001). These data are representative of  separate 
time courses at each dose, as well as individually repeated time points. 
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Airway macrophages in resolution have a different phenotype to those from naïve mice.  
To extend this beyond current knowledge we selected further, novel negative regulators and 
assessed their expression profile during an RSV infection. The negative regulators selected and 
their expression profiles are listed in Table 4.1. 
Table 4.1: Negative regulators of AMΦ 
 
 
 
 
 
Detected on AMΦ 
at homeostasis (% 
above FMO)
Expression during 
RSV
Returns to naïve 
levels in 
resolution?
Expression on BAL 
macropahge higher 
than lung and 
spleen macrophage?
CD200R 75% higher no yes
Trem2 21% higher no not tested
AXL 13% higher no yes
MerTK no no - -
Tyro3 no no - -
PPARγ 18% higher yes yes
ST2L 17% higher yes not tested
IL-10R no no - -
GRK2 no no - -
Ronβ no no - -
LXRα/β no no - -
Socs3 no no - -
NO 58% lower yes not tested
EP2 8% lower no yes
A panel of potential negative regulators of AMΦ were selected following a literature 
review. Expression at homeostasis, during RSV and on macrophage from the lung and 
spleen was assessed by flow cytometry. A summary of the results is presented in this 
table. 
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IL-10R, MerTK, Tyro3, GRK2, Ronβ, LXRα/β and SOCS3 were not detectable (above 
FMO) on AMΦ either at homeostasis or during an RSV infection. This may reflect their absence 
or poor applicability of the chosen antibodies for flow cytometry. However, similar to the 
expression profile of CD200R, AMΦ were found to have higher expression of the negative 
regulators Axl, PPARΥ and EP2 compared to macrophage from the lung tissue or spleen, 
suggesting regulatory site specificity (Figure 4.24).  
 
 
Figure 4.24: Site specificity of negative regulator expression on macrophage 
 
 
 
 
 
 
 
Naïve BALB/c mice were euthanized and macrophage from the BAL (white), lung (grey), and 
spleen (black), were identified by flow cytometry. The expression of Axl (A), PPARγ (B) and 
EP2 (C), were assessed by flow cytometry. Significance was calculated by Kruskal-Wallis 
ANOVA with Dunn‟s multiple comparison test,  p < 0.05 were considered significant (* p<0.05, 
** p<0.01, *** p<0.001). n=5-10 for each tissue. These data are representative of one experiment 
and were carried out with the assistance of Master‟s student Toshifumi Fujimori.
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Similar to the heightened CD200R we observed earlier in resolved AMΦ; TREM2, AXL, 
PPARγ and ST2L were also significantly elevated during RSV infection. Of these negative 
regulators TREM2 and AXL remained significantly elevated even 6 weeks post infection (Figure 
4.25 A-F).  
 
Figure 4.25: Expression of negative regulators by AMΦ during RSV infection 
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BALB/c mice were infected with RSV. At various time points post infection AMΦ were 
identified by flow cytometry and the percentage of AMΦ expressing TREM2 (A+B), Axl 
(C+D) PPARγ (E) and ST2L (F) at each time point was calculated by subtracting the FMO 
fluorescence for each sample. Representative flow cytometry plots for TREM2 (B) and AXL 
(D) for each time point Significance was calculated by Kruskal-Wallis ANOVA with Dunn‟s 
multiple comparison test, p < 0.05 were considered significant (* p<0.05, ** p<0.01, *** p<0.001). 
N=5 for each time point. These data are representative of two separate experiments, as well as 
individually repeated time points. 
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The increase in the expression of some negative regulators of AMΦ function early in the 
RSV infection occurs at times rich in pro-inflammatory cytokines and highlights the 
importance of ongoing inflammatory control in a lung infection. However the expression of 
some negative regulators decreased during RSV infection.  As previously seen in cotton rats 
[235], at homeostasis the majority of AMΦ expressed NO (58%‡16.42), which decreased upon 
infection and returned to naïve levels one week later (Figure 4.26 A-B). Similarly EP2 
expression decreased during RSV infection, but since expression of this negative regulator was 
low on naïve AMΦ (8%‡0.8), the consequence of this slight reduction is questionable. However 
a detectable reduction in the expression of EP2 was noticeable even 6 weeks post infection 
(Figure 4.26C).  
 
Figure 4.26: The expression of some negative regulators of AMΦ function were 
reduced following RSV infection 
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BALB/c mice were infected with RSV. At various time points post infection AMΦ were 
identified by flow cytometry and the expression of NO (A+B) and EP2 (C) was calculated by 
subtracting the FMO fluorescence for each sample. Representative flow cytometry plots of 
NO expression for each time point are shown in A, and the percentage of AMΦ expressing 
NO (B) and EP2 (C). Significance was calculated by ANOVA Kruskal-Wallis with Dunn‟s 
multiple comparison test, p < 0.05 were considered significant (* p<0.05, ** p<0.01, *** 
p<0.001). N=5 for each time point. These data are representative of two separate 
experiments for EP2 and one experiment for NO, as well as individually repeated time 
points. 
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Previous experiments show that during an RSV infection AMΦ turnover takes place, 
such that by 6 weeks post infection less than 50% of the original AMΦ population remain, with 
the remaining cells made up of a newly infiltrating population (Figure 4.19).  Dye experiments 
were therefore set up to see whether phenotypic changes occurred predominantly to 
macrophages present in naïve state (resident AMΦ-dye positive) or those recruited during 
inflammation (dye negative). 
The geometric mean of CD200R did not alter between dye negative and dye positive 
macrophage in mice given PBS (figures 4.27A, C). It should be noted that the number of dye 
negative macrophage in the PBS control group was proportionally low, due to the low turnover 
rate of AMΦ (Figure 4.18). In contrast during RSV infection, the expression of CD200R was 
lower on dye negative macrophage compared to resident AMΦ.  However both populations 
expressed CD200R and in both populations the expression of CD200R increased during the RSV 
infection (Figure 4.27B). 
The expression of AXL by dye positive AMΦ was also significantly higher than on dye 
negative AMΦ (Figure 4.27D). However the expression profile was strikingly different. Whilst 
dye negative AMP consistently expressed low levels of AXL, dye positive, resident AMΦ 
dramatically increased their expression of AXL at 1 week post infection. These cells then lost 
some of this AXL expression, although expression levels remained elevated compared to naïve 
levels, even 6 weeks post infection (Figure 4.27D). 
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Figure 4.27: Assessing the phenotype of resident and infiltrating AMΦ at 
homeostasis and following RSV infection 
 
 
 
BALB/c mice administered with 0.5nM PKH26 Red Florescent Cell linker (Sigma, UK). 
One week later mice were administered with RSV (B+D) or PBS control (A+C). At various 
time points after RSV or PBS administration mice were culled and the  expression of 
negative regulators CD200R (A+B) and AXL (C+D) was assessed on dye positive AMΦ
(red) compared to dye negative AMΦ (black). Statistical significance was measured by two 
way ANOVA, with Bonferroni correction, p < 0.05 were considered significant (* p<0.05, 
** p<0.01, *** p<0.001). N=4 for each time point. This experiment was not repeated in full 
but individual time points post RSV infection were repeated with similar findings. 
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4.2.3: Testing key findings in an influenza infection model 
To understand whether the findings of this chapter were specific to the RSV model of viral lung 
disease, similar characterisation experiments were also carried out in an influenza infection 
model, with the key findings shown in Figure 4.28. An infectious dose of influenza was chosen 
that led to similar disease severity, as measured by weight loss (Figure 4.28A). Cellular 
infiltration into the BAL followed a similar pattern for both viruses, although at peak infection, 
the number of cells was significantly higher in the influenza model (Figure 4.28B). This was 
despite the significantly lower viral dose used for the influenza model compared to the RSV 
model, and no significant difference in weight loss. Similar to RSV infection, by 6 weeks post 
influenza infection less than 50% of the original AMΦ remained (Figure 4.28C). During 
influenza infection, negative regulators such as CD200R, AXL and TREM2 showed similar 
expression profiles to those seen following RSV infection (data not shown), and the expression 
of these negative regulators on resident AMΦ compared to infiltrating AMΦ was also 
comparable to those seen following an RSV infection (Figure 4.28D). 
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Figure 4.28: Confirming key findings in an influenza model 
 
BALB/c mice administered with either RSV (1x106PFU/mouse – red), influenza PR8 strain 
(100 PFU/mouse-blue) or PBS control (data not shown). Weight loss was followed daily 
for 6 weeks (A). At 3 days, 1 week, 2 weeks, 3 weeks and 6 weeks post infection mice 
were culled and the number of live cells present in the BAL assessed by trypan blue 
exclusion using a haemocytometer (B). In a parallel experiment, mice were administered 
with 0.5nM PKH26 Red Florescent Cell linker (Sigma, UK) one week prior to infection. 
At 3 days, 1 week, 2 weeks, 3 weeks and 6 weeks post infection mice were culled and the 
number of dye positive AMΦ present in the BAL assessed by flow cytometry (C). 
Expression of CD200R on dye positive (blue) and dye negative (grey) AMΦ was assessed 
by flow cytometry. Statistical significance was measured by two way ANOVA, with 
Bonferroni correction, n=4 at each time point. p < 0.05 were considered significant (* 
p<0.05, ** p<0.01, *** p<0.001). This experiment was not repeated in full but individual 
time points post infection were repeated with similar findings. 
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4.3: Discussion 
In this chapter we characterised a murine model of RSV infection, with emphasis on the extent 
and subsequent return to homeostasis of physical damage, and changes that occur to the 
number and phenotype of cells in the BAL, especially to AMΦ. A summary of the findings, 
showing the duration of each perturbation assessed in this study can be seen in Table 4.2. 
Table 4.2: Summary table showing the duration of each perturbation measured 
during a murine model of RSV infection 
 
Arrows indicate the direction of any change from naïve levels, „N‟ represents a return to 
naïve levels, and „-‟ represents an inconsistent or not measured time point. Those 
characteristics highlighted in yellow failed to return to homeostatic levels even six weeks 
after the initial infection.
Characteristic 3 days 1 week 2 weeks 3 weeks 6 weeks
Weight loss ↑ ↑ ↑ N N
albumin in BAL N ↑ N N N
protein in BAL ↑ ↑ ↑ N N
Lactate dehydrogenase N ↑ N N N
fluorescent albumin: blood->BAL N ↑ ↑ - -
Fluorescent dextran: BAL ->lung N ↑ ↑ ↑ N
Fluorescent dextran: BAL->serum N ↑ ↑ N N
Caveolin on endothelial cells - ↑ - ↑ N
CD200 on endothelial cells - ↑ ↑ ↑ N
ZO-1 tight junction expression - ↓ ↓ - N
lung function - - - - N
BAL cell number ↑ ↑ ↑ ↑ ↑
Lung cell number ↑ ↑ ↑ ↑ N
Lung weight N ↑ ↑ ↑ ↑
T cell number: BAL ↑ ↑ ↑ ↑ N
T cell proportion: BAL ↑ ↑ ↑ ↑ N
B cells (%, #) - - - - ↑
T cells (%) - - - - ↓
CD8+ T cells (%) - - - - ↑
CD4+ T cells (%) - - - - ↓
γδ T cells (%, #) - - - - ↑
AMΦ number: BAL N N ↑ ↑ ↑
AMΦ proportion: BAL ↓ ↓ ↓ ↓ N
AMΦ: expression of Mannose R ↓ ↓ ↓ ↓ ↓
AMΦ: expression of YM1 ↓ ↓ N N N
AMΦ: expression of CD200R N ↓ ↑ ↑ ↑
AMΦ: expression of TREM2 ↑ ↑ ↑ - ↑
AMΦ: expression of AXL ↑ ↑ ↑ - ↑
AMΦ: expression of ST2L ↑ ↑ ↑ - N
AMΦ: expression of PPARγ ↑ ↑ ↑ - N
AMΦ: expression of NO ↓ N - - N
AMΦ: expression of EP2 - ↓ - - ↓
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 4.3.1: Damage in the lung 
Damage to epithelium and endothelium following RSV infection was dose dependant. 
Experiments assessing the movement of fluorescently labelled dextrans through the epithelium 
and endothelium suggested that damage to the epithelium was more severe following an RSV 
infection, and recovery of this tissue was slower than for the endothelium. Interestingly we 
found that movement from the blood into the airway was pronounced during an RSV infection 
and possibly hinders movement in the opposite direction, which was less apparent. Fluid 
exudate is common in respiratory infections; however the results imply that bacteria are 
unlikely to passively transfer via this route. 
In vitro studies show that RSV is theoretically capable of infecting both epithelial cells 
and endothelial cells [244]. However in our model, damage to both epithelium and endothelium 
peaked several days after virus was cleared from the lungs, and instead correlated closely with 
the influx of immune cells into the BAL from day 3 post infection. As has been previously 
suggested [84], in our model of RSV, lung damage closely reflected cellular infiltration and 
subsequent immunopathology as opposed to cytopathology due to uncontrolled viral replication  
Irrespective of the cause of lung damage, it is striking that all the criteria used to 
measure the extent and duration of lung damage following RSV infection returned to naïve 
levels between 2-6 weeks post infection, with the majority returning to naïve levels by 3 weeks 
post infection (Table 4.2).  In contrast many of the measurements relating to the number and 
phenotype of cells in the lung following RSV infection remained permanently altered, and this 
was particularly true of AMΦ. In chapter 3 we saw that susceptibility to S. pneumoniae co-
infection was also prolonged even 6 weeks after RSV infection. Correlating these time scales 
leads to the conclusion that although lung damage may play a significant role in susceptibility 
to secondary bacterial infection at the earlier stages of a viral infection, at later time points, 
epithelial or endothelial damage is unlikely to play a critical role, and alterations in the number 
and function of the remaining cells in the BAL is likely to be the more important concern. 
Ongoing experiments will dissect the role of lung damage in susceptibility to secondary 
infection in more detail. Anti-CD4/ anti-CD8 antibody cocktails and SIP1 inhibitors will be 
administered during an RSV infection to block cellular infiltration into the lung, thereby 
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reducing immunopathology, in order to assess the subsequent effect on susceptibility to 
secondary bacterial infection.  
 
4.3.2: Cellular changes 
4.3.2.1: Lymphocytes 
As previously reported [84], we found a significant increase in the number of lymphocytes 
infiltrating into the BAL during an RSV infection, peaking at 1 week. By 6 weeks post infection 
the number of lymphocytes in the BAL had returned to naïve levels, however the populations 
of lymphocytes present in the lung tissue had altered, with greater numbers of B cells, γδ T 
cells, IFNγ+ CD4+ T cells and IL-17+ CD8+ T cells. iBALT is a tertiary lymphoid tissue which, 
unlike the foetal development of secondary lymphoid tissues, occurs post-natally and 
ectopically allowing temporal and local optimisation of immunity. Recent research shows that 
adult WT mice generate iBALT in response to influenza infection and that this (re)-generation 
is dependent on LPS exposure during a 1 week neonatal window [249]. Whether iBALT is 
induced following RSV infection in mice has not been studied, however in humans iBALT is 
found in 100 % of neonates presenting with respiratory infections, including RSV [250]. The 
induction of iBALT in the lungs of mice following RSV may explain the alteration in lymphoid 
populations in resolution.  
4.3.2.2: AMΦ 
In naive mice, AMΦ were shown to have a low turnover (Figure 4.18). However following an 
RSV infection the population became more dynamic; with just under half of the original AMΦ 
remaining in the BAL 6 weeks post infection, as well as a 2 fold net increase in the total number 
of AMΦ at this time point (Figure 4.19). During RSV infection there was both a significant 
reduction in resident cells, and an influx of newly differentiated AMΦ into the BAL. To some 
extent these two populations of AMΦ could be differentiated by their expression of certain 
markers such as AXL which was expressed predominantly on resident AMΦ and at a 
significantly lower level on newly infiltrated cells (Figure 4.27). Further phenotypic separation 
of these two populations will be assessed in chapter 5.  
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Previous murine studies suggest that RSV promotes the beneficial differentiation of 
AMΦ into alternatively activated macrophage [219]. In our model it was found that naïve AMΦ 
already express markers of alternative activation at homeostasis, and that the level of these 
markers actually reduces during RSV infection, indicating the development of a more classically 
activated phenotype. The definitions for M1 and M2 macrophage were predominantly 
developed in vitro by treatment with either Th1 or Th2 cytokine milieus [218]. Given the 
mounting evidence that multiple macrophage phenotypes exist with the capability to carry out 
different functions and elicit divergent effects on surrounding cells and tissues, classifying AMΦ 
into a narrow definition of either classically or alternatively activated seems simplistic. Our data 
suggests that this is indeed an over simplification, and that AMΦ are likely to have a unique 
phenotype both at homeostasis and following infection, which encompasses elements of both 
M1 and M2 activation pathways.  Based on the suppressive microenvironment of the airspaces 
in the steady state and an increase of this in resolution, it makes more sense that alveolar 
macrophages start and finish inflammation as a regulatory cell population.  Inflammation then 
alters them to a more inflammatory phenotype.  However, resident macrophages always display 
more markers of regulation than those recruited to the inflamed lung.  It is tempting to 
speculate that the balance between recruited and resident macrophage dictate the onset and 
severity of innate inflammation at this site. It is also tempting to speculate that resident 
macrophages may control incoming inflammatory counterparts. 
In addition to increased dynamics of the AMΦ population during an RSV infection, the 
expression of a panel of negative regulators was seen to alter during an RSV infection. Similar to 
results seen in an influenza infection the expression of CD200R was seen to be highest in 
resolution. A panel of additional negative regulators of macrophage function were also 
investigated. Although no other regulator displayed an identical expression profile to CD200R, 
the expression of several regulators including AXL, TREM2 and EP2 remained significantly 
altered even 6 weeks post infection. An aim of this study was to identify additional negative 
regulators of macrophage function that might contribute to excessive regulation in the resolving 
airway. These three regulators are likely candidates to support the innate immune rheostat 
model of susceptibility to secondary bacterial infection. As additional support for the site 
specific regulation of airway macrophage, we found several of these markers were expressed at 
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higher levels on AMΦ, compared to macrophage from more sterile sites in the spleen and lung 
tissue (Figure 4.24). Blocking these negative regulators, either with specific antibodies or by the 
utilisation of conditional knockout mice would confirm the importance of these negative 
regulators on susceptibility to secondary bacterial infection.  
Given the importance of AMΦ in orchestrating an immune response to bacterial 
challenge, it seems likely that RSV induced changes in the number and effectiveness of AMΦ 
may have a crucial role in the ability to combat secondary bacterial infection. Since lung 
damage appears to have resolved by six weeks post infection, whilst changes to the macrophage 
phenotype persisted, the 6 weeks post infection time point allows the role of AMΦ to be 
assessed with more clarity. In the next chapter we will look at the phenotype of AMΦ at this 
time point post infection in more detail.  
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Chapter 5: AMΦ in resolution 
5.1: Introduction 
Foreword 
Chapter 3 highlights that mice remain susceptible to secondary bacterial complications even 6 
weeks after RSV infection, that cannot be attributed to lung damage as epithelial and 
endothelial permeability are restored (Chapter 4). However, many measurements relating to the 
number and phenotype of cells in the lung following RSV infection remained permanently 
altered. We particularly focused on AMΦ, and hypothesised that changes that occur to these 
cells may reflect the entry of new AMΦ into the BAL. In this chapter we delve deeper into the 
phenotypic and transcriptional changes that occur to the AMΦ population 6 weeks after RSV 
infection. 
5.1.1: TLR desensitisation 
Previous work in the lab has shown that following influenza infection mice mount a restrained 
response to intranasal LPS or flagellin (TLR 2/4 and 5 agonists respectively) and reduced 
recruitment of neutrophils into the BAL due to impairment in the production of neutrophil 
recruiting chemokines. The principal cells responsible for this impairment were AMΦ and 
epithelial cells, with the former showing delayed NFκB nuclear translocation [90]. Whether 
similar TLR desensitisation occurs following other viral challenges such as RSV infection is not 
known. However, recent work shows that TLR desensitisation of AMΦ also occurs following 
induction of allergic airway disease [251]. The exact mechanism of prolonged AMΦ 
desensitisation to TLR challenge is not known.   
 
5.1.2:  AMΦ Transcriptomics  
In recent years the increasing ease and decreasing costs of genome wide system biology 
techniques such as microarrays, has seen an explosion in their use. Simultaneous advances in 
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bioinformatics techniques have greatly facilitated the interpretation and analysis of such results, 
although many limitations still exist.  
 The Gene Expression Omnibus, a NCBI (National Centre for Biotechnology Information) 
public functional genomics data repository lists 594 microarray studies involving AMΦ with the 
majority focusing on human, murine and porcine cells both in vivo and in vitro [252]. Studies 
exist detailing comparisons between AMΦ and other macrophage cell types [253], and a 
multitude of studies exist assessing transcriptome changes that follow a variety of inflammatory 
events, such as smoking, the induction of allergic airway disease as well as viral and bacterial 
infections. To date 1 transcriptomics study is recorded which assess the impact of influenza on 
AMΦ in both a human cell line, and primary human cells ex vivo [254], whilst no 
transcriptome studies have addressed transcriptome changes to AMΦ following RSV infection. 
Despite the plethora of data on differential gene expression by AMΦ during the acute phase of 
inflammation, very few studies have addressed the expressional changes that occur to AMΦ in 
resolution, or whether the genotype of AMΦ returns to naïve levels following infection.   
 miRNA transcriptomics data is also increasingly gathered. A few studies exist looking at 
miRNA transcriptome profiles on whole lung samples or from peripheral blood following 
influenza or RSV infection for example [255]. However to the best of our knowledge no studies 
have assessed differential miRNA expression in AMΦ following either of these viral infections. 
A number of specific miRNA species are revealed as important in the following chapter and so a 
brief overview of these now follows. 
 5.1.4:  Let-7 
Let-7 (lethal-7) was first discovered as a key regulator of nematode development. Subsequently 
it was found to be conserved in higher life forms, and was the first miRNA discovered in 
humans. In more complex organisms gene duplication has resulted in a large family of let-7 
genes. To distinguish between multiple isoforms a letter is placed after let-7 to indicate a let-7 
gene with a slightly different sequence, and a number at the end denotes that the same 
sequence is present in multiple genomic locations (Table 5.1 [256, 257]). Like many miRNA, let-
7 genes are often transcribed as polycistronic clusters. In humans Let-7b is transcribed as a 
cluster with let-7a-3. Mice lack let-7a-3, but instead transcribe let-7c-2 as a cluster with let-7b 
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[256]. This clustering is particularly relevant to the data presented in this chapter. Let-7 genes 
are highly conserved throughout evolution in terms of sequence and in also their position in the 
genome. The selective pressure to conserve these clusters underscores the importance of these 
genes and the need to maintain their correct expression patterns both spatially and temporally 
[256]. 
 In invertebrates such as C. elegans and D. melanogaster, let-7 has a clear role in 
regulating the proper timing of developmental events such as seam development in C. elegans 
and the larval-to-adult transition in D. melanogaster [258, 259].In vertebrates let-7 family 
miRNAs also display a distinct temporal pattern during development, but a precise role for the 
family has yet to be assigned. The difficulty in finding a direct role for the let-7 family results 
from the redundancy apparent in such a large family, and the difficulty associated with 
knocking-out multiple let-7 family members in the same animal. Although the defining role of 
the let-7 genes remains elusive, many biological functions have been assigned to these genes in 
vertebrates, principally in the control of cell differentiation, and let-7 genes function as tumour 
suppressors in a variety of cancers (reviewed in [256]).  
 In an inflammatory context, and relevant to this thesis, let-7 family members regulate 
TLR signalling. TLR-4 mRNA contains a let-7 target site, and in mouse peritoneal macrophages 
the induction of let-7e decreases cell surface expression of TLR-4 [260]. In contrast, transfection 
of macrophage with antisense miRNA to let-7e increases the LPS induced cytokine response 
[260]. The miRNA regulatory feedback loop in response to LPS challenge is regulated by Akt1, 
which is induced upon LPS stimulation [260].  
5.1.4.1:  Let-7b and let-7c 
The let-7b, let-7a-3 (or let-7b, let-7c-2 in mice) cluster seems to be regulated by epigenetic 
methylation, whereby hypermethylation inhibits expression, and hypomethylation enables 
expression [261]. In 2 out of 8 human lung adenocarcinomas and in two lung cancer-cell lines, 
let-7a-3 was hypomethylated resulting in a three-fold up-regulation of the gene and a 
subsequent oncogenic effect [262]. In contrast, like the majority of let-7 family members, let-7b 
has a tumour suppressor role. For example, it is thought that the decreased expression of let-7b 
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in ovarian cancer contributes to a less differentiated cellular state, which results in a more 
aggressive cancer [263]. 
 It is increasing recognised that individual miRNAs can have an effect on global protein 
expression; rather than controlling a small number of mRNA targets, they function at the 
transcriptional and translational level to subtly modulate the proteome. Selbach et al., 2008, 
over-expressed and then knocked out let-7b expression in HeLa cells and found a similar panel 
of approximately 2,700 proteins were repressed in over-expression experiments and de-
repressed in let-7b knockout cells. They concluded that when let-7b is up-regulated or down-
regulated, so is the proteome, meaning that let-7b can fine-tune protein production from 
thousands of genes [264]. 
Table 5.1: Conservation of let-7 family members 
 
The numbers in the table represent the number of copies a given let-7 family member has in 
a particular genome, as annotated in mirBase release 11.0 
(http://microrna.sanger.ac.uk/sequences/). A dash (–) indicates that there are currently no 
annotations for this member in mirBase release 11.0. Adapted from Roush and Slack, 2008. 
Trends in Cell Biology. 
Let-7 family 
member
C. elegans D. Melanogaster M. musculus H. sapiens
let-7a 1 1 2 3
let-7b - - 1 1
let-7c - - 2 1
let-7d - - 1 1
let-7e - - 1 1
let-7f - - 2 2
let-7g - - 1 1
let-7h - - - -
let-7i - - 1 1
let-7j - - - -
let-7k - - - -
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5.1.5: miR-322 and miR-503 
Whilst the let-7 family remain some of the most extensively investigated miRNAs, much less is 
known about miR-322(human orthologue, miR-424) and miR-503. microRNA.org estimates 
that miR-322 has 8033 predicted target genes in the mouse genome, whilst miR-503 has 7,823 
[168]. In humans, miR-424 and 503 have related seed sequences and thus share target genes, 
additionally they are transcribed together as part of a polycistronic cluster that is also thought 
to include mir-542-5p, mir-542-3p, mir-450a, mir-450b-5p and mir-450b-3p [265].  In human 
monoblast cell lines, both miR-424 and miR-503 are pro-differentiative, inducing partial 
monocytic differentiation and cell-cycle arrest in over-expression experiments [265, 266]. In 
the human HL60 leukaemia cell line miR-424 is required to commit promyelocytic blasts to the 
monocytes/macrophage lineage, and is regulated by the transcription factor PU.1 [266]. miR-
322 and mi5-503 are also involved in cell cycle quiescence during muscle differentiation [267].  
5.1.6: Aims and hypothesis 
We hypothesise that naïve and RSV- resolved AMΦ will behave differently to TLR challenge, 
and that this difference is prolonged and caused by modification by specific miRNA species that 
are amenable to therapeutic modulation.  
To address this we aim to: 
1) Assess the ability of naïve and RSV-resolved AMΦ to respond to TLR challenge 
2) Compare the mRNA and miRNA transcriptome of naïve and RSV-resolved AMΦ  
3) Using the data from (2), alter the expression of key regulators thereby altering the 
phenotype of naïve AMΦ so that they resemble resolved AMΦ and vice versa.  
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5.2: Results 
5.2.1: The airway in resolution-phenotypic differences 
5.2.1.1: TLR desensitisation in vivo  
At six weeks post viral infection, resolved mice show a prolonged susceptibility to secondary 
bacterial infection compared to naïve controls (Figure 3.10-16). Since bacterial titres following 
secondary bacterial infection are higher in resolved mice, whether qualitative differences in the 
resolved immune response were due to the initial viral infection, or simply a reflection of 
higher bacterial titre was unclear. To address this issue, mice were allowed to recover from an 
RSV infection.  The immune response of these mice was then compared to PBS treated control 
mice following challenge with LPS, a potent agonist of TLR2 and 4, associated with gram 
negative bacteria, experimental plan - Figure 5.1A. As seen in previous chapters, following RSV 
infection, mice lost approximately 20% of their body weight, returning to 100% body weight by 
two weeks post infection. Naïve control mice did not experience weight loss (Figure 5.1B). As 
seen previously, (Figure 4.10) at 6 weeks post viral infection, the number of cells in the BAL 
was significantly higher in resolved mice compared to naive controls. However, this difference 
was no longer apparent after treatment with LPS (Figure 5.1C).  By subtracting the average 
number of cells in the BAL following PBS treatment from the number found after treatment 
with LPS, it became clear that there was a significant reduction in the number of cells 
infiltrating into the BAL following LPS treatment in RSV-resolved mice compared to naïve 
(Figure 5.1D). Six hours after LPS treatment, the dominant immune response was an influx of 
neutrophils to the site of administration. In keeping with the observed reduction in cellular 
recruitment in resolved mice, we found a highly significant reduction in the proportion of 
neutrophils in the BAL compared to naïve controls following LPS treatment, and an 
accompanying reduction in the number of neutrophils in the BAL of resolved mice compared to 
naïve controls (Figure 5.1E, F).  
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Figure 5.1: Comparison of the response of naïve and RSV resolved mice to LPS 
challenge in vivo 
 
 
 
LPS (or PBS)
RSV (or PBS)
BALB/c mice were infected with RSV (resolved, red) or treated with PBS (naïve, white). 
Weight loss was followed for 6 weeks post infection (B). At 6 weeks post infection mice 
were challenged I/N with 10 μg LPS (Sigma-Aldrich) or PBS control. (Experimental plan, 
(A)). BAL cell number was  determined by haemocytometer using Trypan blue exclusion 
(C). The number of cells infiltrating into the BAL was calculated by subtracting average 
cell counts following PBS treatment from cell counts following LPS treatment (D). 
Neutrophils were defined as Ly6G+, CD11B+ by flow cytometry and expressed as a 
percentage of live cells in the BAL (E). The number of neutrophils in the BAL was 
determined by haemocytometer using Trypan blue exclusion (F). Significance was 
calculated by Man Whitney test, p < 0.05 were considered significant (* p<0.05, ** p<0.01). 
n= 5 for each group. Data representative of 2 separate experiments. 
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In keeping with the reduction in neutrophil recruitment to the BAL there was a 
significant reduction in neutrophil chemoattractants KC and MIP2α in the BAL of resolved 
mice compared to naïve assessed by a multiplex ELISA (Figures 5.2A, B). There was a similar 
trend for pro-inflammatory cytokines like TNFα (Figure 5.2C). Interestingly, the production of 
VEGF in the BAL of resolved mice was also significantly reduced compared to naïve controls, 
suggesting a role for endothelial cells and angiogenesis in the differing responses of naïve and 
resolved mice (Figure 5.2D). In contrast, Th1 associated cytokines like IL-6, IL-12 and IFNγ 
were expressed at significantly higher levels in the BAL of resolved mice compared to naïve 
controls (Figures 5.2F, G, and H). There was a similar trend in cytokines produced in response 
to IFNγ signalling including MIG and IP-10, which are also associated with a Th1 response 
(Figures 5.2I, J). No significant difference in the production of IL-10 was observed between 
naïve and resolved mice (Figure 5.2E). Other cytokines (IL-1a, IL-5, MCP, FGF, IL-1b, IL-17, 
GMC-SF, IL-2 and IL-4), were undetectable (data not shown).  
The difference in cellular recruitment following TLR challenge between naïve and 
resolved animals can be accounted for by the stated differences in cytokine levels. The cells 
which are most likely to be involved in the production of these cytokines are AMΦ and lung 
epithelial cells. We decided to focus on AMΦ.  
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Figure 5.2: Cytokine production following in vivo challenge with LPS in naïve 
and RSV resolved mice 
 
5.2.1.2: TLR desensitisation ex vivo  
In order to assess whether the behaviour of resolved AMΦ differs from naïve AMΦ we again 
infected mice with RSV or treated with PBS. Weight loss following RSV infection was 
consistent with previous experiments (data not shown). Six weeks later alveolar macrophage 
were isolated from the BAL by adherence selection and plated at an identical density of 7x104 
cells per well. Small differences in cell density between wells were corrected for by flow 
cytometric analysis of cell number using CountBright™ Absolute Counting Beads. Once 
alveolar macrophage had adhered to the bottom of the wells, they were challenged with a panel 
of TLR agonists, and the supernatant was analysed for any difference in the production of the 
pro-inflammatory cytokine TNFα (Experimental design-Figure 5.3A).  The level of TNFα 
VEGF
0
20
40
60
80
100
**
p
g
/m
l
IL-6
0
200
400
600
800 **
p
g
/m
l
MIG
0
2000
4000
6000
8000 ns
p
g
/m
l
IL-10
0
50
100
150 ns
p
g
/m
l
IP-10
0
1000
2000
3000
ns
p
g
/m
l
MIP1
0
1000
2000
3000 **
p
g
/m
l
IFN
0
50
100
150
*
p
g
/m
l
IL-12
0
100
200
300 **
p
g
/m
l
KC
0
500
1000
1500
2000
**
p
g
/m
l
TNF
0
500
1000
1500
2000
ns
p
g
/m
l
GF
EDCB
H I J
A
Multiplex ELISA showing the level of detectable cytokines in the BAL from mice infected 
with RSV (resolved-red)or PBS control (naïve-white) and 6 weeks later challenged with LPS. 
Six hours post LPS challenge mice were culled, and BAL supernatant analysed for cytokine 
levels. Detectable cytokines included KC (A), MIP2A (B) TNFA (C), VEGF (D), IL-12 (F), 
IFNG (G), IL-6 (H), MIG (I) and IP-10 (J). Cytokines were detected and analysed using 
LUMINEX multiplex systems (Life Technologies) according to manufactures‟ instructions. 
Significance was calculated by Man Whitney test, p < 0.05 were considered significant 
(* p<0.05, ** p<0.01). n= 5 for each group. Findings were confirmed in repeat experiments by 
individual ELISAs for cytokines of interest (data not shown).
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produced by resolved macrophages to agonists against TLR 2/4 and 5 was significantly lower 
than the level produced by naïve macrophage (Figures 5.3B, C).  
Figure 5.3: TLR desensitisation ex vivo 
 
5.2.1.3: Phagocytosis 
PhrodoTM (Invitrogen, USA), a fluorogenic dye, is non-fluorescent at neutral pH but fluoresces 
bright red in acidic environments, allowing accurate measurement of the engulfment of 
PhrodoTM-labelled bacteria into the acidic phagosome. As proof of principle, the phagocytotic 
capabilities of RAW cells, a mouse leukaemic monocytes/macrophage cell line, were first 
assessed (Figure 5.4A, B) in the presence or absence of the phagocytosis inhibitor cytochalasin 
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BALB/c mice were infected with RSV (resolved-red) or PBS (naïve-white). 6 weeks later 
macrophage were  purified from the BAL by adherence and challenged with TLR agonists 
(Experimental plan (A)). The  amount of pro-inflammatory cytokine TNF was detected by 
ELISA following treatment with 100 ng/ml LPS (TLR 2/4) (B), 100 ng/ml flagellin (TLR 5) 
(C). Small differences in cell numbers and viability between wells were accounted for by 
correcting for cell number as measured by CountBrightTM Absolute Counting Beads 
(Invitrogen, USA). TNF expression following treatment with other TLR agonists 
including, HKML, LTA, ssRNA and ODN1826 was not observed (data not shown). 
Significance was measured by Mann Whitney test, p < 0.05 were considered significant 
(** p<0.01, *** p<0.001). n= 5 for each group, and this data is representative of three 
separate experiments.
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D. Ex vivo, naïve AMΦ were found to phagocytose at a slower rate than the immortalised cell 
line, taking 4 times longer for 50 % of the cells to engulf bacteria (Figure 5.4C, D). In order to 
compare the phagocytic capabilities of naïve vs. resolved AMΦ, BALB/c mice were infected 
with either RSV or influenza, or given PBS control. 6 weeks later AMΦ were selected from the 
BAL and a phagocytosis assay performed ex vivo (Figure 5.4E, F, G). In general the ability of 
naïve and resolved AMΦ to carry out phagocytosis was similar, however at later time points 
there was a repeatable trend for a lower percentage of resolved AMΦ to have engulfed bacteria.  
Figure 5.4: Assessing phagocytosis 
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measured by two way ANOVA with Bonferroni correction, p < 0.05 were considered 
significant (* p<0.05, *** p<0.001).
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5.2.2:  AMΦ in resolution – genotypic changes by microarray 
Having established that RSV-resolved alveolar macrophage respond differently to bacterial 
antigens, and observed that they differentially express key markers of macrophage 
differentiation and negative regulation (see chapter 4); a microarray was carried out to assess 
fully transcriptional differences between naïve and resolved AMΦ. Mice were infected with 
RSV or PBS control (Experimental plan- Figure 5.5A, weight loss-Figure 5.5B). Six weeks later 
AMΦ were purified from the BAL by FACS (Figure 5.5C). RNA was extracted from the 
resulting 97 % pure population and analysed by Illumina mouse_ref_8 Expression Bead Chip 
Array (Illumina, USA). Advantages of this platform include a 30-fold feature redundancy for 
higher confidence fluorescent intensities, the use of 50-mer probe sequences for high selectivity 
and sensitivity, high feature density allowing smaller reagent and sample volumes and standard 
hybridisation set ups for reproducible data generation.  To ensure significant levels of RNA 
three mice were pooled for each replicate. 100 ng of total RNA was measured for quality using 
Agilent Bioanalyser RNA nano chip (Agilent). Samples with an RNA Integrity Number (RIN) 
greater than 7.5 were passed for further processing. RNA was converted to labelled cDNA and 
run on the array where the relative expression of more than 25,000 probe sequences across the 
entire mouse transcriptome was assessed. Data was analysed using Illumina‟s GenomeStudio 
package with Quantile normalisation. Microarray and data analysis was carried out using the 
facilities at the Genome Centre, Barts and the London School of Medicine and Dentistry, with 
particular assistance from Rosamond Nuamah.  
Quality control analysis of the microarray data showed that positive hybridisation 
controls were high, whilst background controls were low (Figure 5.6A,B). In general the total 
gene number for each sample reflected the levels of eight reference housekeeping genes (Figure 
5.6C, D). These data suggest that the RNA was high quality, and any results generated from the 
array were likely to be reliable. On average 6250 probed sequences were detected in each 
sample with a stringency of detection of p=> 0.01 (Figure 5.6E). Decreasing the stringency to 
p=>0.05 gave approximately 8000 probed sequences per replicate (Figure 5.6F). At either 
stringency there was no significant difference in the number of detected genes between naïve 
and resolved AMΦ. A dendrogram of the correlation index showed that naive replicates and 
resolved replicates differed by at least 0.03 % of the detectable transcriptome, whilst variation 
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within groups was on average 0.01% (Figure 5.7). The average fluorescence signal from 
hybridisation to each probe was calculated across biological replicates. Statistically significant 
differences for each probe between naïve and resolved AMΦ transcriptomes were assessed by 
ANOVA with Bonferroni correction, a stringent statistical test for this analysis. Even by this 
stringent analysis 341 probed sequences were differentially expressed between naïve and 
resolved AMΦ, representing 290 unique genes as depicted in Figures 5.8 and 5.9.  
 
Figure 5.5: Preparing AMΦ samples for microarray analysis 
 
 
 
BALB/c mice were infected with RSV (red) or PBS control 
(black). Weight loss was followed for 6 weeks (B). 6 weeks later 
macrophage were  purified from the BAL by FACS 
(experimental plan (A)). Alveolar macrophage  were sorted from 
whole BAL (Ci). Singlets were selected by FSC-A vs. FSC-H 
(Cii). Live cells were selected as PI negative (Ciii). Alveolar 
macrophage were selected by CD11c expression (Civ). The 
sorted alveolar macrophage population were 95-99% pure (Cv). 
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Figure 5.6: Microarray quality control 
 
Figure 5.7: Dendrogram comparing the transcriptome of naïve and resolved AMΦ 
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Figure 5.8: Comparing the transcriptome of naïve and resolved AMΦ 
 
 
 
 
 
 
 
 
 
 
Average fluorescent signal: Naïve AMΦ
The average fluorescent signal of each probe for both naïve (x axis) and resolved (y axis) 
AMΦ was compared. The vast majority of the transcriptome was expressed at similar 
levels in the two groups (black dots), however 345 probe sequences were differentially 
expressed as assessed by ANOVA with Bonferroni correction(blue dots). Analysis 
performed by GenomeStudio (Illumina, USA).
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Figure 5.9: Heat map comparing the transcriptome of naïve and resolved AMΦ 
 
11
4
7.5
NaïveResolved NaïveResolved NaïveResolved NaïveResolved
Heat map with hierarchical 
clustering of samples. Each row 
represents a probe sequence 
identified as differentially 
expressed between naïve and 
resolved AMΦ, and each 
column represents a sample 
(naïve AMΦ – left hand side, 
Resolved AMΦ – right hand 
side). The colour scale illustrates 
relative expression levels of each 
probe sequence relative to the 
geometric mean of all probes in 
the array. Analysis performed 
by GenomeStudio (Illumina, 
USA). 341 probe sequences were 
differentially expressed 
representing 290 unique genes.
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Table 5.2: Differentially expressed genes 
 
The genes with the largest fold change expressed most highly in naïve AMΦ compared to 
resolved (top) and expressed most highly in resolved AMΦ compared to naïve (bottom). 
Functional descriptions from Gene, NCBI (www. Ncbi.nih.gov/gene). Un-characterised 
genes, or those with very little known information are highlighted in gold.
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The genes which analysis revealed to have the largest fold change between naïve and 
resolved AMΦ are shown in Table 5.2, with a brief functional description [268]. Several of the 
genes most highly expressed in naïve AMΦ compared to resolved are involved in cell motility, 
whilst several of the genes most highly expressed in resolved AMΦ compared to naïve are 
components of MHCII. Given the functional differences between naïve and resolved AMΦ, 
namely, TLR desensitisation (see Figure 5.3), several of this genes are worthy of further 
investigation including, Nmes1, (which contains miR-147b, a regulator of TLR signalling), and 
Fgr2b which causes down regulation of activated cells. Additionally, very little information is 
currently known about several of the listed genes, (highlighted in gold) and they are also 
worthy of further investigation.  
5.2.2.1:  MHCII 
MHCII down-regulation is associated with the „alternatively activated‟ macrophage phenotype. 
In Chapter 4 the expression of MHCII was shown to be higher on resolved AMΦ by flow 
cytometry. Microarray analysis revealed that of the 35 genes in the murine MHC cluster [269], 
16 were expressed to detectable levels by AMΦ. Of these 16 genes, 6 were differentially 
expressed between naïve and resolved AMΦ (Figure 5.10) with 4 of these forming components 
of MHCII (Figure 5.10B-E). A further 10 components of the MHC cluster were differentially 
expressed when measuring significance by Mann Whitney t test (data not shown). CIITA is a 
transcription factor, and the master regulator of MHCII expression [270]. Interestingly resolved 
AMΦ also expressed significantly elevated levels of CIITA (Figure 5.10F). 
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Figure 5.10: MHC genes 
 
 
 
Transcriptome date from naïve (white) and resolved (red) AMΦ generated by 
microarray was mined to assess relative expression of members of the MHC cluster 
(A), (taken from: Immunity: The Immune Response in Infectious and Inflammatory 
Disease. Anthony L. DeFranco, Richard M. Locksley, and Miranda Robertson. 2007. 
Oxford University Press ).4 genes which form MHCII were expressed at higher levels 
by resolved AMΦ (B-E). CIITA, a transcription factor that controls expression of 
MHCII genes also showed significantly elevated expression in resolved AMΦ (F).
Additionally resolved AMΦ expressed higher levels of a component of MHCI (G) and 
a non classical MHCI molecules  (H). Significance was measured by ANOVA with 
Bonferroni correction. *** p<0.001.
CIITA
0
100
200
300
400 ***
F
lo
u
re
s
c
e
n
c
e
 s
ig
n
a
l (
a
u
)
H2-Aa
0
200
400
600
800 ***
F
lo
u
re
s
c
e
n
c
e
 s
ig
n
a
l (
a
u
)
H2-Ab1
0
5000
10000
15000
20000 ***
F
lo
u
re
s
c
e
n
c
e
 s
ig
n
a
l (
a
u
)
H2-DMb1
0
5000
10000
15000 ***
F
lo
u
re
s
c
e
n
c
e
 s
ig
n
a
l (
a
u
)
H2-Ea
0
5000
10000
15000
20000
25000 ***
F
lo
u
re
s
c
e
n
c
e
 s
ig
n
a
l (
a
u
)
H2-K1
0
2000
4000
6000 ***
F
lo
u
re
s
c
e
n
c
e
 s
ig
n
a
l (
a
u
)
H2-T23
0
5000
10000
15000 ***
F
lo
u
re
s
c
e
n
c
e
 s
ig
n
a
l (
a
u
)
B C E
F
D
G
A
H
AMCase
120
140
160
180
threshold
Naive
Resolved
F
lo
u
re
s
c
e
n
c
e
 s
ig
n
a
l 
(a
u
)
181  Chapter 5: AMΦ in resolution 
 
 
5.2.2.2:  Alternatively activated macrophage. 
Transcriptome data from naïve and resolved AMΦ generated by microarray was mined to assess 
relative expression of identified markers of alternatively activated macrophage. As previously 
suggested from analysis of protein expression by flow cytometry (Figure 4.21), AMΦ 
transcribed two markers of alternative activation at homeostasis; Mannose Receptor (Figure 
5.11A) and YM1 (Figure 5.11B). There was a significant reduction in the expression of Mannose 
Receptor protein in resolution (Figure 4.21A). Although there was a trend for reduced 
expression of the mRNA, this was not significant (Figure 5.11A). Additional markers for 
alternative activation of macrophage; Relmα, Arginase 1, and AMCase were not expressed by 
AMΦ either at homeostasis or in resolution, again confirming flow cytometry data (Figures 
5.11C, D, E).  
Figure 5.11: Alternatively activated AMΦ markers 
 
Transcriptome date from naïve (white) and resolved (red) AMΦ generated by microarray was 
mined to assess relative expression of identified markers of alternatively activated 
macrophage. Both Mannose Receptor  (A) and YM1 (B) were expressed at high levels by AMΦ
whilst Relmα, Arginase 1, AND AMCase were below the threshold of detection. Significance 
calculated by Mann Whitney test, on individual graphs, and by ANOVA with Bonferroni 
correction on the entire microarray. 
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5.2.2.3:  Negative regulators of AMΦ 
In chapter 4 the expression of a panel of potential negative regulators of AMΦ was assessed by 
flow cytometry.  Data mined from the microarray confirmed the transcriptional expression of 
CD200R, Trem2, AXL, ST2L, PPARγ and EP2 by AMΦ. Additionally transcriptional expression 
of MerTK, Ronβ, GRK2 and LXRβ was shown although protein expression of these negative 
regulators was not apparent by flow cytometry. Transcriptional expression of Tyro3 by AMΦ 
was not apparent (Figure 5.12). 
 6 weeks post RSV infection the protein expression of CD200R, AXL, TREM2 and EP2 
had not returned to naïve levels (Chapter 4). This data was supported by transcriptome 
comparisons between naïve and resolved AMΦ when relative transcriptional expression 
significance was assessed by Mann Whitney t test (black significance stars- Figure 5.12). 
However only the transcriptional expression of Trem2 was significantly different between 
naive and resolved AMΦ when correcting for multiple comparisons over the entire microarray 
by ANOVA with Bonferroni correction (blue significance stars – 5.12). Interesting Trem1, 
which sends a pro-inflammatory signal to AMΦ, was also differentially expressed, with higher 
transcriptional expression in naïve AMΦ compared to resolved AMΦ, in direct opposition to 
anti-inflammatory Trem2, which was more highly expressed on resolved AMΦ (Figure 5.12).  
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Figure 5.12: Negative regulators of AMΦ 
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Transcriptome date from naïve (white) and resolved (red) AMΦ generated by 
microarray was mined to assess relative expr ssion of various negative regulators. 
CD200R (A), Trem2 (B), EP2 (C), and the TAM receptors Axl (D) and MerTK (E) 
were all expressed at higher levels in resolved AMΦ. The Tam receptor Tyro3 was 
below the threshold of detection (F). Trem1 (G), GRK2 (H) and LXR β (I) were 
expressed at lower levels on resolved AMΦ. There was no significant difference in 
the expression of PPARγ (J), ST2L (K) or Ronβ (L) between naïve and resolved 
AMΦ. Significance calculated by Mann Whitney test (black significance stars), and 
by ANOVA with Bonferroni correction on the entire microarray. (blue significance 
stars). 
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5.2.2.4:  Pathway analysis 
In order to better understand the microarray data, pathway analysis was performed to identify 
whether altered genes mapped to specific molecular pathways. Canonical pathway analysis 
identified pathways from the Ingenuity Pathways library that were most significant to the data 
set. The significance of the association between the data set and the canonical pathway was 
measured in two ways. First, a ratio of the number of molecules from the data set that mapped 
to the pathway divided by the total number of molecules that mapped to the canonical 
pathway. Secondly, Fisher's exact test was used to calculate the probability that the association 
between the genes in the dataset and the canonical pathway could be explained by chance 
alone. For this purpose, p=< 0.05 was set as a threshold (Figure 5.13).  
Pathway analysis is obviously limited to the confines of the database used and 
subsequently current scientific knowledge. Many genes are yet to be assigned functions, let 
alone roles in complex pathways, whilst others are extensively studied. Moreover, pathway 
analysis is skewed towards pathways under greater investigation, for example cell 
cycle/oncogenesis pathways and inflammatory pathways. Within these limitations, we found 
that of the 290 unique genes identified as significantly different between naïve and resolved 
AMΦ, 101 were placed in 159 known pathways, with 40 pathways deemed significantly altered 
between naïve and resolved AMΦ by the above criteria (Figure 5.13).  
Certain genes were particularly prominent in this pathway analysis. For example Prkcb 
(a gene which encodes a member of the Protein Kinase C (PKC) family of serine and threonine 
specific protein kinases) was represented in 29 unique molecular pathways. Similarly 7 genes 
encoding murine MHC proteins were represented in between 12 and 22 different pathways.    
The most significantly altered pathway between naïve and resolved AMΦ was the 
„Antigen Presentation Pathway‟. Additionally several pathways associated with interactions 
between innate and adaptive immune systems were altered. NFAT signalling was significantly 
altered between naïve and adaptive AMΦ, which is interesting given the role of NFAT in 
regulating the homeostasis of innate cells [271].The TREM signalling pathway was also 
significantly altered. Also notable was the number of altered pathways associated with the 
mechanism and regulation of cell cycling. 
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Figure 5.13: Pathway analysis of microarray data 
 
 
 
mRNA sequences which were assessed as significantly different between naïve and resolved 
AMΦ were subjected to pathway analysis to assess which molecular pathways were most 
altered between the two groups. Canonical pathway analysis identified pathways from the 
Ingenuity Pathways Library that were most significant to the data set. The significance of the 
association between the data set and the canonical pathway was measured in two ways. First, a 
ratio of the number of molecules from the data set that map to the pathway divided by the 
total number of molecules that map to the canonical pathway (red-right hand Y axis). 
Secondly, Fisher's exact test was used to calculate a p value determining the probability that 
the association between the genes in the dataset and the canonical pathway was explained by 
chance alone (blue-left hand Y axis). For this purpose, p value of less than 0.05 was set as a 
threshold. Analysis performed using Ingenuity free trial software by Arshad Khan (Imperial 
College London).
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5.2.2:  AMΦ in resolution – miRNA genotypic changes  
miRNA are short RNA molecules with an average length of 22 nt. They act as post-
transcriptional regulators that bind to complementary sequences on target mRNA. miRNAs are 
well conserved in eukaryotic organisms and are thought to be a vital and evolutionarily ancient 
component of genetic regulation. Having found significant differences in the mRNA profile 
between naïve and resolved AMΦ, the miRNA profile of these cells was also investigated using 
an RT-qPCR gene panel of 375 murine miRNA (Exiqon, Denmark).  
In an identical set up to that used when collecting AMΦ for mRNA microarray, mice 
were infected with RSV (resolved mice) or treated with PBS (naïve mice). Six weeks later, AMΦ 
were sorted from the BAL by FACS (as in Figure 5.5). miRNA were purified from the resulting 
99% pure macrophage population by chloroform extraction. The amount of miRNA extracted 
from the whole BAL of resolved mice was significantly higher than that extracted from the 
whole BAL of naïve mice as measured by average CP (Figure 5.14A). This reflects the higher 
macrophage numbers seen six weeks after infection (Figure 5.14B). The RNA concentration was 
measured by picochip (Agilent). To assess the validity of the picochip concentration values, data 
was correlated with the CP of the housekeeping miRNA, miR-103 (Figure 5.14C). The quality 
of the miRNA was assessed and samples with a RIN higher than 7 were passed for further 
processing. The samples were assessed for the presence of RT-qPCR inhibition by analysis of 
the linearity of RTs when altering the RNA input per sample. A 10 fold dilution of RNA is 
expected to give a signal approximately 3.3 cycles higher, and a linear response to a series of 
dilutions. There was no sign of inhibition in any sample, and the assays gave Cps in the 
acceptable range for full genome wide profiling (Figure 5.15). Each RNA sample was reverse 
transcribed into cDNA and run on a mercury LNATM Universal RT miRNA panel containing 
375 miRNA assays and a range of positive, negative and inter-plate calibration controls. Melting 
curve analysis was performed on all samples to evaluate the specificity of the assays by 
generating a melting curve for each reaction (data not shown). Any assays that showed multiple 
peaks in this analysis were excluded from the data set. Assay efficiencies were determined and 
individual assays that gave efficiency <1.6 were excluded from the data set. The amplification 
curves were analysed by ROCHE LC software for determination of Cp (by 2nd derivative 
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method) and for melting curve analysis. The data was normalised using the geometric mean of 
miRNA detected in all samples.  
 
 
Figure 5.14: Quality control of sample for miRNA RT-PCR array 
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(A). The BAL cell number was determined by haemocytometer count with trypan blue 
exclusion (B). The concentration of miRNA in each sample was measured by picochip 
and correlated with the Cp of the house keeping miRNA miR-103 (C). Analysis 
performed by Exiqon, Denmark.
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Figure 5.15: Assessing for RT-qPCR inhibition in each sample 
 
 
 
 
 
 
 
Naïve AMΦ replicates
Resolved  AMΦ replicates
In the absence of RT-qPCR inhibition, a 10 fold dilution of RNA is expected to give a 
signal approximately 3.3 cycles higher, and a linear response to a series of dilutions 
(ideal data-orange). Actual RT values across a range RNA dilutions for 5 miRNA genes 
(let7a-blue, hsa-miR-16-red, hsa-miR-21-green, hsa-miR-103-purple and mmu-miR-
155-light blue) were assessed for naïve biological replicates (top) and resolved 
biological replicates (bottom). In all cases the experimental results closely matched the 
ideal results indicating that no inhibition was present in any sample. Analysis 
performed by Exiqon, Denmark.
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78 miRNA were detected in all samples, and analysed by two way hierarchical clustering 
of miRNA and samples (Figure 5.16). The expression of 35 miRNA was significantly different 
between naïve and resolved AMΦ, having a p-value of <0.05 by t-test (Figure 5.17). Of these 35 
miRNA, 15 were expressed more highly in naïve AMΦ, compared to resolved AMΦ (Figure 
5.18), of which 3 (mmu-miR-322, mmu-miR-503 and hsa-miR-450a-5p) were statistically 
significant by more stringent testing using ANOVA with Bonferroni correction (Figure 5.18A, 
D, H). These 3 miRNA are closely located on the X chromosome, and in humans are thought to 
be transcribed as a polycistonic cluster [265]. In this group, mmu-miR-322 was the most 
differentially expressed miRNA, with a fold change of 0.3 between naïve and resolved AMΦ 
and a p-value of 1.56 x10-6 (Figure 5.18A). 20 miRNA were expressed more highly in resolved 
AMΦ compared to naïve AMΦ (Figure 5.19), of which 5 (hsa-let7b, hsa-miR-29c, hsa-miR-16, 
hsa-miR-152 and  hsa-miR-185), were statistically significant by more stringent testing using 
two way ANOVA with Bonferroni correction (Figure 5.19A, E, J, K, N). In this group, hsa-let7b 
was the most differentially expressed miRNA, with a fold change of 10.97 between naïve and 
resolved AMΦ and a p-value of 4.84 x10-6(Figure 5.19A). Further analysis of the RT-qPCR array 
revealed differences between naïve and resolved AMΦ which were excluded from the original 
analysis. Both miR-let7c (Figure 5.19U) and miR-106b (Figure 5.19V) were not detected in any 
of the naïve macrophage samples, but were found in all the resolved macrophage samples. 
These miRNA were excluded from the original analysis which only considered miRNA detected 
in all samples. However due to the obvious difference in expression between naïve and resolved 
samples, these miRNA were included in subsequent analysis of the data set although a  
significance value could not be placed on their relative expression. 
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Figure 5.16: 78 miRNA were detected in all samples  
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Figure 5.17: Differentially expressed miRNA 
 
 
After normalisation against the geomean of miRNA detected in all 8 
samples (Figure 5.16), the expression of 35 miRNAs were identified as 
statistically significantly different between naïve AMΦ (left hand side) and 
resolved AMΦ(right hand side). Statistical significance was assessed by t-
test, and awarded for p-values <0.05. These miRNA are displayed as a heat 
map with two-way hierarchical clustering of miRNAs and samples. Each 
row represents a miRNA and each column represents a sample. The miRNA 
clustering tree is shown on the left of the heat map. The colour scale 
illustrates the relative expression level of each miRNA. Red represents an 
expression level above the mean, whilst green represents expression lower 
than the mean. Analysis performed by Exiqon, Denmark.
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Figure 5.18: 15 miRNA were expressed more highly in naïve AMΦ 
 
 
 
 
 
 
 
 
After normalisation against the geomean of miRNA detected in all 8 samples (Figure 
5.16), the relative expression of 15 miRNAs was higher in naïve AMΦ (white) 
compared to resolved AMΦ (red) by t-test (p values shown for each graph). For 3 
miRNA the difference in relative expression was significant by more stringent testing 
using two way ANOVA with Bonferroni correction (blue boxes, significance levels  in 
blue * p<0.05, ** p<0.01, *** p<0.001).
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Figure 5.19: 22 miRNA were expressed more highly in resolved AMΦ 
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After normalisation against the geomean of miRNA detected in all 8 samples (Figure 
5.16), the relative expression of 20 miRNAs was higher in resolved AMΦ (red) 
compared to naïve AMΦ (white) by t-test (p values shown for each graph). For 5 
miRNA the difference in relative expression was significant by more stringent testing 
using two way ANOVA with Bonferroni correction (blue boxes, significance levels  in 
blue * p<0.05, ** p<0.01, *** p<0.001). Additionally hsa-let-7c and hsa-miR-106b were 
expressed highly in resolved AMΦ, but undetectable in naïve AMΦ (red box-U,V).
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5.2.2.1:  Validating miRNA array data 
Of the 8 miRNA which were differentially expressed between naïve and resolved AMΦ by 
ANOVA with Bonferroni correction, 4 were chosen for validation and further analysis: miR-
322 and miR-503, which were highly expressed by naïve AMΦ, and let-7b and let-7c which 
were highly expressed by resolved AMΦ. 
To validate the miRNA array findings the experiment was repeated: BALB/c mice were 
infected with RSV (resolved-red) or given PBS control (naïve-white). 6 weeks later miRNA was 
extracted from AMΦ, isolated from the BAL by FACS. The expression of the 4 miRNAs was 
tested by RT-qPCR using LNA probes (Exiqon, Denmark) (Figure 5.20B). Expression levels 
were normalised against miR-103, miR-191 and miR-423-3p, since these miRNA were shown to 
perform similarly to the geometric mean of all expressed miRNA in the previous miRNA RT-
qPCR array (Figure 5.21). Validating the miRNA array findings, let-7b and let-7c were 
expressed at higher levels by resolved AMΦ, whereas miR-322 and miR-503 were expressed at 
higher levels by naïve AMΦ.  
To assess whether the validated miRNA pattern was specific to AMΦ in resolution, the 
experiment was repeated, but AMΦ were this time sorted from mice at 1 week post RSV 
(during peak disease severity), as well as after 6 weeks (Experimental plan – Figure 5.20A). 
AMΦ from peak infection were found to more closely resemble AMΦ in resolution than naïve 
AMΦ, expressing higher levels of let-7b, and let-7c, and lower levels of miR-322 and miR-503 
than naïve AMΦ (Figure 5.20C). Clustering analysis confirmed this grouping, with AMΦ from 1 
week post RSV and AMΦ from 6 weeks post RSV clustering more closely than to naïve AMΦ 
(Figure 5.20D).  
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Figure 5.20: Validation of miRNA array results 
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Mice were infected with RSV or given PBS control. 6 weeks later AMΦ were sorted 
from the BAL and miRNA extracted. RT-qPCR was used to test the relative 
expression of let-7b, let-7c, miR-322 and miR-503 in order to confirm the findings 
from the miRNA array. Data was normalised against ‘house keeping’ miRNA (see 
Figure 5.21), and expressed relative to a control sample. Significance was calculated 
by Mann Whitney t test (B). The experiment was repeated and AMΦ were sorted 
from the BAL at 1 week post RSV and 6 weeks post RSV (Experimental plan A). RT-
qPCR of the 4 selected miRNAs was again normalised against house keeping 
miRNA, and expressed relative to control samples. Significance was calculated by 
two way ANOVA with Bonferroni correction (C). GenEx software (MultiD Analyses 
AB, Sweden) was used to create a dendrogram showing data clustering using Ward’s 
algorithm and Euclidean distance measure (D). (* p<0.05, ** p<0.01, *** p<0.001). 
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Figure 5.21: Choosing „house-keeping‟ miRNA for normalisation 
 
 
By ranking genes from the mRNA microarray in order of the significance of their 
differential expression, the gene Nmes1 was found to be the most significantly altered gene 
between naïve and resolved AMΦ (Table 5.2, Figure 5.22). The precursor for miRNA -147 is 
located within the 4th exon of Nmes1, and transcribed simultaneously [272]. miRNA-147 is 
expressed following TLR signalling in murine macrophage, and acts as part of a negative 
feedback loop to subsequently dampen TLR signalling [272]. Although miR-147b was not 
detected in our miRNA array, we decided to test the expression of this gene independently, 
given the differentially expression of Nmes1. AMΦ were sorted from naive mice, and also 1 
week or 6 weeks after RSV infection, and the expression of miR-147b assessed relative to the 
expression of normalisation miRNA (as previous-Figure 5.21). We found the miR-147b was 
indeed highly differentially expressed in AMΦ. Following RSV infection this miRNA was up-
regulated in AMΦ at 1 week post infection, and remained expressed at significantly higher 
levels than naïve AMΦ even 6 weeks post infection (Figure 5.22B).  
 
The expression of miR-103, miR-423-3p and miR191 was found to 
closely match the geomean of the miRNA detected in all 8 samples 
(blue). Therefore these  3 miRNAs were suitable for performing 
normalisation in subsequent individual miRNA assays.
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Figure 5.22: miRNA-147b expression during RSV infection 
 
5.2.2.2:  Validating miRNA array data in other viral models 
To ascertain whether the observed difference in miRNA expression between naïve and resolved 
AMΦ were unique to resolution from RSV infection in BALB/c mice; our chosen panel of 
miRNA were tested in AMΦ following resolution from influenza infection in different mouse 
strains.  
Both BALB/c and BL/6 mice were infected with influenza (PR8 100 PFU/mouse) or 
treated with PBS control. Weight loss was assessed for 6 weeks after the infection (Figure 5.23 
C, D). After 6 weeks the number of cells in the BAL was measured (Figure 5.23B), and then 
AMΦ were sorted from the BAL by FACS (as shown previously) (Experimental plan Figure 
5.23A). miR-Let7b, miR-Let7c and miR-322 and miR-503 were detected by RT-qPCR using 
LNA probes (Exiqon, Denmark). As before, expression levels were normalised against miR-103, 
miR-191 and miR-423-3p. In both mouse strains the pattern of expression of these four miRNA 
were found to be similar to following an RSV infection, with miR-Let7b and miR-Let7c 
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correction, and a fold change of 0.18 (A). Nmes1 gene contains the precursor for miRNA-
147b, and so the expression of this miRNA was also assessed during RSV infection.  
BALB/c mice were infected with RSV or given PBS control. 1 week and 6 weeks later 
AMΦ were sorted from the BAL and miRNA extracted. RT-qPCR was used to test the 
relative expression miR-147b Data was normalised against „house keeping‟ miRNA (see 
Figure 5.21), and expressed relative to a control sample. Significance was calculated by 
ANOVA with Bonferroni correction * p<0.05, ** p<0.01, *** p<0.001. 
Nmes1
PBS RSV
0
500
1000
1500
p=9.45x10-34
fold change: 0.18
Naive
Resolved
R
e
la
ti
v
e
 f
lo
u
re
s
e
n
c
e
 (
a
u
)
miR-147b during RSV
0 1 6-2
0
2
4
6
8
miR-147b
***
***
Weeks post RSV
L
o
g
2
(f
o
ld
 c
h
a
n
g
e
)
A BNmes1
PBS RSV
0
500
1000
1500
p=9.45x10-34
fold change: 0.18
R
e
la
ti
v
e
 f
lo
u
re
s
e
n
c
e
 (
a
u
)
Chapter 5: AMΦ in resolution  198 
 
expressed at higher levels in resolved AMΦ and miR-322 and miR-503 expressed at higher 
levels by naïve AMΦ (Figure 5.23E,F).  
Figure 5.23: Assessing the miRNA panel in resolution from influenza infection in 
different mouse strains 
 
BAL cell number
0
5.0104
1.0105
1.5105
***
**
Influenza     -        +       -       +
C
e
lls
/m
o
u
s
e
Weight loss: BALB/c
0 1 2 3 4 5 6
80
100
120
Weeks post influenza
%
 o
ri
g
in
a
l 
w
e
ig
h
t
Weight loss: BL/6
0 1 2 3 4 5 6
80
100
120
Weeks post influenza
%
 o
ri
g
in
a
l 
w
e
ig
h
t
let 7b let 7c 322 503
-2
0
2
*** *** ***
L
o
g
2
(f
o
ld
 c
h
a
n
g
e
) let 7b let 7c 322 503
-2
0
2
*** **
*** *
L
o
g
2
(f
o
ld
 c
h
a
n
g
e
)
FE
DC
BA
BALB/c (grey) or BL/6 (black) mice were infected with influenza (solid shapes) or PBS 
control (open shapes). Weight loss was followed for six weeks (C,D).  After six weeks 
BAL cells were counted by haemocytometer and trypan blue exclusion (B). Alveolar 
macrophage were sorted from the BAL by FACS (as previous). miRNA was extracted 
from the resultant population (Experimental plan-A) and converted into cDNA. miR-
let7b, miR-let7c , miR-322 and miR-503 were detected by RT-qPCR using LNA probes 
(Exiqon, Denmark) and expression levels normalised against reference genes (Figure 
5.21) and visualised as fold change against a reference sample (E,F). Significance was 
calculated by Man Whitney t test, p < 0.05 were considered significant (* p<0.05, ** 
p<0.01, *** p<0.001). 
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5.2.2.3:  Validating miRNA array data in non viral models 
To see if the panel of miRNA showed a similar expression profile in AMΦ following non viral 
inflammation, we looked at AMΦ following the induction of allergic airway disease, or the 
induction of lung damage by bleomycin treatment. To induce allergic airway disease, BALB/c 
mice were treated with 15ug of HDM (house dust mite, Greer laboratories, NC) I/N 3 times a 
week for 3 weeks or given PBS control (experimental plan- Figure 5.24A). To assess a model of 
lung damage, BL/6 mice were treated with bleomycin I/T (intratracheal administration) or 
given PBS control, and weight loss followed for 3 weeks (experimental plan Figure 5.24B, 
weight loss Figure 5.24C). After 3 weeks of either treatment regime, mice were culled and 
AMΦ sorted from the BAL by FACS (as previous). In treated groups the presence of other 
inflammatory cells resulted in an increased number of cells in the BAL compared to PBS 
control, and a reduced percentage of AMΦ; however the total number of AMΦ sorted was 
similar between treatment and control groups (Figure 5.24 D, E). Following bleomycin 
treatment AMΦ again expressed higher levels of miR-Let-7b, and miR-Let7c, as well as reduced 
levels of miR-322 compared to naïve AMΦ (Figure 5.24F). Following the induction of allergic 
airway disease AMΦ expressed lower levels of miR-322 and miR-503 compared to PBS treated 
AMΦ, however there was no significant increase in the expression of either let7b or let-7c 
(Figure 5.24G).  
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Figure 5.24: Assessing the miRNA panel following non-viral inflammation 
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Allergic airway disease was induced by treating BALB/c mice with house dust mite 
(HDM) I/N 3 times a week for 3 weeks (Experimental plan-(A)). Lung damage was 
induced by treating BL/6 mice I/T with bleomycin (Experimental plan-(B)) and weight 
loss followed for 3 weeks (C). Mice treated with similar regimes of PBS were used as 
controls. After inducing inflammation by either method, mice were culled and the 
number of cells in the BAL ascertained by haemocytometer with Trypan blue exclusion. 
AMΦ were sorted from the BAL by FACS, and the number and percent of AMΦ in the 
BAL calculated (Bleomycin treatment –(D), HDM treatment –(E)). miRNA was extracted 
from AMΦ and let-7b, let-7c , miR-322 and miR-503 were detected by RT-qPCR using 
LNA probes (Exiqon, Denmark). Expression levels were normalised against reference 
genes (Figure 5.21) and visualised as fold change relative to a reference sample 
(Bleomycin-(F), HDM-(G)). Significance was calculated by Man Whitney t test, p < 0.05 
were considered significant (* p<0.05, ** p<0.01, *** p<0.001). Bleomycin administration 
and weight loss carried out by Kate Gowers (Imperial College London. HDM 
administration carried out by Maryam Habibizay (Imperial College London).
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5.2.2.4: miRNA expression by resident and infiltrating AMΦ 
In chapter 4 we saw that during RSV infection there was substantial turnover of AMΦ, such 
that when dye was used to stain resident AMΦ, at 6 weeks post infection, only approximately 
50 % of AMΦ in the BAL were resident dye positive cells (Figure 4.19). In order to see whether 
changes to miRNA expression occurred in original resident AMΦ, infiltrating AMΦ, or both; 
mice were again treated with dye (PKH26 Red fluorescent cell linker [Sigma, UK]), and one 
week later infected with RSV or PBS control. 6 weeks after infection dye positive and negative 
AMΦ were sorted from the BAL by FACS (Experimental plan - Figure 5.25A, representative 
FACS plot – Figure 5.25B). As seen in chapter 4, over 6 weeks there was substantial turnover of 
AMΦ in RSV treated mice, with a reduction in the percentage of dye positive (resident) AMΦ, 
and an increase in the number of dye negative (infiltrating) AMΦ entering the BAL (Figure 
5.26C). This turnover was not apparent in PBS treated mice (Figure 5.26C). miRNA was 
extracted from dye positive and dye negative AMΦ and the expression of let-7b, let-7c, miR-
322, miR-503 and miR-147b assessed by RT-qPCR.  
 Of the miRNA found to be highly expressed in resolved AMΦ: both resident (dye 
positive) and infiltrating (dye negative) AMΦ showed an increase in the expression of let-7c 
and let-7b compared to naïve AMΦ, however expression was significantly higher in infiltrating 
AMΦ (Figures 5.25D, E). In contrast only infiltrating AMΦ expressed greater levels of miR-
147b (Figure 5.25F). Of the miRNA found to be less highly expressed in resolved AMΦ (miR-
322 and miR-503), this reduction was most apparent in resident AMΦ, whilst there was no 
significant difference in the expression of these miRNA by infiltrating AMΦ compared to naïve 
controls (Figures 5.25G, H). 
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Figure 5.25: Changes to miRNA expression in resident and infiltrating AMΦ 
 
BALB/c mice were administered with 0.5nM PKH26 Red Fluorescent Cell linker (Sigma, 
UK) and one week later infected with RSV (solid shapes) or given PBS control (open 
shapes). 6 weeks after infection dye positive (red) and dye negative (grey) AMΦ were 
sorted from the BAL by FACS (Experimental plan –A). Representative FACS plot (B) 
showing incorporation of dye into RSV infected (grey, filled line) and PBS treated (black, 
open line) AMΦ. From flow cytometry data, the percentage of dye positive AMΦ (red 
line - C) and the number of dye negative AMΦ entering the BAL (grey line – C) was 
calculated. miRNA was extracted from dye positive and negative AMΦ and miR-let7c 
(D), let-7b (E), miR-147b (F), miR-322 (G) and miR-503 (H) detected by RT-qPCR using 
LNA probes (Exiqon, Denmark). Expression levels were normalised against reference 
genes (Figure 5.21) and visualised as fold change relative to a reference sample. Too few 
dye negative cells were sorted from PBS treated mice to allow suitable PCR, so these 
samples are excluded. Statistical significance was calculated by ANOVA with  Bonferroni 
Multiple Comparison Test. These data are representative of one experiment where n=5. 
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5.2.4: Using siRNA technology to block specific miRNA expression and 
thereby making naïve AMΦ resemble resolved AMΦ and vice versa  
Naïve and resolved AMΦ displayed an altered phenotype, principally TLR desensitisation 
(Figure 5.1&3), and also a consistent alteration in their expression of a panel of miRNA (Figure 
5.18-20). Since individual miRNA are thought to be able to fine tune the expression of the 
entire transcriptome, we wondered if by blocking these miRNA ex vivo it would be possible to 
make naïve AMΦ resemble resolved AMΦ and vice versa.  
 First we optimised the most efficient means of transfecting miRNA inhibitors into ex 
vivo AMΦ, by measuring the take up of fluorescently labelled probes, or genes which expressed 
fluorescent proteins by flow cytometry (Figure 5.26). We found that lentiviral infection and 
electroporation did not lead to efficient transfection of ex vivo AMΦ (Figure 5.26A-E). 
However, LipofectaminTM (Invitrogen, USA) delivery of fluorescent labelled miRCURY LNA 
microRNA Power Inhibitors (Exiqon, Denmark) lead to efficient transfection of ex vivo AMΦ, 
with 93.1 % of cells staining positive for take up of the inhibitor after 16 hours, and 36.8 % of 
cells remaining positive after washing steps, after 48 hours (Figure 5.26F-H).  
 In order to assess whether blocking specific miRNA would alter the phenotype of naïve 
AMΦ so they resembled resolve AMΦ and vice versa, mice were infected with RSV (resolved) 
or given PBS control (naïve). 6 weeks later, AMΦ were selected from the BAL by adhesion to 96 
well plates. miRNA inhibitors against miR-322 or let-7b were administered in LipofectaminTM 
(Invitrogen USA). As controls, cells were given a scrambled miRNA inhibitor or lipofectamin 
alone, or media alone. Lipofectamin was removed after 16 hours, and after 24 hours, cells were 
challenged with the TLR-5 agonist, Flagellin for 6 hours, and the level of TNFα then assessed 
by ELISA (Experimental plan-Figure 5.27A). Simultaneous administration of a fluorescent 
labelled miRNA inhibitor showed that at the point of analysis 35.8 % of naïve AMΦ and 34.4 % 
of resolved AMΦ had taken up miRNA inhibitors, and this number was not affected by addition 
of TLR agonists (data not shown). 
 Blocking miR-322 (which is expressed highly by naïve AMΦ), in either naïve or resolved 
AMΦ lead to TLR desensitisation, reducing the amount of TNFα produced in response to TLR 
antagonism (Figure 5.27B-D). Blocking let-7b (which is expressed highly by resolved AMΦ) did 
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not have a consistent effect on TLR sensitivity; however it did lead to a reduction in the 
expression of MHCII in both naïve and resolved AMΦ (Figure 5.27E). 
 Figure 5.26: Optimisation of AMΦ transfection 
 
 
AMΦ were sorted from the BAL by adhesion to 96 well plates at a density of 1x10 4 cells/well 
and the efficiency of 3 methods for transfecting fluorescently labelled genes were assessed by 
flow cytometry against untreated cells (grey). Lentivirus carrying GFP was added to each well 
at an MOI of 1 (red line) or an MOI of 0.5 (pink line) in 1:1000 Hexadimethrine bromide. 
GFP expression was assessed at 24 (A), 48 (B) and 96 (C) hours post infection. Lentivirus a 
kind gift from Jasper De Boer, Institute of Child Health, University College London. 
Electroporation of GFP containing plasmid was carried out using a range of recommended 
settings (red, orange, yellow and green lines) according to manufactures instructions (Amaxa TM
NucleofactorTM Technology, Lonza, USA) and GFP expression assessed at 24 (D) \and 48 (E) 
hours post electroporation. FAM labelled miRCURY LNA microRNA Power Inhibitor (Exiqon, 
Denmark)-red line, were introduced using LipofectamineTM 2000 (Invitrogen, USA) 
(Lipofectamine alone-blue line) according to manufactures’ instructions. After 16 hours 93.1 % 
of AMΦ were FAM positive (F). Excess probe and Lipofectamine were washed off, but 36.8 % 
of AMΦ remained FAM positive, even 32 (G) and 48 (H) hours later.
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Figure 5.27: Inhibiting miRNA to alter AMΦ phenotype 
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AMΦ from naïve (white) or resolved (6 weeks post RSV –red) were sorted from the 
BAL by adhesion to 96 well plates. miRCURY LNA microRNA Power Inhibitors 
(Exiqon, Denmark) against miR-322, let-7b or a scrambled control were introduced 
using LipofectamineTM 2000 (Invitrogen, USA) according to manufactures‟ 
instructions (Experimental plan-A). After 16 hours, cells were washed to remove 
excess LipofectamineTM and after a further 24 hr incubation they were treated with 
flagellin (B,C) or LPS (D), and the resultant expression of TNFα assessed by ELISA. 
The expression of MHCII after treatment was assessed by flow cytometry (E). For 
each experiment n=4-8, and are representative of 2-6 repeats. Significance was 
measured by ANOVA with Dunnett‟s correction. (* p<0.05, ** p<0.01, *** p<0.001). 
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5.2.5:  Predicting mRNA targets for miRNA regulation 
Ingenuity Pathways microRNA target filter was used to associate the miRNAs assessed as 
differentially expressed between naïve and resolved AMΦ with experimentally observed and 
predicted mRNA target information provided from the Ingenuity Knowledge Base using 
predicted relationships from TargetScan database and experimentally observed relationships 
from TarBase database. This information was then filtered to reveal targets from our mRNA 
microarray dataset only. miRNA target prediction was carried out by Arshad Khan, Imperial 
College London. Of the 290 unique genes identified by the mRNA microarray as being 
differentially expressed between naïve and resolved AMΦ, 63 % were predicted to be regulated 
by at least one of the differentially expressed miRNA. Predicted gene targets for the miRNAs 
which were highly expressed in naïve AMΦ are shown in Table 5.3. Predicted gene targets for 
the miRNA which were highly expressed in resolved AMΦ are shown in Table 5.4. A detailed 
analysis of the predicted gene targets for the miRNA of special interest (miR-322, miR-503, let-
7b and let-7c) is shown in Table 5.5, showing whether the predicted gene targets are up or 
down regulated in naïve and resolved AMΦ, and showing the strength of the predicted 
interaction. Interestingly, all but one of the genes predicted to be regulated by miR-322, were 
also predicted to be regulated by miR-503. Similarly all but one of the genes regulated by let-7b 
was also regulated by let-7c. 
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Table 5.3: Predicting mRNA and miRNA interactions from our datasets 
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Table 5.4: Predicting mRNA and miRNA interactions from our datasets 
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Table 5.5: Predicting mRNA and miRNA interactions from our datasets 
 
miR-322 miR-503 let-7b let-7c
LUZP1
PLK1
Igsf4a
CBFA2T3 CBFA2T3 CBFA2T3 CBFA2T3
HR FGD6 FGD6
IGF1 IGF1 GAS7 GAS7
LY9 IGF1 IGF1
NAV1 NAV1 RASGRP1 RASGRP1
NUAK1
PHLDA3
SESN1
PPAP2B
ZDHHC14
STAC2 PRKCB PRKCB
PMP22 ESPL1 ESPL1
HIST2H2BE
PSAT1 CARHSP1 CARHSP1
GOLPH3L TYMS TYMS
UHRF1 UHRF1
ANLN ANLN CCND2 CCND2
BCAS1 CIITA
CCND2 CCND2 DUSP16 DUSP16
CHAC1 CHAC1 E2F2 E2F2
FAM122B IGF2BP2 IGF2BP2
KIF23 KIF23 IGF2BP3 IGF2BP3
38047 LIPH LIPH
NRN1 LRIG3 LRIG3
SH3BGRL2 TREM1 TREM1
SEMA6D SEMA6D
PPAP2A PPAP2A
TIPIN CLDN1 CLDN1
CYB561 CYB561 AURKA AURKA
CENPN C20orf54 C20orf54
CLDN1
Ingenuity Pathways microRNA target filter was used to associate 4 miRNAs of special interest 
(miR-322, miR-503, let-7b and let-7c) with experimentally observed and predicted mRNA 
target information provided from the Ingeunity Knowledge Base based on predicted 
relationships from TargetScan database and experimentally observed relationships from 
TarBase database. This information was then filtered to reveal targets from our mRNA 
microarray dataset only. Genes expressed more highly in naïve AMΦ are written in black, 
whilst those expressed more highly in resolved AMΦ are written in red. Experimentally 
observed relationships are highlighted gold, relationships with a high predicted interaction 
are highlighted pale blue, whilst relationships with a moderate predicted interaction are 
highlighted pale green.
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5.3:  Discussion 
Foreword 
The principal finding of this chapter is that naïve and resolved AMΦ are different; both in 
function and in their expression of just over 300 genes, including a number of miRNA.  The 
plethora of data presented reveals several interesting connections which perhaps explain the 
phenomenon of TLR desensitisation and prolonged susceptibility to secondary bacterial 
infection.  
 
5.3.1:  miR-322 and miR-503 
miRNA RT-PCR profiling showed that miR-322 was down-regulated in resolved AMΦ, with a 
fold change of 0.3. miR-503 and miR-450a-5p showed a similar expression pattern with lower 
expression in resolved AMΦ compared to naïve. The similar expression profile of these miRNAs 
validates the reliability of this data, since these miRNA are closely located on the X 
chromosome, and in humans are thought to be transcribed in a polycistronic cluster [265]. Both 
miR-322 and -503 were expressed at the lowest levels during peak inflammation, but remained 
repressed even 6 weeks post infection (Figure 5.20). The reduction in the expression of miR-322 
and -503 was only apparent on resident AMΦ, since incoming AMΦ expressed similar levels of 
miR-322 and -503 to naïve AMΦ (Figure 5.5). Using dye to differentiate resident and incoming 
AMΦ showed that the number of dye negative (incoming) AMΦ was very low at early time 
points during infection (Figure 4.19). For this reason the stimulus which triggers down-
regulation of miR-322 and -503 is likely to be only transiently present at early time points after 
infection, thus affecting resident AMΦ, but not those recruited gradually to the airway in the 
following weeks. The identity of the stimulus which triggers down-regulation of miR-322 and -
503 remains to be investigated, however similar patterns of down-regulation were observed 
following a variety of inflammatory insults which suggests it is a universally induced 
inflammatory mediator and not antigen specific.  
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The TAM receptor, AXL, binds to externalised phosphatidylserine on apoptotic cells via 
the bridging molecules, GAS6 or Protein S [41]. Ligation of AXL dampens TLR signalling via 
the induction of SOCS1 and 3. We consistently show that resolved AMΦ express higher levels 
of AXL mRNA and protein compared to naïve AMΦ. Interestingly the expression data for AXL 
during an RSV infection mirrors the expression profile of miR-322 and -503 (Compare Figure 
4.27D with Figures 5.20 and 5.25G&H). AXL is most highly expressed at peak infection when 
miR-322 and -503 are most highly repressed. At 6 weeks post infection AXL levels remain 
significantly elevated compared to naïve AMΦ, whilst miR-322 and -503 are also significantly 
reduced. Most strikingly AXL is predominantly expressed on resident AMΦ, and not on 
incoming AMΦ; similarly the reduction in miR-322 and -503 expression is also only prominent 
on resident AMΦ and not on incoming AMΦ. As an additional connection between miR-322 
and AXL, exposure to apoptotic cells is a suitably transient stimulus which occurs early 
following an inflammatory challenge and could therefore affect resident AMΦ, but not those 
recruited gradually to the airway in the following weeks. 
miRNAs interact with target mRNA by complementary base-pairing to conserved 
sequences in the 3‟ UTR. This allows potential binding partners to be predicted using 
bioinformatics software. Target prediction software ranks the potential interaction between 
miR-322 and AXL very highly with a mirSVR score of –0.7098 [168]. Assuming this prediction 
is correct we can extrapolate the following pathway (depicted in Figure 5.28). Following an 
inflammatory event AMΦ are exposed to apoptotic cells. This exposure acts as a stimulus to 
down-regulate the expression of miR-322. miR-322 binds to the mRNA of AXL and targets it 
for degradation. Therefore a reduction in the expression of miR-322 leads to an increase in the 
expression of AXL and thus causes dampening of TLR signalling pathways. Incoming AMΦ in 
the weeks following an inflammatory event are unlikely to encounter apoptotic cells, and so do 
not display reduced miR-322 expression and resultant increased AXL expression. In support of 
this potential pathway, experiments using anti-miRs to block miR-322 led to increased TLR 
desensitisation (Figure 5.27). Further experiments looking at the effect of apoptotic cell 
exposure on miR-322 and the effect of over-expressing or blocking miR-322 on AXL expression 
would provide further validation.   
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In vitro, the human orthologue of miR-322 (miR-424) is regulated by the transcription 
factor PU.1 [266]. Microarray data showed that murine AMΦ expressed PU.1, however 
although there was a trend for reduced PU.1 mRNA in resolved AMΦ, this was not significant 
(data not shown).  
Figure 5.28: miR-322 modulation of AMΦ 
 
A
C
In resident AMΦ (red), a transient inflammatory event, perhaps the recognition of 
apoptotic cells, causes a reduction in the expression of miR-322, perhaps due to the 
involvement of PU.1 (A). miR-322 binds AXL mRNA and targets it for destruction (B). 
Reducing the expression of miR-322 increases the expression of AXL (C), which can 
then interact with apoptotic cells to cause TLR desensitisation. Incoming AMΦ (grey) 
are not exposed to apoptotic cells, therefore they show no reduction in miR-322 
expression, allowing miR-322 to inhibit the translation of AXL mRNA, thus reducing 
the expression of AXL. Resultantly these cells to not exhibit TLR desensitisation. 
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5.3.2:   Let-7b and let-7c. 
miRNA RT-PCR profiling showed that let -7b was up-regulated 11 fold in resolved AMΦ, 
whilst let-7c was undetectable in naïve AMΦ but expressed at high levels by resolved AMΦ. 
The similar expression profile of these miRNAs validates the reliability of this data, since these 
miRNAs are known to be transcribed together as part of a polycistronic cluster [256]. Both 
miRNAs were expressed at high levels during peak inflammation, and remained highly 
expressed into resolution. Although both resident and incoming AMΦ expressed higher levels 
of let-7b and -7c than naïve AMΦ; expression was highest on incoming AMΦ. Using dye to 
differentiate resident and incoming AMΦ, showed that the number of dye negative (incoming) 
AMΦ increased steadily following viral infection (Figure 4.19). For this reason the stimulus 
which triggers up-regulation of let-7b, -7c must be consistently present in the airway after an 
inflammatory event, so as to direct the differentiation of resident cells but also the gradually 
recruited incoming AMΦ. The identity of the stimulus which triggers the shift in let-7b, -7c 
expression remains to be investigated, however similar patterns of up-regulation were observed 
following a variety of inflammatory insults which suggests it is not dependent on a specific 
antigen. The only instance where up-regulation of let-7b and –7c was not significant was 
following the induction of allergic airway disease. Perversely, induction of allergic airway 
disease is the only inflammatory trigger tested in this thesis where others have previously 
published an up-regulation of let-7b [273]. For this reason, we suspect that on repeating this 
experiment, an increased n-number will reveal significance.   
The most altered pathway between naïve and resolved AMΦ was the antigen 
presentation pathway. This was due to highly significant increases in the amount of mRNA 
coding for components of the MHCII complex in resolved AMΦ. Validating these findings, we 
also saw increased expression of MHCII in resolved AMΦ at the protein level by flow 
cytometry (Figure 4.22). MHCII transcription is regulated by the transcription factor CIITA, the 
so called master regulator of MHCII expression. Resolved AMΦ express significantly higher 
levels of CIITA (Figure 5.10) thereby explaining the parallel increase in MHCII expression.   
Interestingly let-7b is predicted to target CIITA (Table 5.5). Assuming this prediction is 
correct we can extrapolate the following pathway (depicted in Figure 5.29). During 
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inflammation and in resolution, an altered environmental stimulus causes resident and 
incoming AMФ to increase their expression of let-7b. This miRNA targets the mRNA of CIITA 
and increases its stability. The resultant increased translation of CIITA, leads to up-regulation of 
MHCII. Traditionally miRNAs are thought to be negative regulators of protein expression, 
reducing the expression of their target mRNAs. However in cell-cycle arrest, a small number of 
miRNAs, including let-7b, have been shown to switch from a repressive role to one where they 
activate the translation of their targets [166]. Since AMΦ are not actively replicating, it seems 
feasible that let-7b could be acting as an activator of mRNA translation in this context. In 
support of this potential pathway, experiments using anti-miRs to block let-7b lead to reduced 
expression of MHCII (Figure 5.27).   
CD200R is another interesting target of let-7b and let-7c. miRNA target prediction 
software ranks this potential interaction as highly likely with a mirSVR score of -1.2523 and -
1.3116 for let 7b and let-7c respectively [168]. The large spread of the expression data generated 
for CD200R by microarray meant that at the transcriptional level there was no significant 
difference between naïve and resolved AMΦ (as determined by ANOVA with Bonferonni 
correction). However by flow cytometry we routinely observe that resolved AMΦ express 
much higher levels of CD200R protein. Although we have no direct evidence to confirm the 
link between up-regulated let-7b, -7c and up-regulated CD200R in resolution, the expression 
data for CD200R during an RSV infection is strikingly similar to the expression profile of let-7b, 
-7c, (Compare 4.27B with Figures 5.20 and 5.25D&E). This correlation together with 
consistently observed increases in CD200R protein levels in resolution, and the strength of the 
bioinformatics prediction suggests this interaction should be investigated and validated further. 
A potential pathway for let-7b control of CD200R expression is shown in Figure 5.29.  
Let-7b and -7c are also weakly predicted to target TREM1 (Table 5.5), but since 
expression of this protein decreases in resolution, this connection does not fit the pattern 
described for CIITA and CD200R. It remains possible that let-7 genes can both activate and 
repress gene translation of different targets, but further validation is needed to confirm this 
possibility.    
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Figure 5.29: let-7b modulation of AMΦ 
 
5.3.3:  Future plans 
Further experiments are needed to validate many of the hypotheses presented in this discussion. 
Firstly, from the analysis of predicted miRNA targets, a selection of mRNA will be chosen for 
future investigation. The expression of these genes will be assessed following resolution from 
influenza infection, and also following resolution from non-viral inflammation, for example the 
induction of allergic airway disease and the induction of lung damage by bleomycin treatment. 
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Following an inflammatory event, perhaps due to the altered cytokine milieu or 
effercytosis of apoptotic cells AMΦ upregulate let-7b (A). Mature miR let-7b recruits 
Argonaute (ARGO). Complementary binding between let-7b and the AU-rich element 
of the 3‟ UTR of CIITA, increasing the stability of this mRNA (B). Resultantly there are 
increased levels of CIITA mRNA and increased expression of this protein (C). CIITA 
translocates to the nucleus where it acts as the master regulator of MHCII gene 
expression (D). This leads to increased expression of MHCII (E). In a similar fashion let -
7b binds to the AU-rich element of the 3‟ UTR of CD200R increasing the stability of 
this mRNA (F). Resultantly there are increased levels of CD200R mRNA and increased 
expression of this protein (G). 
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To confirm the strength of the predicted interaction between mRNA and miRNA, selected 
genes will be tested in ex vivo AMΦ following miRNA inhibition, (as in Figure 5.27). Finally 
the expression of these miRNA will be assessed in dye positive and dye negative resolved AMΦ 
(as in Figure 5.25). Ideally it would be useful to optimise lentiviral infection of AMΦ in order to 
transfect miRNAs of interest, and study the effect of miRNA over-expression. It would also be 
interesting to investigate the stimuli that initially cause the shift in miRNA expression 
following inflammation. It is possible that the altered environment of the 
inflammatory/resolving lung instigates an epigenetic change revealing the initiation site for the 
transcription of the let-7b and –7c cluster and masking that of the miR-322 and -503 cluster. 
Investigating whether DNA methylation or histone modification occurs to these miRNA 
genomic clusters may also be revealing. 
 
5.3.4:   Limitations of this discussion 
Systems biology approaches such as the microarray and RT-PCR array presented in this chapter, 
allow an unbiased assessment of the most relevant genes given a particular question. However, 
in this discussion we have focused on pathways for which we have gathered most data. These 
pathway choices are biased towards certain genes which we initially chose to study, based on 
our initial hypotheses. A multitude of interesting findings which we have not focused on are 
worthy of further investigation, and may prove more informative in defining the changes that 
occur in resolution from inflammation. These include the NFAT pathway which is altered in 
resolution, NMES1 which is up-regulated in resolved AMΦ and the related up-regulation of the 
TLR repressor miR-147b, as well as alterations that occur to the additional 280 or so 
differentially regulated genes which we have not discussed in detail. As bioinformatics 
techniques to interpret omics data become more advanced, it may become easier to combine all 
the data presented in this chapter into an overall explanation of inflammatory resolution. 
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Chapter 6: Discussion 
Foreword 
In this thesis we characterised a number of co-infection models, and found that susceptibility to 
secondary bacterial infection with S. pneumoniae was prolonged far into resolution from an 
initial viral infection and long after the restoration of epithelial and endothelial permeability. In 
an attempt to explain this phenomenon we looked at the phenotype of AMΦ in resolution and 
found them to have a dampened response to TLR agonists following viral infection, whilst also 
expressing far higher levels of a number of negative regulators including CD200R, AXL and 
TREM2. When we examined the genotype of resolved AMΦ in more detail we found that in 
fact just over 300 genes were differentially expressed including a number of miRNAs, and in 
some cases differential gene expression was more pronounced on either resident AMΦ or 
incoming AMΦ. As a preliminary proof that the changes we observed in the AMΦ population 
caused prolonged susceptibility to bacterial complication, we found that removing the negative 
regulator CD200R removed susceptibility to secondary infection, whilst blocking miR-322 
(which was expressed at high levels on naïve AMΦ) increased TLR desensitisation, mimicking 
the effect of post-viral resolution. This is the first time that miR-322 has been shown to have a 
role in inflammation and TLR signalling. Bacterial complications are associated with many 
respiratory conditions both viral and non-viral. We found similar patterns of gene expression 
on AMΦ following a number of inflammatory insults, suggesting a universal mechanism of TLR 
desensitisation may be at play. Key findings are depicted in Figure 6.1. 
 In this final chapter we will address a number of questions posed by these findings, 
discuss their implications, and attempt to explain the evolutionary forces that have shaped the 
innate immune rheostat.  
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Figure 6.1: Education of AMΦ 
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AMΦ are constantly balancing both pro- and anti-inflammatory signals which determine their 
threshold of activation to TLR challenge. At homeostasis (A), regulatory signals from the 
epithelium, low expression of MHCII and high expression of CD200R ensure they have a higher 
threshold of activation, (they are more repressed) than macrophage from more sterile sites. 
However at this time point they also express amplifiers of TLR signalling such as TREM1. 
Following sufficient TLR stimulation AMΦ become activated and initiate inflammation (B). 
Changes in the cytokine milieu of the BAL during inflammation, perhaps due to loss of epithelial 
regulation, or the presence of alarmins/pro-inflammatory cytokines or the engulfment of 
apoptotic cells is hypothesised to cause an epigenetic shift in the miRNA profile, with a 
persistent stimulus causing the up-regulation of let-7b -7c and a transient stimulus causing the 
down-regulation of miR-322 and 503. This results in global transcriptional changes to important 
molecular pathways. Down-regulation of miR-322 leads to increased expression of its target 
gene, AXL which can interact with apoptotic cells to instigate pathways which dampen TLR 
signalling. Let-7b up-regulation causes an increase in the expression of CD200R, and a decrease 
in the expression of TREM1, shifting the TREM1/2 balance towards TREM2 which dampens 
TLR signalling. These negative feedback loop whereby increased TLR signalling activates 
pathways that dampen TLR signalling prevents excessive inflammation and promotes resolution 
of inflammation. Let-7b may also stabilises CIITA mRNA resulting in higher expression of 
MHCII in inflammation and therefore enhanced communication with the adaptive immune 
system. In resolution (C), those resident (red) AMΦ that remain in the BAL maintain their shift 
in miRNA expression, and expresses higher levels of TREM2, AXL than at homeostasis and 
higher levels of CD200R than in inflammation. Additionally elevation of MHCII expression 
persists. Resultantly resident AMΦ display TLR desensitisation, compared to naïve AMΦ, this 
increases their threshold of activation so a larger stimulus is needed to initiate subsequent 
inflammation. However once this threshold is surpassed, higher expression of MHCII ensures 
communication with the adaptive immune system will be more rapid and efficient. In resolution 
the AMΦ population is also replenished by incoming AMΦ (grey). These cells are unique from 
either naïve or resolved AMΦ, expressing high levels of let-7b and -7c like resolved AMΦ, but 
also high levels of miR-322 and -503 like naïve AMΦ. The differential expression profile of these 
cells is perhaps caused by interactions with resident AMΦ, or by interactions with a remodelled 
epithelium.
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6.1: Innate „memory‟, and the innate immune rheostat 
Infection history influences the way in which a specific tissue responds to subsequent immune 
stimulation. We often attribute such immune „education‟ to the adaptive immune response and 
its unique ability to generate memory T and B lymphocytes. However there is a growing body 
of evidence, to which the data presented in this thesis contributes, to suggest that the innate 
immune system is also capable of adapting and modifying its response to subsequent challenge.  
 Invertebrates lack an adaptive immune system and are therefore particularly useful for 
examining modifications in the innate immune response uncomplicated by simultaneous 
adaptive immune education. Studies in a number of invertebrate model organisms has added 
credence to the concept of long term innate immune adaptation [274]. For example injection of 
LPS protects mealworm beetles from their natural fungal pathogen M. anisopliae [275], and 
Copepods (which are miniature crustaceans) react more efficiently to parasitic tapeworm 
infection if they have had a prior infection with an antigenically similar pathogen [276]. 
 In vertebrate systems, evidence of modulated innate immunity also exists. For example, 
prior influenza infection protects from RSV induced immunopathology [102], and LCMV 
infected mice show heightened clearance of the unrelated vaccinia virus [277, 278]. Importantly 
these models map the immune response to heterologous infection, and are therefore 
uncomplicated by the beneficial effects of the generation of adaptive immune memory.  
The mechanisms governing innate education are not fully understood, however stromal 
cells have been shown to have a role in tissue imprinting, For example epithelial metaplasia can 
continue in ex-smokers for more than two years after they have stopped smoking [279], whilst 
epithelial resistance to peroxide exposure occurs through long-term changes in cytoskeletal 
structure and genome wide re-programming [280]. Our lab has described innate immune 
imprinting of AMΦ, which display TLR desensitisation following influenza infection or the 
induction of allergic airway disease [90, 251]. This thesis expands this work, showing similar 
desensitisation following RSV infection, and by suggesting a possible mechanism involving the 
epigenetic shift in the expression of key miRNAs. The shift in the expression of these key 
miRNAs is conserved in AMΦ following a range of inflammatory challenges suggesting that a 
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universal mechanism of TLR desensitisation may occur. Figure 6.1 summarises the potential 
mechanism of AMΦ desensitisation caused by innate imprinting or education of AMΦ. 
 
6.2:  Evolutionary forces driving an adaptable innate immune system.  
A crucial role of the innate immune system is to detect and assess encountered antigens, and 
critically to decide whether to respond to or ignore a particular insult. This decision is 
particularly complicated at mucosal sites where the immune system is inundated with 
innocuous antigen and commensal flora and the consequences of the immunopathology 
associated with an inflammatory response can be life threatening. The threshold above which a 
particular antigen is perceived as a threat and therefore necessitates the initiation of an immune 
response can be termed the threshold of activation. In this thesis we described mechanisms 
which modulated the threshold of activation of AMΦ, thereby reducing the immune response 
to subsequent challenge. In our models this desensitisation explained prolonged susceptibility to 
bacterial complication which is a common consequence of a multitude of respiratory diseases, 
encompassing viral infections, and inflammatory disorders such as COPD and asthma. Since 
bacterial complications are clearly deleterious to health, the evolutionary benefit of innate 
imprinting in this context is not immediately apparent. 
 A successful immune response must be perfectly balanced, vigorous enough to fight 
invading pathogens, but restrained enough to limit resultant immunopathology. Strategies 
which reduce immunopathology and the metabolic burden associated with an unnecessarily 
exuberant immune response will be evolutionarily beneficial. The adaptive immune system is 
such a successful adaptation because it allows clearance of a recognised pathogen with minimal 
inflammation. Here we describe mechanisms whereby the innate immune system minimises 
inflammation to an unseen heterologous pathogen without the need for prior antigen 
education.  
In both RSV and influenza infection, disease severity correlates closely with the 
infiltration of inflammatory cells into the airway, which peaks several days after peak viral load 
and often after viral clearance. This suggests that excessive immunopathology may contribute 
more to disease severity than viral cytopathology. In fact all the respiratory inflammatory 
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triggers described in this thesis, RSV and influenza infection as well as COPD and asthma, are 
striking in that a reduction in the resultant immune response improves outcome. For example 
in mice, reducing the entry of T cells into the airway following an RSV infection reduces 
weight loss [88], whilst reducing T cell proliferation in the airway via OX40 blockade, 
minimises disease severity following influenza infection [85].  
Although innate imprinting increases vulnerability to secondary bacterial infection it is 
possible that this negative effect is balanced by the benefits associated with educating the 
immune system to respond in a more tempered fashion to subsequent antigen challenge thereby 
reducing immunopathology. Although this balance, which ultimately determines the 
responsiveness of the innate immune system, may be active in all organs, it is possible that the 
disastrous consequence of excessive inflammation in the  delicate architecture of the lung 
pushes the balance towards regulation in this organ, thus explaining why the lung is 
particularly associated with bacterial complications.  
 
6.3: The consequences of innate immune imprinting 
A clear difference between our experiments and respiratory viral infection in the human 
population is that our mice were housed in a specific pathogen free environment and so were 
naïve when they experienced a severe viral infection. From birth, humans are constantly 
exposed to a myriad of innocuous and harmful antigens. We hypothesise that this exposure will 
reduce the threshold of activation and thereby create a subtle but unique inflammatory rheostat 
determined by individual genetics and the sequence of infections or antigenic insults we are 
exposed to. This desensitisation may explain why young adults rarely experience severe disease 
following influenza or RSV infection, whilst neonates, who have not yet set their innate 
immune rheostat, are more vulnerable to severe disease.  
 All infants are infected with RSV at least once within the first three years of life. In the 
majority of cases this results in mild upper respiratory tract symptoms. However, 0.5-2 % suffer 
from severe lower respiratory tract infection requiring hospitalisation [49]. Severe RSV in 
neonates has long been linked with a number of predispositions to subsequent disease and 
altered lung function including bacterial pneumonia [281], acute and recurrent otitis media 
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[202], as well as other inflammatory disorders such as wheeze and asthma [203]. Our model of 
severe RSV infection in naïve mice most similarly models severe RSV infection in „naïve‟ 
human neonates, and perhaps explains the altered respiratory immune responses and dysbiosis 
they subsequently experience.  
Our findings suggest that initial encounters with antigen and pathogens may be 
formative to the subsequent responsiveness of the innate immune rheostat. The commensal 
microbiome is recognised as increasingly important in regulating the responsiveness of the 
innate immune system [282]. Studies of microbiota and inflammatory conditions have 
traditionally focused on the gut, however our lab has recently shown the presence of 
commensals in both the upper and lower respiratory tracts [32]. For these reasons, it would be 
very interesting to model the responsiveness of AMΦ during the neonatal window following 
initial exposure to commensal bacteria and to make direct comparisons with AMΦ from germ-
free mice. Preliminary experiments to assess the responsiveness of neonatal AMΦ have indeed 
shown that they express lower levels of certain negative regulators of AMΦ function such as 
TREM2 and CD200R as well as subtle differences in their transcriptome and expression of 
certain miRNA (A. Godlee, data not shown).   
Although RSV is often thought of as a disease of infancy, both RSV and influenza cause 
significant mortality and morbidity in the frail elderly [283, 284]. In recognition of this 
vulnerability, in the UK all citizens over 65 are recommended to receive a seasonal influenza 
vaccination. If we extrapolate our ideas about the innate immune rheostat into old age, this may 
also explain the increased burden of viral respiratory disease in the elderly. If after every 
inflammatory event in the lung, the threshold of innate activation is set slightly lower, over 
time a situation may arise when an insufficient immune response is generated resulting in 
excessive disease and mortality in old age (Figure 6.2).  
 
 
 
 
Chapter 6: Discussion    224 
 
Figure 6.2: Hypothetical graph showing how RSV mortality risk (red) may 
correlate with the responsiveness of the innate immune system (blue) 
 
 
6.4: Do we ever recover from viral infection, and if not, why don‟t we 
continuously suffer from bacterial complications?  
In our models of bacterial complication we found that susceptibility correlated with viral 
disease severity. As such susceptibility was determined by the dose of the initial virus, and also 
temporally, such that peak susceptibility correlated with the peak of viral disease severity. In 
fact complications caused by Hib or endogenous bacteria were only significant at the peak viral 
disease time point. Susceptibility to secondary infection is likely to be a multifactorial process, 
with possible mechanisms including lung damage, mucociliary dyskinesia, phagocyte apoptosis, 
neutrophil dysregulation, up-regulation of bacterial adhesion molecules as well as changes to 
Neonates are particularly susceptible to severe RSV infection, when 
perhaps their innate immune system  is especially active. Rapid 
desensitisation of the innate immune system occurs in early infancy as 
neonates are introduced to commensal bacteria and a myriad of inhaled 
innocuous antigens thereby reducing the risk of RSV associated 
immunopathology. Over time subsequent inflammatory episodes in the 
airway further reduce the responsiveness of the innate immune system, 
such that in old age, the immune system no longer mounts a sufficient 
response to RSV infection, thereby ensuring that mortality rates 
increase. 
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AMΦ function. It is at peak viral disease severity that the greatest number of these mechanisms 
will be relevant, perhaps explaining the temporal trend of susceptibility. Similar temporal 
relationships between viral infection and subsequent secondary bacterial pneumonia are 
implied from human epidemiological studies [190].  
However, in our co-infection models we saw that susceptibility to secondary infection 
was prolonged into resolution and that AMΦ function and genotype remained altered even 6 
weeks post infection, long after viral clearance. This suggests that the lung remains 
permanently altered following an inflammatory challenge. If these findings hold true in 
humans, it seems relevant to ask: do we ever recover from a severe viral infection, and if not 
why don‟t we continuously suffer from bacterial complications?  
6.4.1: Perhaps we do suffer from bacterial complications in resolution from severe 
viral infection  
Following viral infection altered responsiveness in the airway has not been extensively studied 
in the human population. In epidemiological studies secondary complications are defined by the 
presence of both viral and bacterial infectious agents. However our results show that viral 
clearance may precede the development of bacterial pneumonia. For this reason the importance 
of viral triggers may be grossly underestimated since reliable viral detection may not be possible 
at the point of hospitalisation. Bacterial pneumonias remain a deadly global health burden with 
S. pneumoniae and Hib responsible for as many worldwide child deaths as HIV/AIDS, malaria 
and tuberculosis combined [179]. Given that both bacterial species are opportunistic and form 
part of the normal commensal load, it seems feasible that many cases of invasive bacterial 
pneumonia are preceded by an unrecognised viral trigger or underlying condition. In our 
murine influenza models we routinely see increased neutrophil numbers in the BAL of mice 6 
weeks after infection. It would be interesting to see if these results stem from endogenous 
secondary bacterial infection. 
Recent advances in personalised healthcare suggest that in the future iPOPs (integrative 
personal omics profiles) will be routinely available. Such studies use integrated analysis of 
transcriptomic, proteomic, metabolomic, and autoantibody profiles to generate an iPOP which 
can be monitored over time to detect changes that occur at homeostasis and during infection, 
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and importantly to accurately map the temporal relationships between successive infections 
[255]. Such studies will allow us to accurately determine the longevity of susceptibility to 
secondary infection following a viral trigger.  
We did not look at AMΦ beyond 6 weeks post viral infection but it would be interesting 
to fully map the longevity of altered responsiveness in mice. Our data suggests that down-
regulation of miR-322 in resolution is important in instigating TLR desensitisation, since 
blocking this miRNA mimicked post-viral desensitisation. Down regulation of miR-322 was 
particularly apparent on resident AMΦ but not on incoming AMΦ. Therefore it seems likely 
that post viral desensitisation will last as long as the life span of these AMΦ and in the absence 
of additional challenge will slowly be re-set as this population is gradually replenished. 
 
6.5:  Therapeutics 
6.5.1:  Antibiotic treatment of viral infections 
In Chapter 3 we saw that the commensal load of the nasopharynx increased during influenza 
infection, and that commensal outgrowth contributed to viral disease severity since treatment 
with antibiotics reduced cellular infiltrate into the airway and the associated immunopathology. 
Antibiotic treatment of community respiratory viral infections is currently not advised, in order 
to limit the emergence of antibiotic resistant bacterial strains. Our data suggests that antibiotic 
treatment of severe viral disease could be beneficial and should perhaps be recommended. A 
thorough trial of the benefits of antibacterial therapy during viral infection in different patient 
cohorts is long overdue. 
 
6.5.2: Anti-miR therapies 
Therapeutics which modulate the immune response are an attractive proposition and the 
number of potential targets increases with our increasing understanding of the pathways 
involved in regulating inflammation and instigating immunopathology. However the role of the 
immune system in so many aspects of life from fighting infection to maintaining homeostasis 
227  Chapter 6: Discussion 
 
means that such therapeutics can have disastrous side-effects. In 2006, trials of the 
immunomodulatory compound TGN1412, an antibody agonist of CD28, resulted in catastrophic 
systems organ failure in trial subjects, due to the unforeseen initiation of cytokine storm [285]. 
In contrast anti-TNF therapy has proved hugely successful in treating rheumatoid arthritis, 
although patients increase their risk of succumbing to bacterial infection particularly the 
reactivation of latent TB [286]. As potential modulators of immune function, therapeutics 
which target miRNAs may prove to be very useful in the future, not least because the degree of 
target down-regulation imposed by miRNA tends to be quantitatively modest and potentially 
tissue specific. As such anti-miR treatment may allow subtle alterations to immune function 
specifically at the site of injury [287]. A recent study in mice showed that anti-miR therapy 
against miR-145 was as effective at treating allergic airway disease as glucocorticoid treatment 
[273].  
 Our results showed that ex vivo anti-miR treatment of AMΦ mimicked the effect of 
post-viral resolution, by causing TLR desensitisation. Anti-miR therapy against miR-322 may 
well prove useful in treating conditions associated with excessive immunopathology in the 
airway such as severe RSV infection. It would be very interesting to carry out trials of this agent 
in vivo in a variety of inflammatory contexts.   
 
6.6:  Conclusion 
Out initial hypothesis was that following viral infection, resolved AMΦ would be more 
regulated than naïve AMΦ. In the light of the findings presented in this thesis we make two 
subtle caveats.  
Firstly, although to some extent we find resolved AMΦ are more regulated than naïve in 
that they display TLR desensitisation, and express higher levels of a number of negative 
regulators including CD200R, AXL and TREM2, we also find that resolved AMΦ express 
molecules associated with activation such as MHCII. Rather than simply being more regulated, 
AMΦ in resolution can be seen as more highly educated. The changes that have occurred set 
the threshold of activation at a higher level so that a larger antigen challenge is necessitated to 
trigger inflammation. Despite this increased threshold of activation, if inflammation does occur, 
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increased expression of MHCII will allow more efficient communication with T cells reducing 
the quantity of the adaptive immune response without affecting its quality. This more educated 
phenotype acts to reduce the risk of cytokine storm, protecting the airway from subsequent 
immunopathology, with the unfortunate side effect of increasing the risk of secondary bacterial 
infection.  
Secondly we find that in resolution two distinct AMΦ populations exist which should be 
considered separately. Resident AMΦ, which were exposed to the plethora of pro-inflammatory 
stimuli during peak inflammation, and resolved AMΦ which gradually infiltrate into the lungs 
in the weeks following inflammation. The phenotype and genotype of these AMΦ appears to be 
different and worthy of further investigation, especially given preliminary data which shows 
that these different populations may influence each other.  
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